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Abstract

Mycoplasma hyopneumoniae colonise swine ciliated respiratory epithelia, leading to the
development of porcine enzootic pneumonia. Heparin and other glycosaminoglycans are
known to block adherence of this pathogen to porcine tracheal cilia, however adhesins
with heparin-binding capacity have not been identified. Previous studies have implicated
a 97 kDa surface protein of M. hyopneumoniae, P97 that appeared to be involved in the
interaction of M. hyopneumoniae with swine cilia. This study aimed at identifying other
potential adhesins of M. hyopneumoniae.

In this study, immuno-electron microscopy and trypsin degradation analyses
demonstrated that a 159 kDa protein (P159) resides on the surface of M. hyopneumoniae.
Furthermore, proteomic analyses indicate that this molecule is post-translationally
cleaved. In vitro, these proteins are found to be cleaved and highly expressed at all stages
during the growth cycle of M. hyopneumoniae. This molecule was also shown to be
immunogenic due to its reactivity with sera from pigs naturally infected with M.
hyopneumoniae. Recombinant expression of P159 domains was undertaken (F1, F2, F3,
and F4). Two of these domains (F3 and F4) were found to bind heparin in a dosedependent, saturable and specific manner. The Kd for this interaction was 142.37 + 22.01
nM for F3 and 75.37 + 7.34 nM for F4. Some pathogenic bacteria have been shown to
bind heparin which can then bind to further components on the surface of cells, thereby
acting as a bridging molecule in adhesion to host cells. Non-labeled heparin was shown to
competitively inhibit this interaction with an IC50 value of 52.92 + 1.03 µg/ml for F3 and
66.63 + 1.02 µg/ml for F4. Fucoidan was also shown to competitively inhibit the binding
of heparin to F3 (IC50 96.28 + 1.19 µg/ml) and F4 (IC50 36.23 + 1.14 µg/ml). Fluorescent
and electron microscopic studies employing latex beads coated with P159 domains
iv

revealed that F2, F3 and F4 promoted adherence to the porcine epithelial-like cell line
PK15. Additionally, F2 and F4 also mediated the uptake of the latex beads into PK15
cells. Collectively this data suggests that P159 is a good candidate for an adhesin of M.
hyopneumoniae and thus may play a role in the colonization of the respiratory tract of
swine.

Ribosomal protein L7/L12 has been shown to play a role in the pathogenesis of a number
of bacterial pathogens in vitro, and has been found to be expressed on the cell surface of
some pathogenic bacteria. While work in this study revealed that the L7/L12 molecule is
cytoplasmically expressed in M.hyopneumoniae, an immunoreaction with convalescent
pig serum indicated the protein has immunogenic properties. The immunogenicity of the
M. hyopneumoniae L7/L12 protein may make it a potential target for vaccine
development.
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Chapter 1: Review of Literature

1.1

General notes on Mycoplasmas

Mycoplasmas are distinguished phenotypically from other bacteria by their small size
(0.15-0.30 µm) and lack of a cell wall. Taxonomically, the lack of a cell wall was used to
separate mycoplasmas from other bacteria into the class Mollicutes (mollis, soft; cutis,
skin). However, 16S rRNA analyses revealed that the Mycoplasmas are phylogenetically
related to Gram-positive bacteria (Fig. 1.1) and evolved regressively (by genome
reduction) from Gram-positive bacteria (Razin, 1992). As a result of regressive evolution,
members of the Mollicutes possess small genomes (580 kb – 2,200 kb). The genome sizes
of the mycoplasmas vary not only within the same Genus but even among strains of the
same species (Carle et al., 1995; Humphery-Smith et al., 1997; Ladefoged and
Christiansen, 1994; Robertson et al., 1990). One of the reasons for this variability is the
frequent occurrence of repetitive elements and insertion sequences (Razin et al., 1998). It
is also notable that the mycoplasma genome has a characteristically low G+C content.
With a few exceptions, the G+C content is within the range of 24 to 33 mol%.
Furthermore in mycoplasmas, the codon UGA encodes for a tryptophan codon whereas in
most other bacteria UGA encodes a stop codon. A consequence of this phenomenon is the
difficulty in expressing cloned mycoplasma genes in E. coli, as termination occurs at
UGA codons resulting in truncated proteins. Table 1.1 highlights some of the most
distinguishing features of the Mollicutes.

1

Fig. 1.1. A phylogenetic tree derived by maximum likelihood analysis of small-subunit
rRNA sequences, showing the taxonomy of the mycoplasmas and their relatedness to
Gram-positive bacteria. For the complete tree and list of organisms from which the
sequences used in this figure were obtained see Olsen et al., 1994.

2

Table 1.1. Properties distinguishing mollicutes from other bacteria a

Property
Cell wall
Plasma membrane
Genome size
G+C content of genome
No. of rRNA operons
5S rRNA length
No. of tRNA genes
UGA codon usage
RNA polymerase
a
b

Mollicutes
Absent
Cholesterol present in most species
550-2,220 kb
23-40 mol%
1 or 2 b
104-113 nucleotides
30 (M. capricolum), 33 (M. pneumoniae)
Tryptophan codon in Mycoplasma, Ureaplasma,
Spiroplasma, Mesoplasma
Rifampin resistant

Other bacteria
Present
Cholesterol absent
1,050->10,000 kb
25-75 mol%
1-10
>114 nucleotides
84 (B. subtilis), 86 (E. coli)
Stop codon
Rifampin sensitive

Taken from Razin et al., 1998.
Three rRNA operons in Mesoplasma lactucae (Bove, 1993).

Mycoplasmas are widespread in nature as parasites of humans, mammals, reptiles, fish,
arthropods, and plants (Razin, 1992). The list of hosts known to harbor mycoplasmas is
continuously increasing, as is the number of established mycoplasma species. There are
approximately 180 characterised mycoplasma species, but it is widely agreed that these
constitute only a fraction of the number of mollicutes in nature (Razin et al., 1998).
Mycoplasmas generally have a rather strict host, organ and tissue specificity, probably
reflecting their nutritionally exacting nature and obligate parasitic mode of life. The
primary habitats of human and animal mycoplasmas are the mucosal surfaces of the
respiratory and urogenital tracts, the eyes, alimentary canal, mammary glands and joints.
Recent mycoplasma genome projects have revealed a paucity of genes involved in
biosynthetic pathways, and as a consequence, many field strains are difficult to culture in
vitro. For example, both M. genitalium and M. pneumoniae lack genes involved in amino
acid biosynthesis (Fraser et al., 1995; Himmelreich et al., 1996), making them totally
dependent on exogenous sources of amino acids. Most mycoplasmas live as commensals.
Infections with pathogenic mycoplasmas are rarely of the fulminant type but rather,
follow a chronic course. It could be argued that mycoplasmas are close to the concept of
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"ideal parasites", usually living in harmony with their host. The molecular basis of
mycoplasma pathogenicity remains largely elusive.

Lacking a cell wall and intracytoplasmic membranes, the mollicutes have only one type
of membrane, the plasma membrane. Proteins constitute over two-thirds of the
mycoplasma membrane mass, with the rest being membrane lipids. The abundance of
lipoproteins in mycoplasma membranes is in contrast to other bacteria which contain a
limited number. Furthermore, membrane lipoproteins are among the most dominant
antigens in mollicutes and a majority of the mycoplasma cell surface antigens known to
undergo antigenic and size variation are lipoproteins (Razin et al., 1998). This unusually
large number of lipoproteins may be attributed to the absence of a periplasmic space in
the wall-less mollicutes. Virtually all mycoplasma lipids are located in the cell membrane
and, as in other biological membranes, consist of phospholipids, glycolipids, and neutral
lipids. However, the mycoplasmas are either partially or totally incapable of fatty acid
synthesis and depend on the host or the culture medium for their supply. Due to the lack
of a cell wall, the mycoplasma cell membrane is exposed to the environment and is in
direct contact with the eukaryotic host cell. The fusion of the two membranes could
enable the transfer or exchange of membrane components (Razin, 1978; Razin, 1985;
Razin and Jacobs, 1992), possibly allowing mycoplasma proteins to enter host cells.

1.2

Mycoplasma adhesion to host cells

Most human and animal mycoplasmas adhere to the epithelial linings of the respiratory or
urogenital tract and appear to rarely invade tissues. Adhesion of mycoplasmas to host
cells is a prerequisite for colonisation and for infection. The loss of adhesion capacity by

4

mutation results in a loss of infectivity, and reversion to the cytadhering phenotype is
accompanied by regaining infectivity and virulence (Razin et al., 1998).

Mycoplasma colonization results from the interaction between adhesin proteins on the
mycoplasma surface and sulfated glycolipid or sialoglycoprotein molecules on the host
cells. The attachment tip organelle is a polar structure (Fig. 1.2) that orients mycoplasma
binding to host cells and functions in cell division and gliding motility (Krause and
Balish, 2001). This organelle has been found in M. pneumoniae, M. genitalium (Razin et
al., 1998), M. gallisepticum (Markham et al., 1994; pMGA), M. pirum (Tham et al.,
1994) and M. penetrans (Lo et al., 1993). Although adhesins play a major role in
cytadhesion, the process appears to be multifactorial, also involving a number of
accessory proteins acting in concert with cytoskeletal elements to facilitate the lateral
movement and concentration of the adhesin molecules at the attachment tip organelle.
Panel B of Fig. 1.2 shows the cell structure of M. pneumoniae, with a terminal organelle,
colonizing hamster tracheal ring in organ culture (Krause and Balish, 2004).
Alternatively, Fig. 1.3 shows M. hyopneumoniae cells, which do not possess a terminal
organelle, colonizing swine tracheal ring epithelium (DeBey and Ross, 1994). Therefore
mycoplasma species not possessing a terminal organelle still have an adherent ability.

Several adhesins of mycoplasmas have been described, however the best understood are
those of M. pneumoniae. The number of proteins associated with cytadherence in M.
pneumoniae is large and include high molecular weight proteins 1-3 (HMW1-3), P30, P1,
P65, B (P90) and C (P40), Fig. 1.2. Some of these proteins are structural elements of the
attachment organelle (Krause and Balish, 2001). The structure and assembly of the
terminal organelle of M. pneumoniae is very complex and is abbreviated below but is
reviewed in Krause and Balish (2004). Strains that lack P1 or are not able to properly
5

position P1 at the surface of the tip organelle fail to attach to the respiratory epithelium
(Baseman et al., 1982; Krause et al., 1982). However, the finding that P1 is usually not
lost from non-adhering cells indicates that P1 alone is not sufficient for mediating
cytadherence. It is known that cytadherence competence requires proper localization of
P1, B, C and P30 to the terminal organelle. P65 is found at the surface of the terminal
organelle, co-localizing with P30 (Jordan et al., 2001; Seto et al., 2001; Seto and Miyata,
2003) but its function is unknown. However, P30 is required for P65 to remain fully cell
associated. P1 localization to the terminal organelle requires stable HMW1 and it is also
known that P30 fails to localize to the terminal organelle without HMW3. HMW3
stabilizes the electron-dense core of the terminal organelle. No core is observed in the
absence of HMW1 or HMW2 which appear to be required early in assembly of the
terminal organelle (Krause and Balish, 2004).

The receptors on host cell membranes responsible for mycoplasma attachment, identified
so far, are mostly sialoglycoconjugates and sulfated glycolipids (reviewed in Razin, 1985;
Razin and Jacobs, 1992; Zhang et al., 1994a,b). It has been shown that there is more than
one type of receptor for M. pneumoniae, and presumably other adhering mycoplasmas as
well. This is not surprising considering that each mycoplasma may carry more than one
adhesin type (Razin and Jacobs, 1992).
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Fig. 1.2. M. pneumoniae cell morphology and ultrastructure. A. Scanning electronmicrograph of M. pneumoniae cells cultured on glass. Arrow denotes the terminal
organelle. Bar, 0.5 μm (Courtesy S. Ross). B. Transmission electron micrograph of M.
pneumoniae cells colonizing hamster tracheal ring in organ culture. Arrow indicates
electron-dense core of terminal organelle. Bar, 0.5 μm. (Courtesy J. Jordan). C. Schematic
illustration of protein localization in the terminal organelle of M. pneumoniae as depicted
in longitudinal and cross-sections (left and right respectively). The number of proteins
associated with cytadherence in M. pneumoniae is large and include high molecular
weight proteins 1 and 3 (HMW1 and HMW3 [which stabilizes the electron-dense core]),
P30, P65, P1, B (P90) and C (P40) (Krause and Balish, 2004).

Fig. 1.3. Colonization of tracheal ring epithelium by M. hyopneumoniae (M) 5 days after
inoculation. Mycoplasma cells are closely associated with cilia (C). Bar 0.83 μm. (DeBey
and Ross, 1994).
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1.3

Internalisation by mycoplasmas

While certain human and animal mycoplasmas are known to be taken up by
polymorphonuclear leukocytes and macrophages (Marshall et al., 1995), the question of
whether mycoplasmas can enter epithelial cells has not been easy to resolve. However,
studies have shown that some species can invade the epithelia. Studies using confocal
microscopy and flow cytometry of fluorochrome-labelled mycoplasmas, revealed that M.
penetrans, M. pneumoniae, and M. genitalium entered the intracellular spaces and were
located throughout the cytoplasm and perinuclear regions of cultured human cells
(Baseman et al., 1995). The mechanism of entry of mycoplasmas is still unclear. While
mycoplasmas such as M. penetrans and M. genitalium appear to enter the cells through
the specialised tip structure (Jensen et al., 1994; Lo et al., 1993), other mycoplasmas
which have been shown to internalise, such as M. fermentans and M. hominis, have no
such tip structure (Taylor-Robinson et al., 1991).

Invasion of mycoplasmas into host cells may disrupt the cells integrity and function. Lo et
al. (1993) stated that extensive invasion of cells by M. penetrans eventually results in cell
disruption and necrosis. Furthermore, Mernaugh et al. (1993) showed by electron
microscopy the complete lysis of human lung fibroblasts 96 h after infection of M.
genitalium, accompanied by large numbers of mycoplasmas in the milieu. Internalisation
of mycoplasmas, even if only for a brief period, may protect them against the effects of
antimicrobials and the host immune system and may account to some extent for the
difficulty of eradicating mycoplasmas from infected cell cultures (Razin et al., 1998).
Thus, intracellular localisation may promote the establishment of latent or chronic
infection states and circumvent bactericidal immune mechanisms and selective drug
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therapies (Baseman and Tully, 1997). Cell invasion may also allow the systemic
dissemination of the pathogen to other tissues within the host.

1.4

Mycoplasmas of swine

Many mycoplasma species are present in the respiratory tract of swine without being
pathogenic. Such species include M. flocculare, M. sualvi and M. hyopharyngis (Ross,
1992). M. hyorhinis and M. hyosynoviae however are pathogenic and can cause
polysterositis and arthritis (Kobisch and Friis, 1996). The most prevalent species of
Mycoplasma found in the respiratory tract of swine and the species causing the greatest
economic impact is M. hyopneumoniae.

Porcine enzootic pneumonia (PEP) is one of the most common and economically
important diseases occurring in swine. Mycoplasma hyopneumoniae is the causative agent
of PEP and is the focus of this study. M. hyopneumoniae has also been implicated in
another swine respiratory syndrome, porcine respiratory disease complex (PRDC) which
is prevalent in countries (Europe, U.S.A.) that harbour porcine reproductive and
respiratory syndrome virus (PRRSV; Thacker et al., 2000). These diseases are responsible
for retarded growth and poor weight gain in affected herds and together they have
resulted in significant economic losses in major swine producing countries. Furthermore,
infected swine may be predisposed to secondary bacterial pulmonary infections (Frey et
al., 1994; Ross, 1992). A study conducted in 1991 estimated that economic losses to the
pig industry are estimated at $20 million a year in Australia and up to $1 billion a year
worldwide (Clarke et al., 1991). M. hyopneumoniae transmission occurs through direct
contact, aerosol, sow-to-pig transmission and can be spread in litters, with increased
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animal density influencing disease prevalence (Maes et al., 1996). Therefore control of
PEP requires good management practices and effective vaccination regimes.

Antibiotics have been useful in treating the symptoms of PEP but do not eliminate M.
hyopneumoniae. Eliminating the bacteria is required to prevent secondary infections and
to avoid re-infection. Antibiotics that interfere with cell wall synthesis, such as penicillin
and ampicillin, are ineffective as M. hyopneumoniae lacks a cell wall. Currently
quinolines, which inhibit the activity of bacterial DNA gyrase which is essential for DNA
replication, are the most effective antibiotics (Maes et al., 1996). It is believed that
vaccines that effectively block adherence and colonisation will be the best way to prevent
PEP. Currently the use of denatured M. hyopneumoniae membrane protein antigens as
vaccine components have been investigated with the aim to identify essential antigens to
be used in future vaccines (Djordjevic et al., 1997). Studies with bacterin M.
hyopneumoniae vaccines show protection against experimental M. hyopneumoniae
challenge, although pneumonia is often not completely eliminated and colonization is
only marginally reduced (Thacker et al., 1998).

Under field conditions, grower pigs are the major source of infection with M.
hyopneumoniae; however pigs of all ages can develop acute pneumonia and appear to be
equally susceptible to the disease (Kobisch et al., 1993; Ross, 1992). Enzootic pneumonia
is characterised by high morbidity and low mortality. Coughing is the principal clinical
sign, observed over a few weeks or months, but is not constant. If the infection is
complicated by other bacteria, particularly Pasteurella multocida, other symptoms such
as laboured breathing and fever, and even death, may occur (Kobisch and Friis, 1996).
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1.5

M. hyopneumoniae colonization of swine respiratory epithelia

Electron microscope studies show that colonisation of the epithelium is visible during the
first or second week after challenge of a pig with M. hyopneumoniae (Kobisch and Friis,
1996). Two to eight weeks after inoculation, clumping and loss of cilia is evident,
reflecting the colonization of the mucosal surface. Studies of the respiratory tract of
infected swine show that M. hyopneumoniae cells predominantly adhere to trachea,
bronchi, and bronchiolar epithelial cilia (Fig. 1.4), but were also seen in association with
the epithelial microvilli and surfaces, and on leukocytes in the trachea (Blanchard et al.,
1992; Mebus and Underdahl, 1977; Tajima and Yagihashi, 1982). Buttenschon and
colleagues (1997) have also cultured M. hyopneumoniae from the pericardium, which is a
double layer of serous membrane surrounding the heart, in Danish slaughter pigs. Thirtythree isolates of M. hyopneumoniae were cultured from 46 pigs showing fibrinous
pericarditis. M. hyopneumoniae however, has not been shown to be able to invade the
epithelial cells and it is not known how these bacteria were able to localize in the
pericardium. A number of pig respiratory pathogens such as Haemophilus parasuis,
Actinobacillus pleuropneumoniae, Pasteurella multocida and Mycoplasma hyorhinis are
known to induce pleurisy (inflammation of the membrane surrounding the lungs, pleura)
and pericarditis. When there is acute inflammation of the lungs and pleura, inflammatory
exudate can flow into the thoracic cavity and spread the infection to the pericardium.
Although M. hyopneumoniae is not known to induce pleurisy, in conjunction with other
bacteria pleurisy may occur and allow M. hyopneumoniae to spread to the pericardium.

During in vitro studies, observation by electron microscopy shows that after infection the
mucosal surface of the swine respiratory tract is less ciliated and mycoplasmas are
associated with the remaining cilia. Organisms have also been observed to be attached to
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cellular debris and to sloughed cilia (Zielinski and Ross, 1993). Mucopurulent exudate in
small airways is a prominent feature of M. hyopneumoniae pneumonia in pigs and may be
attributable to hypersecretion of mucus as well as ciliostatsis (DeBey et al., 1992) which
are common in M. hyopneumoniae infections.

Fig. 1.4. A scanning electron micrograph of trachea 2 weeks post infection with M.
hyopneumoniae. M. hyopneumoniae appear closely associated with the upper part of cilia,
bar = 1 μm (Blanchard et al., 1992).

M. hyopneumoniae infection is associated with a marked infiltration of lymphocytes,
macrophages, neutrophils and plasma cells to the lungs, trachea and bronchi, which are
believed to be responsible for the lesions seen on these surfaces as early as two weeks
after infection (Livingston et al., 1972). Throughout the disease progression ciliostasis,
loss of cilia and epithelial cell death occurs (Blanchard et al., 1992). Excessive mucous
production, in combination with cilial damage, decreases the function of the mucociliary
escalator (DeBey and Ross, 1994), which is responsible for moving trapped bacteria up to
12

the back of the throat where they are swallowed. Loss of this function increases the risk
of secondary respiratory infections.

For cilial damage to occur M. hyopneumoniae must attach to the swine respiratory
epithelial cells. Non-pathogenic M. hyopneumoniae and excessively in vitro passaged M.
hyopneumoniae are unable to adhere to ciliated cells (Zielinski and Ross, 1990), and are
therefore unable to colonize the respiratory epithelium and establish infection, confirming
that adherence is essential for the initiation of epithelial cell damage. This was also
confirmed by DeBey and Ross (1994) where it was found that epithelial cell damage did
not occur when M. hyopneumoniae was separated from ciliated epithelium with a 0.1-µmpore-size membrane. Evidence that attachment is necessary for induction of ciliary
damage occurring during M. hyopneumoniae infection in vitro further demonstrates the
importance of identifying the adhesins associated with attachment of M. hyopneumoniae
in vivo for production of vaccines that prevent infection in the pig (DeBey and Ross,
1994).

During a study of the mechanisms by which M. pneumoniae induces loss of cilia of
respiratory epithelium, it was noted that an increase in the concentration of Ca2+ in the
medium resulted in the loss of cilia (Zhang et al., 1994a,b). Park and colleagues (2002)
later showed that M. hyopneumoniae activates receptors that are coupled to Gi or Go,
which in turn activates a phospholipase C pathway, thereby releasing Ca2+ from the
endoplasmic reticulum. Thus, an increase in Ca2+ may serve as a signal for the
pathogenesis of M. hyopneumoniae (Park et al., 2002).
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1.6

Adhesins of Mycoplasma hyopneumoniae

M. hyopneumoniae lacks the specialised tip attachment organelle that M. pneumoniae and
M. genitalium use to attach to host cells (Dybvig and Voelker, 1996; Krause, 1996; Razin
et al., 1998). Nevertheless M. hyopneumoniae is capable of adhesion to ciliated epithelia.
Pre-incubation of M. hyopneumoniae cells with periodate and trypsin abolished
attachment of the bacteria to ciliated respiratory tract cells (Zielinski and Ross, 1993),
indicating that adherence is mediated by proteins and carbohydrates on the surface of the
organism.

A 97-kDa surface protein of M. hyopneumoniae, P97, has been implicated as playing a
role in host cell adhesion. MAbs F1B6 and F2G5, which recognise P97 in immunoblots
(Zhang et al., 1995) reduce adherence in vitro (by 67%) to purified cilia and to ciliated
cells. DNA sequence analysis revealed an open reading frame coding for a 124.9-kDa
protein in strain 232 (pathogenic strain; Hsu et al., 1997) and 123 kDa in strain J
(laboratory adapted non-pathogenic strain; Wilton et al., 1998). In J strain the product is a
94kDa protein (P94) as opposed to P97 (Wilton et al., 1998). The only significant
hydrophobic stretch representing a potential trans-membrane domain was found at the Nterminus. The N-terminal sequence of purified P97 and P94 mapped at amino acid 195 of
the translated sequence, indicating that a significant processing event takes place
removing the only potential trans-membrane domain in M. hyopneumoniae (Hsu et al.,
1997). This processing results in the production of a 22-kDa protein, P22, which
represents the N-terminal 195 amino acids of the cilium adhesin pre-protein, as well as
P97 or P94. This observation suggests that M. hyopneumoniae secretes proteins destined
for the cell surface very differently compared with models proposed for Gram-positive
organisms, from which mycoplasmas evolved.
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Using swine cilia adherence assays, binding of recombinant P97 to cilia was inhibited by
the exogenous addition of heparin and fucoidan (Hsu et al., 1997). These substances were
shown to prevent M. hyopneumoniae binding to swine cilia (Zhang et al., 1994b),
supporting the hypothesis that P97 was involved in M. hyopneumoniae binding to cilia in
vivo.

The cilium binding activity of P97 or P94 is localised at the carboxy-terminus of the
protein and includes two repeat regions, R1 and R2 (Hsu et al., 1997). Studies show that
the cilium binding site is located in the R1 repeat sequence (AAKPV(E)). In M.
hyopneumoniae strain 232 there are 15 tandem copies of this sequence in the R1 region of
P97 while in strain J there are 9 tandem copies in P94 (Hsu and Minion 1998a; Wilton et
al., 1998) and it is this difference that largely accounts for the size variation between the
homologous proteins. For functional binding to swine respiratory cilia Hsu and Minion
(1998a) suggest that eight AAKPV(E) repeats are required. The adherence-blocking
monoclonal antibody F1B6 also recognises this region but requires only three AAKPV(E)
repeats for recognition. A comparison of the R1 regions of M. hyopneumoniae strains
displaying variation in cilium adherence failed to identify changes that could account for
the differences in adherence shown by the strains examined (Hsu and Minion, 1998a) as
only eight AAKPV(E) repeats are required for cilium binding and both strains 232 and J
contain this minimum number while strain 232 can adhere to cilia but strain J cannot.
Thus, other proteins, in addition to P97 or P94, are likely to be involved in adherence,
possibly in combination with P97 or P94. The R2 region is composed of four repeats of
the 10-amino acid sequence GTPNQGKKAE in M. hyopneumoniae strain 232 and 5
repeats in strain J and does not appear to be directly involved in cilium binding (Hsu et
al., 1997). The function of this repeat region remains unknown.
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Recently, Djordjevic et al. (2004) demonstrated that the P97 cilium adhesin is
proteolytically processed on the surface. Proteomic analysis of M. hyopneumoniae strain J
and 232 identified cleavage products of 22, 28, 66 and 94 kDa in strain J and 22, 28, 70,
and 97 kDa in strain 232, (Fig. 1.5). N-terminal sequencing showed that the 66- and 94kDa proteins possessed identical N-termini and that the 66-kDa variant was generated by
cleavage of an R2 containing 28-kDa fragment from the C-terminus. As stated earlier, the
22-kDa product represents the N-terminal 195 amino acids of the cilium adhesin preprotein. Comparative studies with pathogenic M. hyopneumoniae strain 232 found that
the major cleavage products are similar but differ slightly in size, although P22 and P28
appear to be further processed in 232. Immunoblotting studies demonstrated that the
processing is complex and strain specific, with cleavage occurring with different
frequencies at multiple sites. Immuno-gold electron microscopy of M. hyopneumoniae
cells showed that protein fragments containing the cilium-binding site remain associated
with the cell surface whereas cleavage products not containing the R1 element are located
elsewhere (Djordjevic et al., 2004).

F1B6

R2

R1

J strain
Mass
123 kDa
94 kDa
66 kDa
28 kDa
22 kDa

232 strain
Mass
126 kDa
97 kDa
70 kDa
28 kDa
22 kDa

Fig. 1.5. Map of the cilium adhesin of M. hyopneumoniae. This map shows the antibody
epitope location of F1B6 as a bar above the map. The major cleavage event at amino acid
195 (thick arrow) and another event at amino acid 891 (thin arrow) are shown. The
locations of the R1 and R2 repeat regions are represented by grey-shaded boxes. The
cleavage products of strains J and 232 are shown as bars below the map and their
molecular masses are indicated on the right (adapted from Djordjevic et al., 2004).

16

Further analysis of the DNA sequences surrounding the P97 structural gene revealed that
it is located in a two gene operon with an ORF coding for a 102.3 kDa protein (designated
P102). Although Southern hybridisation data indicated that the P97 adhesin-encoding
gene is present as a single copy in the M. hyopneumoniae chromosome, these studies
indicated that P102 or P102-related sequences may exist in multiple copies in the genome
of M. hyopneumoniae (Hsu et al., 1997). Within the M. hyopneumoniae genome six
paralogs of P97 and six of P102 were discovered. The P97 paralogs only show a small
degree of homology to P97 at the DNA level and thus were unable to hybridise in
Southern experiments but are more homologous at the amino acid level (>30% amino
acid identity over 70% of their length; Minion et al., 2004). A database search of other
bacterial genomes for genes homologous to p102 revealed no significant match to any
known sequence, including other bacterial adhesin genes. It was also found that P102 is
expressed in vivo because convalescent swine sera recognised a clone containing only
P102 sequences (Hsu and Minion, 1998b). The function of P102 is not known, but the
translated sequence shows a prominent transmembrane domain, suggesting that it may be
a cell surface protein (Hsu and Minion, 1998b). A potential role for P102 in cilium
adherence is speculative and requires further study, but accessory proteins are often found
in multigene operons with adhesin structural genes in mycoplasmas (Hsu and Minion,
1998b) and other mycoplasma species have been shown to require more than one protein
for adhesion, for example the terminal organelle of M. pneumoniae. Electron microscopy
studies confirm P102 to be located exclusively on the surface of M. hyopneumoniae
(Djordjevic et al., 2004).

Djordjevic et al. (2004) examined whether the protein, P102 like P97, undergoes
proteolytic cleavage in M. hyopneumoniae. Results showed that cleavage of this molecule
occurs at one or two sites generating a 42-kDa protein representing the C-terminal
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cleavage fragment of P102. Further studies are required to confirm the identity of the
remaining protein with a predicted molecular mass of 72-kDa.

1.7

Extracellular matrix components and bacterial interaction

The importance of microbial adhesion to epithelia in mucosa-associated infections has
been recognised for many years. The discovery by Kuusela in 1978 that Staphylococcus
aureus strains bind to the intricate network of macromolecules known as the extracellular
matrix (ECM), and specifically the glycoprotein fibronectin launched a new and extensive
field of research. Investigations have revealed how microorganisms (bacteria, parasites,
fungi and viruses) interact with the ECM components and have highlighted the
importance of these interactions in pathogenesis (Ljungh and Wadström, 1995).

Zhang and colleagues (Zhang et al., 1994b) established a microtiter plate adherence assay
for M. hyopneumoniae using purified swine tracheal cilia. M. hyopneumoniae was found
to bind specifically to plates coated with solubilized cilia. The ECM components and
glycosaminoglycans dextran sulfate, heparin, chondroitin sulfate, laminin, mucin and
fucoidan significantly inhibited the binding of the mycoplasmas in the assay and also
disrupted the adherence of the mycoplasmas to intact ciliated cells. Pre-incubation with
either mycoplasmas or cilia indicated that heparin, mucin, fucoidan and chondroitin
sulfate interacted with the adhesive molecules on the surface of the mycoplasmas, while
laminin blocked the receptors in cilia. The basis of the inhibition induced by dextran
sulfate was unknown.
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1.7.1 Host extracellular matrix (ECM)
Tissues are not solely made up of cells, a substantial part of the volume is extracellular
space which is filled by the extracellular matrix (ECM). The ECM is composed of
glycoproteins and glycosaminoglycans (GAGs) which form a network by means of a
number of specific interactions between different ECM components. The composition of
the ECM differs in various organs, but the dominating molecules are fibronectin,
collagens type I to XV, laminin and GAGs such as, heparan sulfate, chondroitin sulfate
and others (Kreis and Vale, 1993), see Fig. 1.6. Of these, type IV collagen, laminin and
heparan sulfate are major constituents of basement membranes. Some constituents are
found exclusively in the ECM, such as collagen and laminin. Others are part-time ECM
molecules and also occur in soluble forms in body fluids, these include fibronectin,
fibrinogen and vitronectin. The conformation of some ECM components, including
fibronectin and vitronectin, differ significantly when the glycoprotein is immobilised in
tissues or on surfaces, or appear in soluble form. Other ECM ligands such as heparan
sulphate proteoglycans occur both in ECM forms and as intercalated cell membrane
proteoglycans (Patti et al., 1994b). The ECM serves a structural function, but also
profoundly affects eukaryotic cell adhesion, migration, differentiation and proliferation.

1.7.2 ECM components and bacterial interaction
Bacterial adherence requires bacterial surface components recognising and binding to
host extracellular matrix and cell surface components. The cell surface adhesins of
bacteria that specifically interact with extracellular matrix components can be designated
as MSCRAMMs (microbial surface components recognizing adhesive matrix molecules)
(Patti et al., 1994a).
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Fig. 1.6. Schematic overview of the types of molecules that bind cells to each other and to
the extracellular matrix. Cell-adhesion molecules (CAMs) are integral membrane
proteins. Some interact with similar molecules on other cells and, via intracellular
attachment proteins, form anchors for cytoskeletal proteins. Other CAMs form
connections with components of the extracellular matrix and also, via attachment
proteins, with cytoskeletal proteins. Multiadhesive proteins bind to cell-surface receptor
proteins and to other matrix components. Proteoglycans, consisting of a core protein, to
which glycosaminoglycan chains are attached, also participate in adhesion of cells to one
another and to the protein components of the matrix. Together, these interactions allow
cells to adhere to one another, interconnect the cytoskeletons of adjacent cells, and give
tissues their strength and resistance to shear forces (Lodish et al., 2000).
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A single MSCRAMM can bind several ECM ligands. For example, the plasmid-encoded
outer membrane protein YadA, which appears to be a collagen-binding MSCRAMM on
enteropathogenic Yersinia enterocolitica and Y. pseudotuberculosis (Emödy et al., 1989),
can also bind laminin and an isoform of fibronectin (Tertti et al., 1992). In addition, a
microorganism can express several MSCRAMMs that recognize the same matrix
molecule. For example, Staphylococcus aureus appears to express several fibrinogenbinding proteins (Bodén and Flock, 1989; McDevitt et al., 1994).

How does the ECM become exposed to bacteria? One obvious mechanism is trauma that
would disrupt the skin or epithelial integrity. Also, viral and bacterial infections of
mucosal surfaces cause exposure of the ECM through the action of proteolytic enzymes
and toxins. The normal shedding of epithelia also exposes ECM components at the
epithelial surface. Finally, pathogenic bacteria may gain access to various body fluids.
Bacteria which are capable of binding ECM components may coat themselves with these
components, thereby representing an important mechanism to evade the immune defence
mechanisms (Höök et al., 1989).

Understanding the role of MSCRAMMs in pathogenesis and determining their potential
as targets for antimicrobial therapy relies on knowledge of the ECM components with
which they interact. The next part of this review focuses on some of the most important
components of the ECM and some bacterial MSCRAMMs that interact with them.
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1.7.3 Proteoglycans
The proteoglycans have a much higher ratio of polysaccharide to protein than do
collagen, fibronectin, and similar glycoproteins in the ECM. The polysaccharide chains in
proteoglycans are long repeating linear polymers of specific disaccharides called
glycosaminoglycans (GAGs). Usually one sugar is uronic acid and the other is either Nacetylglucosamine or N-acetylgalactosamine (Lodish et al., 2000). Frequently some of
the residues in a GAG chain are modified after synthesis; dermatan sulfate is formed from
chondroitin sulfate, for instance. Similarly, heparin is formed only in mast cells, as a
result of enzymatic addition of sulfate groups at specific sites in heparan sulfate (Fig.
1.7).

Proteoglycans can be found in the extracellular matrix as well as on the surface of many
cells, particularly epithelial cells. A class of proteoglycans present in the basal lamina
(syndecan) consists of a core protein to which are attached several heparan sulfate chains.
Such proteoglycans bind to type IV collagen and other structural proteins, thereby
imparting structure to the basal lamina (Lodish et al., 2000). The core protein of cellsurface proteoglycans spans the plasma membrane and contains a short cytosolic domain,
as well as a long external domain to which a small number of heparan sulfate chains are
attached. Some cell surface proteoglycans also contain chondroitin sulfate (Lodish et al.,
2000).
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Fig. 1.7. Structure of various glycosaminoglycans, the polysaccharide components of
proteoglycans. The number (n) of disaccharides typically found in each
glycosaminoglycan chain is given (adapted from Lodish et al., 2000).
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1.7.3.1 Heparin and heparan sulfate
Heparin is a highly sulfated polysaccharide that is similar in structure to heparan sulfate.
Heparin is made up of repeating units of disaccharides containing a uronic acid residue
(either D-glucuronic acid or L-iduronic acid) and D-glucosamine, which is either Nsulfated or N-acetylated. Heparin is an intracellular product found in the secretory
granules of mast cells in complexes with basic proteases. Heparan sulfate (originally
called “heparitin sulfate”) on the other hand is produced by most animal cells and is
structurally similar to heparin. It is less highly sulfated but contains all of the structural
motifs found in heparin. Heparan sulfate, in contrast to heparin is normally secreted from
cells. As a major component of the extracellular matrix, it is well positioned to play a
prominent role in the physiology of the cell. Heparin and heparan sulphate are unique
among the glycosaminoglycans in their ability to bind to a large number of different
(primarily extracellular) proteins (Conrad, 1998). It is often convenient, because of the
structural similarities between these two polymers, to refer to them together as
“heparinoids”.

A number of bacterial (Chlamydia trachomatis, Helicobacter pylori, Neisseria
gonorrhoeae), viral (herpes simplex virus, cytomegalovirus, human immunodeficiency
virus) and parasitic (Leishmania donovani, Plasmodium spp.) pathogens have been shown
to express surface proteins that interact with specific glycoconjugates on cell surfaces
(Rostand and Esko, 1997; Norkin, 1995). Many of these pathogens have evolved to use
these cell surface glycolipids, glycoproteins and GAGs as receptor molecules for cell
attachment, as well as eukaryotic cell invasion and intercellular migration processes
(Wadström and Ljungh, 1999).
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A novel strategy in microbial pathogenesis has been described which involves specific
bacterial recruitment of glycosaminoglycans such as heparin, or related sulfated
polysaccharides, which in turn serve as universal binding sites for a diverse array of
mammalian heparin binding proteins, including adhesive glycoproteins (vitronectin and
fibronectin), inflammatory and immunomodulatory intermediates, and fibroblast growth
factor (Duensing et al., 1999). Adhesive proteins such as fibronectin and vitronectin have
been implicated as intermediates in bacterial interactions with host cell integrin receptors,
resulting in bacterial colonisation and invasion of epithelial cells (Ljungh et al., 1996).
This process is utlilised by Neisseria gonorrhoeae where the OpaA adhesin binds
proteoglycans, resulting in bacterial adherence, and vitronectin acts as a bridging
molecule linking the Opa-proteoglycan complex and integrin receptors at the host cell
surface, resulting in internalization of the bacteria by HEp-2 epithelial cells (Van Putten
et al., 1998).

Studies of Listeria monocytogenes, Helicobacter pylori and Neisseria gonorrhoeae
(Alvarez-Dominguez et al., 1997; Chen et al., 1995a,b; Chmiela et al., 1997) suggest that
GAG-binding surface molecules confer resistance to phagocytosis. For example,
treatment of H. pylori with heparin caused a decrease in phagocytosis by 55 to 70%
(Dubreuil et al., 2002).

1.7.4 Laminin
After type IV collagen, laminin, a large multi-adhesive matrix protein, is the most
prevalent constituent of all basal lamina. Laminin is important for the structure of the
basement membrane by its formation of networks with type IV collagen,
entactin/nidogen, and heparan sulfate proteoglycans such as perlecan (Yurchenco and
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Schnittny, 1990) (Fig. 1.8). The laminin molecule is a 900-kDa glycoprotein consisting of
multiple domains, arranged in an extended four-armed cruciform shape (Beck et al.,
1990) (Fig. 1.9). In addition to domains binding collagen and heparan sulfate in the
basement membrane, other domains include a cell-signalling site with mitogenic action, a
region involved in calcium-dependent aggregation, and a receptor-mediated cell
attachment site (Beck et al., 1990; Gehlsen et al., 1988; Liotta et al., 1986). Laminin is
composed of three polypeptide chains: an A chain (400 kDa), a B1 chain (220 kDa), and a
B2 chain (220 kDa) (Beck et al., 1990; Timpl, 1989). A characteristic feature of the
laminin molecule is its high carbohydrate content of 12 to 27%, most of which is present
in complex-type oligosaccharides (Arumugham et al., 1986; Fujiwara et al., 1988; Knibbs
et al., 1989) which plays a role in cellular adhesion processes (Dean et al., 1988; Dennis
et al., 1984; Zhou and Cummings, 1990).

Fig. 1.8. Model of the basal lamina (Yurchenco and Schittny, 1990).
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A chain (400,000 MW)
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sulfated lipids
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sulfated lipids
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coiled coil
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and entactin
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binding site

Fig. 1.9. Structure of laminin. The cross-shaped molecule contains globular domains and
a coiled-coil region in which three chains are covalently linked via several disulphide
bonds. Different regions of laminin bind to cell-surface receptors and various matrix
components (adapted from Lodish et al., 2000).

H. pylori is the primary cause of active chronic gastritis and plays a pivotal role in the
development of peptic ulcer disease (Blaser and Parsonnet, 1994; Graham et al., 1992;
Marshall and Warren, 1984; Rauws and Tytgat, 1990; Warren and Marshall, 1983). The
maintenance of the integrity of the gastric epithelium involves specific interaction of
epithelial cell surface, integrins, with distinct extracellular matrix adhesive proteins, one
of which is laminin (Gehlsen et al., 1988; Ruoslahti and Pierschbacher, 1987). H. pylori,
particularly haemagglutinating strains, were earlier shown to bind the basement
membrane protein laminin (Valkonen et al., 1993). Ljungh and colleagues (1996) suggest
that laminin binding by H. pylori is unlikely to play a role in the initial adherence
mechanisms. However, once adherent to gastric epithelium, laminin binding expressed by
H. pylori lipopolysaccharide may inhibit the binding between laminin and its cell receptor
on the gastric epithelium (Slomiany et al., 1991;Wadström et al., 1996).
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1.7.5 Fibronectin
Fibronectin is a mammalian glycoprotein found in a soluble form (molecular mass, 550
kDa) in body fluid such as plasma as well as in an insoluble form in the interstitial
connective tissues and extracellular matrices (Peterson et al., 1989; Ruoslahti, 1988).
Differences in structure between plasma and cellular fibronectin result partly from
distinct splicing patterns of the fibronectin gene (Peterson et al., 1989; Schwarzbauer,
1991). Fibronectin serves diverse biological functions including cell to cell adhesion,
spreading, and migration, tissue development and differentiation, blood clot stabilisation,
and wound healing (Carson, 1989; Ruoslahti, 1988; Yamada, 1989).

Fibronectin is composed of repeating structural units, presented in two similar disulphidelinked subunits (Fig. 1.10) (Naito et al., 2000). Fibronectin contains distinct binding sites
for a variety of other extracellular molecules; including fibrin, heparin, and collagen, as
well as for a number of cell surface integrins (Joh et al., 1999; Naito et al., 2000).

Many MSCRAMMs interacting with fibronectin have been characterised and fibronectin
binding has been extensively studied over the past 30 years. The interaction of bacteria
with fibronectin is believed to contribute significantly to the virulence of a number of
microorganisms (Joh et al., 1999). Fn-binding MSCRAMMs have been implicated in the
pathogenic process of a number of infectious diseases such as urinary tract infections
(Westerlund et al., 1991), pharingitis (Molinari et al., 1997) and infective endocarditis
(Kuypers and Proctor, 1989).
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Fig. 1.10. Schematic representation of the domains of the fibronectin molecule.
Fibronectin consists of two similar disulphide linked subunits. Functional domains that
interact with heparin (I and II), fibrin (I and II), collagen, gelatin, and cell surface
integrins are labelled above the respective domains. Binding to integrins is dependent on
an Arg-Gly-Asp (RGD) sequence. Bacterial binding regions are indicated in italics
(adapted from Naito et al., 2000; van der Flier et al., 1995).

Concentrating on two of the most studied interactions; fibronectin binding by S. aureus is
mediated by two surface-exposed proteins with molecular weights of 110 kDa, designated
FNBP-A and FNBP-B. The genes encoding these proteins have been cloned and
sequenced (Jonsson et al., 1991). The fibronectin binding region is found in a 38 amino
acid repeated domain (D repeat region) located outside a segment rich in proline residues.
Williams et al. (2002) identified a second binding region within the N-terminal part of
FNBP-A and FNBP-B. The S. pyogenes fibronectin-binding protein SfbI interacts with
fibronectin on nonphagocytic Hep-2 cells which triggers bacterial internalization, as
discovered by coating inert latex beads with SfbI which were ingested by the eukaryotic
cells (Molinari et al., 1997). S. pyogenes was also found to recruit collagen via surfacebound fibronectin through the SfbI protein which resulted in bacterial aggregation,
colonization

of

collagen

fibres

and

protection

from

adhering

to

human

polymorphonuclear cells in the presence of opsonizing antibodies (Dinkla et al., 2003).
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1.7.6 Collagen
Collagen is the major insoluble fibrous protein in the ECM and in connective tissue and is
a major constituent of cartilage. In fact, collagen is the single most abundant protein in
the animal kingdom. There are at least 16 types of collagen, but 80-90% of the collagen in
the body consists of types I, II and III. Type IV is a major constituent of the basal lamina
of the ECM. It was thought that all collagens were secreted by fibroblasts in connective
tissue, but we now know that numerous epithelial cells make certain types of collagen.
Staphylococci express surface antigens that bind collagen. The role of collagen binding
by S. aureus in arthritis was elucidated using polystyrene beads coated with purified
collagen binding protein (CNBP). Beads coated with CNBP adhered to cartilage whereas
beads coated with FNBP did not (Switalski et al., 1993). Studies have shown that the
collagen-binding MSCRAMM on S. aureus is both necessary and sufficient for the
adhesion of these cells to cartilage (Patti et al., 1994b).

1.7.7 Interactions of bacteria with the ECM
Table 1.2 shows some bacterial species and the proteins at the site of tissue injury with
which they interact. Both structural and adhesive components of the ECM are utilised in
bacterial adherence. Just as an example, the capacity of Streptococcus pyogenes to invade
host cells is thought to provide a mechanism whereby the organism can gain access to
deep tissue and blood, providing at least partial protection from host defences and
antibiotics (Cue et al., 1998) and it may be that the S. pyogenes binding to ECM proteins
is what allows this microorganism to invade host cells. MSCRAMMs that act as adhesins
and virulence determinants represent potential targets for the development of novel
antimicrobial agents, including vaccines and adhesion blockers. In summary, the initial
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studies of MSCRAMMs have revealed a family of microbial proteins that participate in
host interactions in a sophisticated fashion.
Table 1.2. Some examples of bacterial species capable of binding proteins of the ECM.
Species

Host protein used for
bacterial binding
Plasminogen

Mycoplasma
fermentans
Mycoplasma sp. bovine Plasminogen
group 7
Staphylococcus aureus Fibronectin
Fibrinogen
Vitronectin
Collagens
Yersinia enterocolitica Collagens
Laminin
Enterococcus faecalis
Pseudomonas
aeruginosa
Helicobacter pylori

Streptococcus
pyogenes
Neisseria meningitidis
Haemophilus
influenzae
Haemophilus ducreyi
Treponema denticola

Reference
Yavlovich et al., 2001
Bower et al., 2003

Fibronectin
Collagen I, IV
Laminin
Laminin
Collagen I, IV
Laminin
Collagen IV
Vitronectin
Fibronectin
Fibrinogen
Laminin
Plasminogen
Fibronectin
Collagens I, III, V
Plasminogen
Fibronectin
Laminin
Collagen I, III
Plasminogen
Fibronectin
Collagens I, III
Laminin
Fibronectin
Plasminogen
Laminin
Fibronectin
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Cho et al., 2001
Cho et al., 2001
McGavin et al., 1993
Switalski et al., 1989
Shultze-Koops et al., 1992
Flugel et al., 1994; Skurnik et al.,
1994
Tertti et al., 1992
Xiao et al., 1998
Xiao et al., 1998
de Bentzmann et al., 1996
de Bentzmann et al., 1996
Trust et al., 1991; Valkonen et al.,
1993; Valkonen et al., 1994
Trust et al., 1991
Ringner et al., 1992
Courtney et al., 1994
Katerov et al., 1998
Cue et al., 1998
Winram and Lottenberg, 1996
Eberhard et al., 1998
Eberhard et al., 1998
Ullberg et al., 1992
Virkola et al., 1996
Virkola et al., 1996
Virkola et al., 1996
Virkola et al., 1996
Bauer and Spinola, 1999
Bauer and Spinola, 1999
Bauer and Spinola, 1999
Umemoto et al., 1993, Haapasalo et
al., 1992
Fenno et al., 2000
Haapasalo et al., 1992
Haapasalo et al., 1992

Chapter 2: General Methods

This section contains methods that are common to more than one chapter of this thesis
and the specific details of each experiment can be found in the proceeding chapters. A
list of commonly used buffers and solutions and their ingredients can be found in
Appendix A. A list of all extracellular matrix components and the kits used in this study
can be found in Appendix B and C, respectively. The cell lines and bacterial strains can
be found in Appendix D and maps of the vectors used for cloning in this project are given
in Appendix E.

2.1

M. hyopneumoniae in vitro culture sample preparation

Cultures of M. hyopneumoniae were grown by inoculating modified Friis media
(Appendix A) with a 1:50 volume inoculum of a previously grown culture (either from 80oC storage or fresh). The culture was left rotating slowly at 37oC until the pH in the
media had changed to 6.9-7.2, resulting in a change of colour from orange to yellow
(approximately 2-3 days). The cultures were then pelleted by centrifuging at 10,000 rpm
for 30 min at 4°C in a Sorvall RC5C plus centrifuge (GSA rotor). The supernatant was
discarded and the pellets resuspended in 2 ml of PBS. The volume was made up to 50 ml
with PBS and samples were re-centrifuged as above. The supernatant was discarded and
the pellets resuspended in 1 ml of PBS. The cells were transferred to pre-weighed sterile 2
ml microcentrifuge tubes and the bacteria pelleted by centrifugation using a benchtop
centrifuge (Biofuge Pico, Heraeus) at 10,000 rpm for 10 min. The supernatant was
removed and the weight of the bacterial pellet was determined and the pellet stored at 20°C.
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2.2

Cloning

2.2.1

PCR amplification

The reaction mix for PCR consisted of 5 µl of 10X Taq buffer (Roche), 1.5 µl dNTPs (2.0
mM; Astral Scientific), 1 µl of each of the forward and reverse primers (20 pmol/µl;
Sigma-Genosys), 0.2 µl Taq DNA Polymerase Enzyme (Roche), 2 µl (20 ng) of DNA and
sterile MilliQ water up to a final volume of 50 µl. PCR reactions were carried out on
either a PC-960G gradient thermal cycler or an FTS thermal cycler (Corbett Research).
All PCR products were stored at -20oC.

2.2.2

Agarose gel electrophoresis

For electrophoresis of PCR products or restriction enzyme digestion products a 1-2.5%
agarose (w/v) gel was prepared in 0.5X TBE buffer. Gels were electrophoresed in 0.5X
TBE Buffer (Appendix A) containing 2 µl (5 µg/ml) ethidium bromide. Approximately 2
µl of loading buffer (0.25% bromophenol blue, 15% ficoll) was added per 10 µl of
sample. Electrophoresis was carried out at 100 V (constant voltage). GeneRuler™ 100 bp
DNA Ladder Plus (1.5 µg; Progen) was used for sizing the resolved fragments. All gels
were viewed under UV light and recorded using a GelDoc™ 1000 computer system
(BioRad).

2.2.3

Restriction enzyme digestion

Restriction enzyme digestions were carried out for at least 2 h at 37oC on a dry block
heater (Thermoline) with the appropriate restriction enzymes according to the
manufacturers’ instructions. These digested products were then electrophoresed through
agarose gels, to verify digestion or for gel extraction.
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2.2.4

Ligation and transformation

Ligations were performed by adding appropriate amounts of the pQE-9 vector and PCR
product or pPCR-Script plasmid which contains the insert that is to be ligated into pQE-9
(see appropriate chapter), in a total volume of 17 µl with MilliQ water and incubated at
65oC for 1 min, 37oC for 10 min, RT for 10 min and on ice for 10 min. Subsequently 2 µl
of 10X T4 DNA Ligase Buffer (Roche) and 1 µl of T4 DNA Ligase (Roche) were added
to the reaction mix and incubated overnight at 10oC. A control with digested vector only
was also included. The following day the ligation mix was transformed into either 300 µl
of chemically competent (CaCl2-treated) E. coli M15 (pREP4) cells (Appendix D) or
electroporated into electro-competent E. coli M15 (pREP4) cells (Appendix D) using a
BioRad Gene Pulsar and using the pre-set E. coli protocol at 2.5 kV. For chemical
transformations the tubes containing cells and vector were left on ice for 30 min and then
placed in a 37oC incubator for 5 min and subsequently centrifuged at 14,000 rpm on a
bench-top microcentrifuge (Biofuge Pico, Heraeus) for 1 min. The supernatant was
discarded and the pellet resuspended in 0.5 ml of LB broth. The tubes were then
incubated at 37oC for 1 h with shaking at 150 rpm (Certomat® R, B-Braun). The cells
were then plated on appropriate selective medium (LB with 25 µg/ml kanamycin and 100
µg/ml ampicillin) and incubated overnight at 37oC. The electroporated cells were added to
1ml of LB media and incubated at 37oC with shaking at 250 rpm for 1 h. The cells were
then plated onto appropriate selective media and incubated overnight at 37oC.

2.2.5 DNA sequence analysis of M. hyopneumoniae genes
The

primers

pQEF

(5’-CGGATAACAATTTCACACAG-3’)

and

pQER

(5’-

GTTCTGAGGTCATTACTGG-3’) (Sigma-Genosys) were used to sequence M.
hyopneumoniae genes inserted into the pQE-9 vector. Two PCR sequencing reaction
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mixes containing 5 µl MilliQ water, 5 µl purified pQE-9 clone DNA, 8 µl DTCS
Quickstart Master Mix (Beckman Coulter) and 3 µl pQEF or pQER primer (3.2 pmol/µl;
Sigma-Genosys) were prepared. The cycle sequencing protocol for the reactions was as
follows 96oC, 20 sec; 50oC, 20 sec; 60oC, 4 min (30 cycles) (FTS-960 Thermal
Sequencer, Corbett Research). Sequencing reactions were stopped by addition of 5 µl of
stop solution premix (Appendix A). Then, 60 µl of cold 95% (v/v) ethanol was added to
the reaction mix which was centrifuged immediately at 14,000 rpm (Biofuge Pico,
Heraeus) for 15 min at 4oC. The supernatant was removed and the pellet rinsed twice
with 200 µl of 70% (v/v) ethanol, followed by centrifugation at 14,000 rpm for 5 min at
4oC.

The pellets were resuspended in 40 µl of sample loading solution (Beckman

Coulter) and the samples analysed using a CEQ8000 Genetic Analyser (Beckman
Coulter).

2.2.6

Plasmid mini-preparations

Transformants were screened through small-scale plasmid preparations using a
FlexiPrep™ Kit (Amersham Pharmacia Biotech). The method was as follows: a 3 ml
overnight E. coli culture was transferred into a microcentrifuge tube and centrifuged at
13,000 rpm (Biofuge Pico, Heraeus) for 30 sec to pellet the cells. The supernatant was
removed and the pellet resuspended in 200 µl of Solution I by vigorous vortexing. 200 µl
of Solution II was added (mixed by inversion) followed by 200 µl of Solution III (mixed
by inversion). The tube was centrifuged at 13,000 rpm (Biofuge Pico, Heraeus) for 5 min
and the supernatant removed. 420 µl of isopropanol (0.7 volume) was added to the
supernatant which was then vortexed and incubated for 10 min at RT. The sample was
centrifuged at 13,000 rpm for 10 min to pellet plasmid DNA, after which 150 µl of
Sephaglas FP slurry was added to the pellet, vortexed gently for 1 min and centrifuged at
35

13,000 rpm for 15 sec. The Sephaglas pellet was washed with 200 µl of Wash Buffer and
centrifuged at 13,000 rpm for 15 sec (Biofuge Pico, Heraeus). A 300 µl aliquot of 70%
ethanol was added to the pellet to resuspend it before centrifugation at 13,000 rpm for 15
sec. The supernatant was removed and the tube vortexed to disperse the pellet before airdrying for 10 min. Then, 50µl of sterile MilliQ water was added to the pellet to elute
bound DNA, the tube vortexed and incubated for 10-30 min at RT (vortexing
occasionally). Tubes were centrifuged at 13,000 rpm for 1 min and the supernatant
transferred to a clean microcentrifuge tube. Plasmid preparations were analyzed using
agarose gel electrophoresis and restriction enzyme analysis was performed which was
subsequently analysed by agarose gel electrophoresis.

2.2.7

Plasmid DNA Extraction - Midi/Maxi Preparation

A culture of E. coli JM109 (pQE-9) was harvested and the plasmid extracted using a
Midi/Maxi Prep Kit (Qiagen) as described below. Recombinant plasmids from positive
clones were also extracted using this method. A 400 ml overnight culture was centrifuged
at 6,000 g for 15 min in a Sorvall RC5C Plus centrifuge and the supernatant discarded.
Kit buffers P1, P2, P3, QBT, QC and QF are shown in Appendix A. The bacterial pellet
was resuspended in Buffer P1 (10 ml). Buffer P2 was added (10 ml), mixed gently by
inversion and incubated at RT for 5 min. Buffer P3 (10 ml) was added and the solutions
mixed immediately and incubated on ice for 20 min. The solution was centrifuged at
20,000 g (Sorvall RC5C Plus centrifuge) for 30 min and the supernatant promptly
removed.

The supernatant was then applied to a QIAGEN-tip 100 that had been

equilibrated in Buffer QBT (10 ml). The column was washed with Buffer QC (35 ml)
and DNA eluted with Buffer QF (14 ml). The DNA was precipitated with 0.7 volumes of
isopropanol and pelleted by centrifugation at 15,000 g (Sorvall RC-5C Plus centrifuge)
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for 30 min. The supernatant was removed and the plasmid DNA washed with 3 ml of
70% ethanol, centrifuged at 15,000 g (Sorvall RC-5C Plus centrifuge) for 10 min and the
pellet allowed to air dry. The pellet was resuspended in 250 µL of TE Buffer. The
resulting DNA was analysed by agarose gel electrophoresis.

2.3

Protein expression

100

ml

E.

coli

cultures

containing

the

pQE-9-based

isopropyl-β-D-

thiogalactopyranosidase (IPTG) inducible plasmids were grown to an optical density at
600 nm of 0.6 (measured with an Ultrospec 3300 Pro, Amersham) and induced with 0.11.0 mM IPTG (Roche) final concentration. 1 ml SDS-PAGE samples were taken at preinduction, 1 h, 2 h, 4 h and overnight post-induction and centrifuged at 13,000 rpm
(Biofuge Pico, Heraeus) for 2 min. Cell pellets were stored at –20oC. These samples were
analysed to determine the optimum IPTG concentration and induction times. Larger scale
cultures (500-2000 ml, inoculated with a 5% starter culture) were then grown and induced
for the optimal times.

2.4

Protein purification under denaturing conditions

After the cultures were induced for the optimal time the cells were harvested by
centrifugation at 4,000 g and at 4oC for 30 min (Sorvall RC5C Plus centrifuge). The
pellet from a 250 ml culture was resuspended in 20-30 ml of urea buffer B (Appendix A)
and rocked on ice for 30 min until cell lysis was complete. The lysate was centrifuged at
10,000 g for 30 min (Sorvall RC5C Plus centrifuge). The cleared lysate was removed and
10 ml of 50% Ni-NTA superflow resin (Qiagen) was added and the tube rocked at RT for
1 h. The lysate-resin mixture was loaded onto an empty column and the flow-through
discarded. The columns were washed with 100 ml of urea buffer C (Appendix A), and
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bound 6x His-tagged protein was eluted from the columns with 4 x 5 ml of urea buffer D
(Appendix A) and 4 x 5 ml of urea buffer E (Appendix A). These volumes were altered to
scale depending on the culture size. A 25 mm YM10 ultrafiltration membrane (Millipore)
was equilibrated in MilliQ water. An ultrafiltration cell (Amicon) was assembled, and
purified protein in urea buffer was ultrafiltered with sterile PBS to ensure removal of the
urea from the sample and replacement with PBS and the initial volume was reduced to
concentrate the protein samples.

2.5

Bradford assay to calculate protein concentration

Protein standards were made by dissolving BSA in sample buffer to give concentrations
ranging from 0.2-1.0 mg/ml. Samples were routinely diluted 1:2, 1:5 and 1:10 in sample
buffer to a final volume of 30 µl. A total volume of 20 µl of each standard and diluted
sample were mixed with 1 ml of Bradford reagent (Appendix A) in a plastic cuvette.
Cuvettes were incubated for 5 min at RT. The OD at a wavelength of 600 nm was
determined for each standard and sample using an Ultraspec 3300 Pro spectrophotometer
(Amersham Pharmacia). The spectrophotometer was set to generate a regression line and
if that was linear then the OD measurement and concentration were determined for the
test samples.

2.6

Generation of polyclonal antiserum in rabbits

A New Zealand White rabbit was injected subcutaneously with a mixture of purified
protein in PBS and Freund’s incomplete adjuvant (Sigma-Aldrich) with a total injection
volume of 500 µl. Prior to immunisation, a sample of blood was taken and the serum
collected, representing the pre-immune serum. A 500 µl booster injection was given
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subcutaneously after 14-21 days. Marginal ear vein test bleeds were taken at 2 weeks
post-immunisation, and blood left to clot overnight at 4oC. Clear serum was collected in
microcentrifuge tubes and the remaining clot separated into quarters and centrifuged at
2,300 rpm (Beckman GS-6 centrifuge) for 10 min at RT. The red serum was collected in
microcentrifuge tubes, and all tubes centrifuged at 5,300 rpm (Biofuge pico, Heraeus) for
5 min to pellet red blood cells. Antiserum was collected in fresh sterile microcentrifuge
tubes and stored at –20oC.

2.7

One-Dimensional protein gel electrophoresis (SDS-PAGE)

Whole-cell extracts of bacterial cells and expressed proteins in PBS or PBS with 0.1%
SDS were reduced in SDS-PAGE reducing solution (Appendix A) and boiled for 5 min.
Proteins in urea buffer were combined with 5 µl of bromophenol blue loading dye
(Appendix A) for every 25 µl of sample. Samples were loaded onto 12-15% acrylamide
resolving gels (Appendix A) and electrophoresed with SDS-PAGE running buffer
(Appendix A) in a Hoefer Scientific Mighty Small II electrophoresis unit at 20-30 mA
(maximum voltage) for at least 1 h using the method described by Laemmli (1970). The
stacking gel was discarded and the resolving gel stained in Gel Code Blue (Progen) or
Coomassie (Appendix A) for at least 1 h, and de-stained with washes in MilliQ water or
Coomassie de-stain solution (Appendix A).

2.8

Mass spectrometry analysis of proteins

SDS-PAGE gels were run as previously described and stained with colloidal Coomassie
(Appendix A). The resulting protein bands of interest were then excised from the gel
using a sterile scalpel blade and placed into 96-well V bottom trays (Greiner), analysed
by mass spectrophotometry (courtesy of APAF) and resulting peptide fragment sizes were
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analysed against the M. hyopneumoniae database for peptide matches. The method used is
as described in Djordjevic et al. (2004). Briefly, the gel pieces in the tray were washed
with 100 µl 50 mM ammonium bicarbonate-100% acetonitrile (60:40 v/v) by shaking at
RT for 1 h, the buffer was then removed and the gel pieces dried in a vacuum desiccator
for 90 min. Gel pieces were hydrated in 8 µl of 17 ng/µl sequencing-grade modified
trypsin (Promega) for 1 h at 4oC. Excess trypsin solution was removed, and the gel pieces
were immersed in 25 µl of 50 mM ammonium bicarbonate and incubated overnight at
37oC with gentle shaking. Eluted peptides were concentrated and desalted using C18 ZipTips (Millipore). The peptides were washed on a column with 10 µl of 5% formic acid.
The bound peptides were eluted from the Zip-Tip in 0.8 µl matrix solution (10 mg of α–
cyano-4-hydroxycinnamic acid [Sigma-Aldrich]/ml in 70% acetonitrile) directly onto the
target

plate.

Matrix-assisted

laser

desorption

ionization-time-of-flight

(mass

spectrometry) (MALDI-TOF [MS]) mass spectra were acquired using a Voyager DE-STR
apparatus (PerSeptive Biosystems). The instrument was equipped with 337 nm nitrogen
lasers and all spectra were obtained in reflectron-delayed extraction mode, averaging 256
laser shots per sample. Two-point internal calibration of spectra was performed on the
basis of the use of internal porcine trypsin autolysis peptides (842.5 and 2211.10 [M+H]+
ions). A list of monoisotopic peaks corresponding to the mass of generated tryptic
peptides was used to search a modified translated version of the M. hyopneumoniae
genome (Minion et al., 2004). Successful identification of proteins was made on the basis
of the number of matching peptide masses and the percentage of sequence coverage
afforded to those matches.

2.9

Western transfer and ligand/western blot

For specific and sensitive detection of proteins, western transfer and blotting techniques
were performed using the method described by Burnette (1981).
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Proteins were

transferred from the polyacrylamide gels onto a polyvinylidene difluoride membrane
(PVDF) in western transfer buffer (Appendix A) using a Hoefer Scientific TE Series
Transphor Electrophoresis Unit. The membrane was cut to the size of the gel and the gel
was western transferred onto the membrane at 268 mA and maximum volts for 1.5 h for
2-D gels and 20-30 V overnight for 1-D gels. After transfer the membrane was blocked
overnight (16 h) for 2-D gels and for 1 h for 1-D gels at RT in 5% w/v skim milk in trissaline, unless otherwise indicated. The blot was then incubated with ligand if needed for
1-1.5 h at RT with gentle agitation and then washed 3 x 10 min using 0.1% w/v skim milk
in tris-saline, unless otherwise indicated. The primary antibody was then added and
incubated for 1-1.5 h at RT with gentle agitation. The membrane was washed as above
and incubated with the secondary antibody for 1 h at RT with gentle agitation. After 3
final washes, the membrane was equilibrated in 100 mM Tris, pH 7.6 for 5 min and
developed in DAB (Appendix A) for up to 1 h. The membrane was rinsed in MilliQ water
and air dried. The resulting blot was scanned using a BioRad scanning densitometer (GS800).

2.10 ELISA
The basic protocol for an ELISA consisted of coating 100 µl total volume of proteins (510 µg/ml) overnight in carbonate coating buffer (Appendix A) onto wells of an ELISA
plate (Linbro/Titretek; ICN Biochemicals). The plates were washed five times in an
automated plate washer (SLT Lab instruments) with 0.05% v/v Tween20 in PBS (200 µl
per well) patted dry and then blocked for 1 h by addition of 100 µl per well blocking
solution (2% w/v skim milk in PBS). The plates were stored in the humidifying chamber
at RT for 1 h. The plates were washed again as above and the ligands (if necessary, e.g.
fibronectin, heparin, fibrinogen, laminin) were added to appropriate wells at varying
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concentrations. Dilutions of the ligands were made in 1% w/v skim milk in PBS to
generate varying concentrations. The plates were then incubated for 1.5 h in the
humidifying chamber at RT. The plates were washed as above and 100 µl of primary
antibody was added to the appropriate wells diluted in 1% w/v skim milk in PBS. The
plates were incubated in the humidifying chamber at RT for 1.5 h. After this time the
plates were washed as above and secondary antibody was added to the appropriate wells.
The plates were incubated for 1 h in the humidifying chamber, then washed and
developed by the addition of ABTS substrate (Appendix A). The substrate was added to
each well (100 µl) and the plates were left shaking on an ELISA plate shaker (Heidolph
Titramax 1000) and the absorbance values read at 414 nm after various time periods up to
1 h using a Multiskan Ascent ELISA plate reader (Thermo Labsystems). Controls were
included throughout this assay to ensure that there was no false positive reactivity due to
components of the detection system binding non-specifically to the ELISA plate. Controls
ensuring the proteins were binding adequately to the plate were also included.
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Chapter 3: P159 is an immunogenic surface antigen of
M. hyopneumoniae that is proteolytically processed

3.1

Introduction

Current commercial vaccines against M. hyopneumoniae are limited in their
effectiveness; they do not protect against colonization of the organism and herds are
breaking with the disease. Since adherence to epithelial surfaces is the initial event in
colonization and disease, a better understanding of the adherence mechanisms of M.
hyopneumoniae will improve our chances of developing more effective vaccines.

Little is known concerning the adherence mechanisms of M. hyopneumoniae, but it is
clear that this species adheres only to the cilia of the respiratory epithelium and not to
other cells in the upper respiratory tract (Hsu and Minion, 1998b). This is in contrast to
other mycoplasmal species that adhere to various cell types, including epithelial and
tissue culture cells (Razin and Jacobs, 1992). Because of this binding specificity, in vitro
models have relied upon swine ciliated cells or purified swine cilia (DeBey and Ross,
1994; Zhang et al., 1994b; Zielinski and Ross, 1993). These studies led to the
identification of the ciliary adhesin P97. Although studies of this molecule represent an
important first step in our understanding of the adherence mechanisms of M.
hyopneumoniae, studies with other mycoplasmal pathogens indicate that adherence is a
complex process involving multiple gene products (Layh-Schmitt et al., 2000; Papazisi et
al., 2002). Adhesins of other mycoplasma species are found within multigene operons
(Inamine et al., 1988; Reddy et al., 1995) and are present as multiple copies within the
chromosome (Baseggio et al., 1996; Dallo and Baseman, 1991; Su et al., 1988).
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Further analysis of the DNA sequences surrounding the p97 structural gene revealed an
operon composed of two ORFs, p97 and one coding for a 102.3-kDa protein designated
P102, the function of this protein is poorly understood. Further investigations into the
genome sequence of M. hyopneumoniae by Minion and colleagues (Minion et al., 2004)
identified several paralogs of the cilium adhesin p97 residing in two-gene operons mostly
with paralogs of p102 and Fig. 3.1 below shows the structure of these gene families
(Minion et al., 2004). One exception is a gene termed p159, which resides in a two gene
operon with a paralog of p97 (p216) but it has no significant homology to p102 (see
operon 1 in Fig. 3.1). As shown for the cilium adhesin P97 (Djordjevic et al., 2004), P159
also seems to undergo post-translational modification generating various sized products
ranging from 27 to 110 kDa. This protein is therefore the focus of the following chapter.
The post-translational modification of this protein, its localization in the M.
hyopneumoniae cell, the P159 protein expression differences between a pathogenic (232)
and a non-pathogenic (J) strain of M. hyopneumoniae and its ability to be recognised
during an immunogenic response using sera from pigs that have naturally been infected
with M. hyopneumoniae have been investigated.
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Fig. 3.1. Diagram of the p97/p102 gene families in M. hyopneumoniae 232 strain.
Number 4 is the p97/p102 operon and others show the p102 gene paralogs (P102*) in
conjunction with p97 gene paralogs. The diagram to the right shows their location in the
genome of M. hyopneumoniae strain 232. Adapted from Minion et al., 2004.
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Chapter 3: P159 is an immunogenic surface antigen of
M. hyopneumoniae that is proteolytically processed

3.2

Methods

3.2.1 Detection of transmembrane domains in protein P159

Programs available through the Expert Protein Analysis System (Expasy) website
(ca.expasy.org) were used to perform database searches and alignments. Sequences of
P159 from strains 232 (GenBank accession number AF279292) and J (GenBank
accession number AF279293) of M. hyopneumoniae were aligned using Eclustalw
mutiple sequence analysis. Trans-membrane regions of the M. hyopneumoniae P159
protein sequence were predicted using the TMpred program located on the European
Molecular Biology website (www.ch.embnet.org).

3.2.2

Proteomic analyses: 2-D gel electrophoresis

Two-dimensional gel electrophoresis (2-DGE) was carried out essentially as described by
Cordwell and colleagues (Cordwell et al., 1997). Dimension immobilized pH gradient
(IPG) strips (Amersham Biosciences) were prepared for focusing by submersion in 2DGE buffer (Appendix A) overnight. A M. hyopneumoniae bacterial pellet (strain 232)
prepared as in 2.1 was resuspended in 1 ml lysis buffer (Appendix A) for each 0.1 g of
bacterial pellet. The cells were disrupted with a Microson Ultrasonic sonicator (Misonix)
for 6 x 30 sec and centrifuged at 50,000 g for 2 h at 15°C in an ultracentrifuge TL 100
(TLA 100.3 rotor, Beckman). The supernatant and pellet were both stored at -80°C. A
total of 300-350 µg or 800 µg of M. hyopneumoniae protein extract was diluted with
sample buffer to a volume of 100 µl for application to the anodic end of each re-hydrated
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11 cm or 17 cm pH 3-10 first dimension IPG strip (BioRad), respectively, in an applicator
cup using a horizontal Multiphor electrophoresis apparatus (Amersham Pharmacia). The
IPG strip was then subjected to the electrophoresis protocol shown in Table 3.1 at 20oC.
Following electrophoresis the IPG strip was frozen at -80oC until electrophoresis in the
second dimension was performed. IPG strips were detergent exchanged, reduced, and
alkylated in equilibration buffer (Appendix A) for 20 min prior to loading the IPG strip
onto the top of a 8-18% 20cm by 20 cm polyacrylamide gel. Second-dimension
electrophoresis was carried out at 5oC using the electrophoretic conditions described in
Table 3.2 and using a Multiphor horizontal electrophoresis unit. Gels were fixed in 40%
methanol and 10% acetic acid for 1 h, then stained overnight in Sypro Ruby (Molecular
Probes). Images were acquired using a Molecular Imager Fx apparatus (Bio-Rad). Gels
were then stained in colloidal Coomassie (Appendix A). Selected proteins covering the
entire proteome were excised and subjected to mass-spectrometry analysis as described in
section 2.8.

Table 3.1. First dimension electrophoresis protocol for 11 cm or 17 cm IPG strips.
Phase

Volts

Current

Watts

1

150

1

5

Time (h)
11cm
17cm
0.01
0.01

2

150

1

5

0.5

0.5

3

300

1

5

0.01

0.01

4

300

1

5

5

6

5

3500

1

5

5

5

6

3500

1

5

10

37.40

20.52

48.92

Total
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Table 3.2. Second dimension electrophoresis protocol.
Phase

Volts

Current

Watts

Time (h)

1

200

10

30

1.20

2

200

10

30

0.15

3

600

30

30

4

3.2.3 N-terminal sequencing of P159 cleavage products
N-terminal Edman sequencing was performed as described previously (Nouwens et al.,
2000). The procedure was as follows; protein spots were excised from 2-D gels and the
protein eluted overnight in 100 µl of buffer containing 100 mM sodium acetate
(unbuffered), 0.1% SDS and 50 mM DTT at 37oC with shaking. The eluant was removed
and spotted onto a ProSorb Insert (PE Biosystems) membrane wetted with methanol. The
protein was washed twice with 200 µl 0.1% (v/v) trifluoroacetic acid and allowed to dry.
Edman sequencing was conducted on a Procise 494 protein sequencer (PE Biosystems)
for five residues per protein to obtain an N-terminal tag.

3.2.4 PCR amplification of the p159 gene of M. hyopneumoniae
Combinations of the various primers listed in Table 3.3 were used to PCR amplify
fragments of the p159 gene from M. hyopneumoniae strain 232 chromosomal DNA. The
template for the amplification of p159 sequences was Hyop 232p110 SDM c1 supplied by
Steven Geary (University of Connecticut). This pPCR2.1 TA plasmid (Invitrogen)
contained the entire open reading frame of p159 which had all 9 mycoplasma tryptophanencoding TGA codons modified to TGG by site-directed mutagenesis. This mutagenised
pPCR2.1 plasmid was supplied in E. coli TOP10 cells and plasmid DNA was prepared
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using a QIAGEN MidiPrep. kit as described in 2.2.7 and the DNA used in these PCR’s.
P159Ff and P159Rd were combined to amplify P159 fragment 1 (minus the signal
peptide), P159Fb and P159Rb were combined to amplify P159 fragment 2, P159Fc and
P159Rc were combined to amplify P159 fragment 3, P159Fd and P159Ra were combined
to amplify P159 fragment 4, P159Ff and P159Ra were combined to amplify the whole
P159 gene (minus the signal peptide), P159Ff and P159Re were combined to amplify
P159 fragment 5 (N-terminal half of pP159 minus the signal peptide), P159Fe and
P159Ra were combined to amplify P159 fragment 6 (C-terminal half of pP159). SalI and
PstI restriction enzyme sites incorporated into the forward and reverse primers
respectively are underlined. An initial gradient PCR was setup to establish the optimal
PCR conditions for each primer pair, as described in 2.2.1. The established conditions are
listed in Table 3.4. The reaction mix was the same as outlined in section 2.2.1 although 4
µl dNTPs were used and 0.6µl Expand DNA Polymerase Enzyme (Boehringer
Mannheim) was used instead of Taq.

For electrophoresis of PCR products, 1% agarose (w/v) gels were used as described in
section 2.2.2. GeneRuler™ 100 bp DNA Ladder Plus (1.5 µg, Progen) or Hyper I DNA
ladder (Bioline) were added for sizing the resolved fragments.
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Table 3.3. Primer sequences used to amplify various fragments of the p159 gene. The
incorporated restriction enzyme sites are underlined.
Primer name

Sequence 5'-3'

P159Fa

GGGTCGACATGAAGAAACAAATTCGCAAC

P159Fb

GGGTCGACCAAACAAGTCAAAGCTCAGAA

P159Fc

GGGTCGACAAGACCTCAGAGGCAAGTAAT

P159Fd

GGGTCGACCACAAAATAACAACTTTCCAA

P159Fe

GGGTCGACTATAAATTAGAATTTGATCTT

P159Ff

GGGTCGACAATTCAGCGCTTAGATCC

P159Ra

GGCTGCAGTCAATATTGATCCATAAAGGC

P159Rb

GGCTGCAGTCATGGTGCTGTCTCTGGTGA

P159Rc

GGCTGCAGTCAATCTTTTTCTTGGTCATG

P159Rd

GGCTGCAGTCACCCTTTTTGATCTGTTGA

P159Re

GGCTGCAGTCATATTTGTCCGGCGTCAAT

Table 3.4. Reaction conditions of the various P159 primer combinations.
Primer pair

Amplified product

Reaction conditions x30 a

P159Ff +
P159 fragment 1 - 699bp
92oC 30 sec, 60oC 30 sec, 68oC 2.5 min
P159Rd
P159Fb +
P159 fragment 2 - 764bp
92oC 15 sec, 65oC 30 sec, 68oC 2 min
P159Rb
P159Fc +
P159 fragment 3 - 1052bp
92oC 15 sec, 65oC 30 sec, 68oC 2 min
P159Rc
P159Fd +
P159 fragment 4 - 1340bp
92oC 15 sec, 60oC 30 sec, 68oC 2 min
P159Ra
P159Ff +
Whole P159 – 4125 bp
92oC 15 sec, 65oC 30 sec, 68oC 4 min
P159Ra
P159Ff +
P159 fragment 5 – 2043 bp 92oC 15 sec, 60oC 30 sec, 68oC 2.5 min
P159Re
P159Fe +
P159 fragment 6 – 2244 bp 92oC 15 sec, 57oC 30 sec, 68oC 2.5 min
P159Ra
a
Note: Each PCR cycle began with an initial denaturation step at 92oC for 4 min followed
at the end by a final extension at 68oC for 7 min.
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3.2.5 Construction of a pQE9-based expression plasmid system for M.
hyopneumoniae P159 proteins

3.2.5.1 Cloning into pPCR-Script plasmid
The PCR products for P159 fragments 1-4 obtained in 3.2.4 were cloned into the pPCRScript Amp SK (+) Cloning Vector using pPCR-Script Cloning Kit (Stratgene). The PCR
products were purified and polished to ensure blunt-ended products using the StrataPrep
PCR Purification Kit available in the pPCR-Script Cloning Kit. A ligation reaction
consisting of 4 µl of the blunt-ended PCR product, 1 µl 10X Reaction Buffer, 1 µl pPCRScript Amp SK (+) cloning vector (10 ng/µl), 0.5 µl of 10 mM rATP, 1 µl of SrfI
restriction enzyme (5 U/µl), 1 µl T4 DNA Ligase (4 U/µl) and 1.5 µl sterile MilliQ water
was incubated at RT (25oC) for 1 h. The ligation reaction was then heated for 10 min at
65oC and stored on ice until ready for transformation or stored long term at -20oC. An
aliquot of 40 µl of XL10-Gold Kan ultra-competent cells was incubated with 1.6 µl of the
XL10-Gold ß-mercaptoethanol mix provided with the kit for 10 min on ice to ensure
highest transformation efficiency. Then 2 µl of each ligation mix was added directly to
the cells, mixed gently and incubated on ice for 30 min. The reaction was heat shocked at
42oC for 30 sec then placed on ice for 2 min. Then 450 µl of NZY+ media (Appendix A)
was added to the reactions and incubated at 37oC for 1 h shaking at 250 rpm, before
plating on appropriate selective media and incubated at 37oC overnight. Resulting white
colonies containing recombinant plasmids were screened for the PCR product insert using
a Flexiprep Kit (Amersham Biosciences) as described in section 2.2.6. DNA samples
were digested overnight at 37oC using PstI and SalI according to the manufacturer's
instructions and analysed by agarose gel electrophoresis as described previously.
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3.2.5.2 Cloning into pQE9 plasmid
A 400 ml culture of E. coli JM109 (containing the pQE9 plasmid) was harvested and
extracted using a Maxi Prep Kit (Qiagen) exactly as described in section 2.2.7. The P159
fragments now cloned into pPCR-Script (section 3.2.5.1), and the pQE9 plasmid were
digested overnight at 37oC on a dry block heater (Thermoline) with restriction enzymes
PstI and SalI according to the manufacturers instructions. The enzymes in the digestions
were then heat-inactivated by heating at 80oC for 20 min before ligation. The P159
fragments in pPCR-Script were cloned into pQE9 by incubating overnight digestions of
each in different ratios (1:1, 5:3, 3:1) as described in section 2.2.4. The ligations were
then electroporated into E. coli M15 (containing the plasmid pREP4) cells (Appendix D)
using a BioRad Gene Pulser as described in 2.2.4. The electroporated cells were then
placed into 1 ml of LB media and incubated at 37oC shaking at 250 rpm for 1 h
(Certomat® R, B-Braun). The cultures were than plated on appropriate selective media
and incubated overnight at 37oC. Recombinant plasmids were screened through colony
blotting, for large screening.

3.2.5.3 Colony blotting for screening of recombinants
The PCR method was followed exactly as stated in section 3.2.4 with the following
modification to produce DIG-labeled P159 fragments 1-4 only. The PCR DIG-labeling
mix contained 2.0 mM each of dCTP, dGTP and dATP, along with 1.9 mM of dTTP and
0.1 mM DIG-dUTP (Roche). After the PCR, the DIG-labeled products were passed
through a QIAquick PCR column to remove unincorporated PCR reagents, using the
protocol supplied with the QIAquick PCR purification kit (Qiagen). Colonies from the
transformation of 3.2.5.2 were picked and patched onto a nitrocellulose membrane
(Hybond N+) placed onto an LB agar plate (plus 100 µg/ml ampicillin and 25 µg/ml
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kanamycin) and incubated overnight at 37oC. The colonies on the nitrocellulose were then
lysed by treatment in denaturation solution (Appendix A) for 30 min, neutralisation
solution (Appendix A) for 30 min, followed by 2X SSC (Appendix A) for 20 min. The
membranes were then left to air dry and the DNA was bound to the nitrocellulose by
baking at 80oC for 30 min. The membranes were then subjected to proteinase K treatment
by adding a 2 mg/ml solution of Proteinase K to each membrane and incubating at 37oC
for 1 h. The hybridization method used reagents from the Roche DIG wash and block
buffer set. The membranes were placed in a hybridisation bottle with EasyHyb solution
(Roche) and pre-hybridised at 58oC for 2 h in a Hybaid hybridisation oven. The probe
(QIAquick cleaned up DIG-labeled PCR product from above) was denatured by heating
to 100oC for 10 min. The pre-hybridisation solution was then replaced with hybridisation
solution (5 µl denatured probe in 25 ml EasyHyb solution). Hybridisation was carried out
at 65oC for 1.5 h and then at 42oC overnight with the same solution. The next day the
hybridisation solution was removed and stored at -20oC for possible re-use. The
membranes were washed 2 x 15 min at RT (25oC) with 2X SSC/0.1% SDS and then 2 x
15 min at 68oC with 0.5X SSC/0.1% SDS. The membranes were equilibrated for 1 min at
RT with wash buffer (2X SSC/0.1% SDS) after which they were blocked with blocking
solution (made up in 1X maleic acid, from kit) at RT for 80 min. The anti-DIG-AP
(antibody; 1:10,000 dilution, Roche) was added to the membranes and incubated at RT
for 30 min. The membranes were finally washed at RT for 2 x 15 min with wash buffer
before transferring to a plastic bag for detection. Detection buffer (5 ml; Roche) was
added to the membranes and then 50 µl CSPD chemiluminescent substrate [Disodium 3(4-metho xyspiro {1,2-dioxetane-3,2-(5-chloro)tricyclo [3.3.1.13,7]decan}-4-yl)phenyl
phosphate] was added and the membranes kept in the dark. The bag was sealed and
placed in an x-ray cassette against autoradiography film (Hyperfilm MP) in the dark.
Exposure was carried out for varying times from 5 min to 2 h to obtain the most
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information from the blot. Each film was then developed with Kodak developer for 2-5
min, placed in water (stop solution) for 1 min and fixed (Kodak fixer) for 2-3 min.
Recombinant plasmids that hybridised to the DIG-labelled probes were then screened to
confirm the presence of the p159 fragment insert using the Flexiprep. Kit (Amersham
Biosciences) as described in 2.2.6 for plasmid DNA extraction, followed by digestion
overnight and analysis by agarose gel electrophoresis. A 100 ml culture of E. coli M15
(pREP4 pQE9) was harvested and extracted using a Midi Prep Kit (Qiagen) essentially as
described in 2.2.7.

3.2.5.4 DNA sequencing of the M. hyopneumoniae p159 fragment gene inserts
The

primers

pQEF

(5’-CGGATAACAATTTCACACAG-3’)

and

pQER

(5’-

GTTCTGAGGTCATTACTGG-3’) were used to sequence the M. hyopneumoniae P159
fragment gene inserts in the pQE9 vector as described in 2.2.5.

3.2.6 Expression of P159 protein fragments
A 200 ml culture containing each E. coli M15 (pREP4 pQE9) was grown to an optical
density at 600nm of 0.6 and induced with 0.1 mM IPTG final concentration. Based on
the samples from the test induction (see 2.3), the cultures were left for 1 h, 2 h or 4 h and
then centrifuged at 6,000 rpm at 4oC for 30 min (Sorvall RC5C Plus) and stored at –20oC
overnight. Purification was carried out as described in section 2.4. Whole-cell extracts of
E. coli M15 (pREP4 pQE9) were prepared by resuspending cells in SDS-PAGE cracking
buffer (Appendix A) and boiling for 5 min. 5 µl of bromophenol blue loading dye
(Appendix A) was combined with 25 µl of eluted P159 protein fragments from the
purification. Samples were loaded onto either 10% or 12% acrylamide resolving gels
(Appendix A) and electrophoresed with SDS-PAGE Running Buffer as outlined in 2.7.
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Mass spectrometry was carried out on the purification products as shown in section 2.8 to
confirm the integrity of the cloning process. 10ml of purified P159 protein fragments
from section 3.2.6 were ultrafiltered with sterile PBS (see 2.4) to a final volume of
approximately 3 ml. P159 fragment 4 was unstable in PBS alone and therefore was
ultrafiltered with PBS containing 0.1% SDS.

3.2.7 Generation of polyclonal antiserum in rabbits
A New Zealand White rabbit was injected subcutaneously with each P159 protein
fragment in Freund’s incomplete adjuvant (Sigma-Aldrich) as described in 2.6. P159
proteins were loaded onto 12% acrylamide gels as outlined in 2.7 and western transferred
from the polyacrylamide gels onto a polyvinylidene difluoride membrane (PVDF) by
electrophoresis with western transfer buffer and blotted as in section 2.9. The membrane
was then incubated with primary antibody (pre-immune sera diluted 1:200, or anti-P159
fragments rabbit sera diluted 1:250-1:500. Sheep anti-rabbit HRP conjugated secondary
antibody (Silenus) was used at a dilution of 1:1000.

3.2.8 Growth time-course assay for detecting P159 expression
This assay was conducted to see the expression levels of P159 during the entire growth
cycle of M. hyopneumoniae by taking whole cell samples of a culture during the entire
growth cycle and immunoblotting the protein profiles with antisera for the proteins to be
detected. Numerous tubes with 6 ml of M. hyopneumoniae medium were inoculated with
a viable culture of M. hyopneumoniae strain J and another with strain 232. These tubes
were then left slowly rolling at 37oC. Over various times up until 72 h post-inoculation
the tubes were removed, the optical densities of each sample were determined at 560 nm
using an Ultraspec 3300 Pro spectrophotometer (Amersham Pharmacia) and then the
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samples were centrifuged at 13,000 rpm (Biofuge Pico, Heraeus) for 6 min. The pellets
were washed twice with PBS and then resuspended in 1 ml of PBS. These samples were
then separated using reducing 15% SDS-PAGE gels and subsequently western blotted as
described previously.

3.2.9 Determining cellular location of P159
3.2.9.1 Trypsin treatment of M. hyopneumoniae
Cells of M. hyopneumoniae strains 232 and J from 250 ml cultures were harvested by
centrifugation at 9,000 rpm (Sorvall, GSA rotor) for 30 min. The pellets were gently
washed in 50 ml PBS and re-centrifuged as above. The pellets were then gently
resuspended in 5 ml PBS and frozen until subjected to trypsin treatment. The OD of the
cells was determined so that a comparative number of cells were subjected to the
treatment. A total of 0.5 ml of cells for each strain was aliquoted into 10 separate
microcentrifuge tubes and warmed to 37oC in a dry block heater. Dilutions of trypsin
were prepared in PBS ranging from 0, 0.1, 0.5, 1.0, 3.0, 5.0, 10.0, 50 and 150 µg/ml and
were warmed to 37oC. A volume of 0.5 ml of pre-warmed trypsin was mixed with the
cells and incubated at 37oC for 15 min. Finally 100 µl of reducing solution was added to
the samples and they were boiled for 5 min before being subjected to reducing SDSPAGE as described in 2.7. The lane loadings were optimised for western analysis and
consisted of loading 17µl of the 232 strain samples and 25µl of the J strain samples onto
reducing 12% SDS-PAGE gels and western transfer onto PVDF at 20 V overnight. The
membranes were blocked in 5% skim milk and reacted with a pool of rabbit sera from the
four P159 recombinant fragments or rpL7/L12 antisera (see Chapter 5), all at 1:100 for
1.5 h. After subsequent washing the membranes were incubated with sheep anti-rabbit
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HRP-conjugated antibodies for 1 h. The membranes were equilibrated and developed in a
DAB solution.

3.2.9.2 Immuno-electron microscopy of intact M. hyopneumoniae
Immunogold labelling of whole M. hyopneumoniae cells was performed as follows:
Parlodion/carbon coated 300 mesh nickel grids (Pro. Sci. Tech.) were floated on drops of
a fresh M. hyopneumoniae (strain 232) suspension in a moist petridish for 2 min. The
grids were floated on drops of undiluted anti-P159 sera, pre-immune for control and postimmune for tests, and incubated at 37oC for 90 min. The grids were washed with
phosphate buffer (pH 6.8) 3 x 5 min and then floated on drops of protein A gold (15 nm,
BBInternational) diluted 1:50 for 45 min. The grids were washed with phosphate buffer
and distilled water and stained with 2% aqueous uranyl acetate (Merck). The grids were
blotted dry and examined under a Phillips 208 transmission electron microscope.

3.2.10 Triton X-114 extraction of M. hyopneumoniae for 2-DGE
A 250mL Mycoplasma sp. culture was prepared as outlined in 2.1. A triton solution of 1%
triton X-114 (Appendix A) was added at approximately 1 ml per 0.1 g of bacterial pellet.
The bacterial pellet was completely resuspended in the triton solution and then left
shaking overnight at 4°C. The samples were then centrifuged at 15,000 rpm (Biofuge
Pico, Heraeus) for 15 min at 4°C. The supernatant was removed and the pellet (insoluble
prep.) frozen at -20°C. The supernatant was heated at 37°C for 10 min on a dry cell
heating block (Thermoline) to induce condensation of TX-114 then centrifuged at 13,000
rpm (Biofuge Pico, Heraeus) for 5 min at RT. After this centrifugation two phases are
produced; an aqueous (top) phase and a detergent (bottom) phase. The aqueous phase was
removed to a new microcentrifuge tube upon which neat triton X-114 was added to give a
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1% solution (approximately 20 µl). The detergent phase had 1 ml of the 1% triton
solution added. Both microcentrifuge tubes were then left shaking at 37°C for at least 3 h.
The microcentrifuge tubes were then heated again at 37°C for 10 min on a dry cell
heating block (Thermoline) and centrifuged as stated above to generate the two phases.
The top aqueous phases from both tubes were pooled as were the bottom detergent phases
for both.

A 10X volume of cold 100% acetone was added to each preparation (aqueous and
detergent), mixed and then left at –20°C overnight. The tubes were then centrifuged at
13,000 rpm in a Sorvall SS-34 rotor at 4°C for 30 min. The supernatant was removed and
the centrifuge tubes containing the pellet were dried in a vacuum desiccator for
approximately 1 h or until completely dry and free of acetone.

The pellet of the aqueous phase was resuspended in SSS (standard solubilisation solution,
Appendix A) at a volume of approximately 1 ml per 0.25 g initial bacterial pellet weight.
The pellet of the detergent phase was resuspended in MSS (multiple surfactant solution,
Appendix A) at a volume half that of the aqueous phase sample (1 ml per 0.5 g initial
bacterial pellet weight). The tubes were left to stand at RT for 30 min to help resuspend
the pellets. The suspensions were aliquoted into microcentrifuge tubes and subjected to
sonication for Mycoplasma cell disruption for 4 x 90 sec cycles. After this the samples
were centrifuged at 13,000 rpm for 15 min at RT on a bench top microcentrifuge (Biofuge
Pico, Heraeus). The supernatant was transferred to a new microcentrifuge tube and the
pellet and supernatant were frozen at -80°C. These samples were subsequently analysed
by 2-DGE as outlined in 3.2.2. Duplicate gels were subjected to western transfer and
blotted with anti-P159 rabbit sera as outlined in section 2.9.
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3.2.11 Convalescent pig sera ELISA
This assay followed the method outlined in section 2.10 and was as follows: wells were
coated with 5 µg of recombinant P159 proteins in PBS or PBS with 0.1% SDS (from
section 3.2.6). A total of 16 different pig sera were chosen from a collection held at
EMAI. Sera from pigs that had been subjected for M. hyopneumoniae testing using the M.
hyopneumoniae ELISA diagnostic test used at EMAI were chosen. Pigs with various
ELISA ratios (which indicate a positive or negative reaction, Djordjevic et al., 1994),
ranging from 0-3 (negative), 5-10, 10-15 and 15 or above were used. These sera were
diluted 1:100 with 1% w/v skim milk in PBS after which 100 µl of each were added to the
wells of an ELISA plate. Goat anti-swine HRP conjugated antibody (Silenus) diluted
1:1000 in 1% w/v skim milk in PBS was then added to the ELISA plate. The plate was
then developed in ABTS, and readings taken over various times up to 1 h.
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Chapter 3: P159 is an immunogenic surface antigen of
M. hyopneumoniae that is proteolytically processed

3.3

Results

3.3.1 P159 possesses a transmembrane domain
The p159 gene contains 4230 nucleotides coding for a protein 1410 amino acids long with
a predicted molecular mass of 158.67 kDa and pI 8.50. A search of protein databases with
BlastP found no significant matches for P159, indicating that this is a novel protein.
Using the TMpred program (EMBnet website; www.ch.embnet.org/software/TMPRED_
form.html), a transmembrane domain was found at the N-terminus of P159 (Fig. 3.2) with
the sequence 9AIIVLAGLSFIGTAGVGLAV29. The scores for an inside (cytoplasmic) to
outside (luminal) and outside to inside transmembrane helix were 2150 and 2028,
respectively. These values are significantly higher than the statistically significant cut-off
value of 500, with an inside to outside helix being the preferred conformation. This data
suggests that the N-terminus of P159 is located inside the cell while the C-terminus is
exposed on the outside of the cell membrane in M. hyopneumoniae.

3.3.2 Proteomic analysis of P159 expression in M. hyopneumoniae
Initial proteomic analysis of M. hyopneumoniae strain 232 whole cell extracts identified
three protein spots (P27, P52 and P110) with apparent molecular masses of 27, 52 and
110 kDa (Fig. 3.3A) that represented different fragments of P159 spanning the entire
molecule (Fig. 3.3B; GenBank accession number AF279292). Fragments were identified
on the basis of molecular weight and peptide mass fingerprint. The N-terminal sequence
of P27 (MKKQIRN) mapped to amino acids 1 to 7 in the N terminus of P159. TMpred
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predicts that this N-terminus contains the transmembrane domain (amino acids 1-29); this
transmembrane domain is not cleaved during in vitro expression. The peptide matches of
P27 from MALDI-TOF (MS) covered amino acids 36-219 of the P159 sequence (Fig.
3.3B). N-terminal sequencing of P110 and P52 were unsuccessful (data not shown),
however, the peptide matches for P110 spanned amino acids 303-841 while the peptide
matches for P52 covered amino acids 978-1387 (Fig. 3.3B). Therefore a cleavage event
appears to have occurred between amino acids 220-302 and 842-977. P110 is the largest
P159 product found in the proteome of M. hyopneumoniae with an apparent molecular
weight of 110 kDa (based on the 2-DGE size markers). The peptide matches spanned an
area representing approximately 61 kDa of the P159 protein however, as the exact
cleavage site of P110 is unknown the product could be as large as 85 kDa. This indicates
that this protein may migrate aberrantly during SDS-PAGE. The full-length P159 product
is not seen in 2-D gels and perhaps it is not present in any significant amount in vivo.
Protein fragments will henceforth be referred to by their apparent molecular weights
(P27, P52 and P110) while the full-length molecule will be referred to as P159 (Fig.
3.3C).

3.3.3 Cloning and expression of different regions of P159 within E. coli
Upon analysis of the above data, which showed production of various P159 products by
M. hyopneumoniae, we set out to clone and over-express four fragments of P159 (Fig.
3.3C) representing the length of the p159 gene product (AF279292). Expression of large
AT rich genes in Escherichia coli has proven difficult in the past so the P110 fragment
was cloned in two halves (F2 and F3). Attempts to clone the entire p159 gene into E. coli
were unsuccessful; however, recombinant expression and Nickel-NTA agarose affinity
chromatography of the four P159 fragments was achieved (fragment 1 [F1], amino acids
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31-264; fragment 2 [F2], 265-519; fragment 3 [F3], 558-909; and fragment 4 [F4], 9581405). All clones generated in this study were DNA sequenced to confirm the integrity of
the constructs. Purified recombinant proteins were subjected to MALDI-TOF massspectrometry and their identities as P159 fragments confirmed (results not shown).

TMpred output for P159

Cut-off value indicating a trans-membrane domain (score of 500 or above)

Fig. 3.2. TMpred output for P159. The boxed area shows the potential trans-membrane
domain in P159, located at the N-terminus of the protein. This trans-membrane domain
scored 2150 and 2028 in TMpred, showing that it is a significant trans-membrane domain
as it scored well above the 500 cut-off value (broken line).
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Fig. 3.4A shows the expressed products of P159 F1-F4 as they resolve on a 15% reducing
SDS-PAGE gel. Clearly visible for F4 is the presence of two higher bands (circled), as
well as the expected (52 kDa) band. Mass-spectrometry analysis gave peptide matches
corresponding to F4 for the higher molecular weight bands indicating that these are
multimeric or modified forms of F4 (Fig. 3.4B).

Rabbit antisera raised against each recombinant purified P159 fragment was used to
investigate the post-translational cleavage pattern of P159 in M. hyopneumoniae. Western
blots were performed on purified F1-F4 and M. hyopneumoniae 232 whole cell extracts
(Fig. 3.5 panels A-D). Antisera raised against recombinant F1 (panel A, lane 2) weakly
recognizes a M. hyopneumoniae protein equivalent in size to native P27 (panel A, lane 1).
The size difference between F1 and this protein may be attributed to the 6x His-tag
contained within F1.

The antiserum raised against F2 and F3 reacted with a M.

hyopneumoniae protein equivalent in size to native P110. Additional lower molecular
weight bands (panel B and C, lane 1), including a strongly immunogenic band of 78 kDa
(P78), were also detected which may represent additional cleavage products of P159 not
identified in proteomic analyses. Anti-F4 sera reacted with a M. hyopneumoniae protein
equivalent in size to native P52 (panel D, lane 1).
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Fig. 3.4. (A) Recombinant P159 expression products as they resolve on a 15% reducing
SDS-PAGE gel. (B) Peptide matches from MALDI-TOF mass spectrometry of F4. The
sequence of F4 is highlighted in grey. The solid underlines represent matches for the
higher F4 bands (circled), dashed underlines represent matches for the lower F4 band
(asterix) and double underlines represent those that match both.

65

To determine if the P159 protein was expressed continuously during the growth cycle, a
series of samples from an in vitro grown culture of M. hyopneumoniae strain 232 were
taken at various time points and then reacted with a pool of anti-P159 rabbit sera from the
four recombinant fragments. The expression pattern of P159 during the growth cycle
from early log (8 h), through mid-log (16 to 28 h) and into the stationary phase (40 to 72
h) was analysed. P159 was shown to be expressed and always cleaved over the entire M.
hyopneumoniae strain 232 growth cycle (Fig. 3.5 panel E). P159 was also found to be
constitutively expressed and cleaved in a similar experiment with M. hyopneumoniae
strain J (results not shown).
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Fig. 3.5. Immunoblot analyses with anti-P159 sera. (A-D) contain a whole cell protein
extract of M. hyopneumoniae strain 232 (Lane 1, panels A-D) and a sample of purified
F1, F2, F3 and F4 (Lane 2, panels A-D respectively). After western transfer these samples
were reacted with each P159 rabbit serum: anti-F1, anti-F2, anti-F3 and anti-F4,
respectively. Highlighted with closed arrows are the recombinant F1-F4 bands, open
arrows represent the expected cleavage product in the M. hyopneumoniae whole cell
protein extract. Highlighted with an asterix (*) is the multimeric form of F4. (E)
Immunoblot patterns of M. hyopneumoniae strain 232 cultures harvested at different
times post-inoculation. The blot was reacted with a pool of the four anti-P159 rabbit sera.
Equivalent amounts of protein were loaded in each lane. Lanes 1-9 correspond to M.
hyopneumoniae growth times (in hours) of 8, 16, 24, 28, 32, 40, 48, 56 and 72.
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3.3.4 Cellular location of P159 fragments
Immunoblot analysis of M. hyopneumoniae strain 232 cells digested with increasing
concentrations of trypsin (0-150 µg/ml) was used to investigate the cellular location of
P159 cleavage fragments. Exposure of intact M. hyopneumoniae cells to trypsin
concentrations from 0.1 to 10 µg/ml showed a gradual loss of the high molecular weight
P159 cleavage fragments; all immunoreactive P159 protein fragments were lost at a
trypsin concentration of 50 µg/ml (Fig. 3.6A). This observation suggests that the P159
cleavage products are surface accessible. As a control, identical blots (Fig. 3.6B) were
reacted with antiserum raised against recombinant ribosomal protein L7/L12 (a known
cytoplasmically located protein of M. hyopneumoniae; see Chapter 5). These experiments
show that rpL7/L12 remained detectable with trypsin concentrations of up to 150 µg/ml,
indicating that the integrity of the cells was not significantly disrupted during digestion
with up to 150 µg/ml trypsin. Thus, digestion of the P159 fragments at low trypsin
concentration was attributed to surface accessibility.

To confirm the surface location of P159, immuno-gold labeling of intact M.
hyopneumoniae cells was conducted using antisera raised against F2 and F4 (Fig. 3.7
panel B and D) and pre-immune serum (Fig. 3.7 panel A and C). The abundance of gold
particles observed on the anti-F2 and anti-F4 treated cells, but not the cells treated with
pre-immune serum further supports the hypothesis that P159 fragments are surface
located on M. hyopneumoniae. Experiments with anti-F1 and anti-F3 serum were
inconclusive due to the considerably high cross-reactivity with the pre-immune serum
(results not shown).
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Fig. 3.6. Whole cell preparations of M. hyopneumoniae strain 232 subjected to trypsin
treatment. The concentrations of trypsin are 0, 0.1, 0.5, 1, 3, 5, 10, 50 and 150 µg/ml
(lanes 2-10). The trypsin treated cells were then subjected to immunoblot analyses with a
pool of anti-P159 rabbit sera (A) and anti-rpL7/L12 rabbit sera (B). Open arrow indicates
position of the rpL7/L12 protein.
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Fig. 3.7. Immunolocalization of P159 cleavage products on the surface of M.
hyopneumoniae strain 232. Cells were successively labeled with pre-immune rabbit
antiserum of F2 (A), rabbit anti-F2 serum (B), pre-immune rabbit antiserum of F4 (C),
and rabbit anti-F4 serum (D) and 15-nm-diameter gold-conjugated protein A and stained
with 2% aqueous uranyl acetate. Arrows indicate gold particles. Bars, 500 nm.
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3.3.5 Comparison of P159 from M. hyopneumoniae strains 232 and J
3.3.5.1 Sequence comparison
Fig. 3.8 shows the Eclustalw (ANGIS website: www.angis.org.au/html/index.html)
alignment of the P159 sequence from M. hyopneumoniae strains J (Genbank accession
AF279293) and 232 (GenBank accession AF279292). The two sequences were found to
be 95.7% identical with a total of 61 differences which included several
insertions/deletions and conserved and non-conserved amino acid substitutions. The
largest difference was a 12 amino acid deletion in strain 232 (or insertion in strain J)
between amino acids 870 and 882.

3.3.5.2 Comparison of P159 expression products
From 1-D western blots many of the P159 expression products are common to both the
pathogenic strain 232 and the non-pathogenic strain J of M. hyopneumoniae. There are
three highly expressed proteins present in both strains. The approximate sizes of these
proteins are 110, 78 and 52 kDa (P110, P78, P52). However, an immunoreactive protein
of approximately 38 kDa (P38) was found to be highly expressed in J strain and not in
232 (Fig. 3.9). This expression product was also detected when using anti-F3 serum alone
(results not shown) indicating it reacts with anti-F3 serum and may represent a protein
within the F3 region of P159. Expression of the N-terminal P27 protein was not readily
detected by the pooled antiserum.
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P159_J
MKKQIRNKAIIVLAGLSFIGITAGVGLAVQNSALRSSYLNQFKNDKSATELLSPINDTEL
P159_232 MKKQIRNKAIIVLAGLSFIGITAGVGLAVQNSALRSSYLNQFKNDKSATELLSPINDTEL
************************************************************
P159_J
SKIISNFSLKENWSKISAGQAFELHKNPLYAFKLTDAIDFSKIDKKFAHLFFNVQVNDNT
P159_232 SKIISNFSLKENWSKISAGQAFELHKNPLYAFKLTDAIDFSKIDKKFAHLFFNVQVNDNT
************************************************************
P159_J
KVEGNSIRNLTVFVFDAITKKEVATRAFHTSLSGFSSVAKEDFIENFVAESSTYELDKDQ
P159_232 KVEGNSIRNLTVFVFDAITKKEVATRAFHTSLSGFSSVAKEDFIENFVAESSTYELDKDQ
************************************************************
P159_J
LKKNFATEIVLPSAFSIKFQDVLLTHLRKTSPESFQETKTIQVRALTNSITEFQQQQQQE
P159_232 LKKNFATEIVLPSAFSIKFQDVLLTHLRKTSPESFQETKTIQVRALTNSITEFQQQQQ-E
********************************************************** *
P159_J
GGSGG---SGGSSGGSSSGSTDQTAQTSQSSEKESKSEKEKGKDQQSTQGSEQKQDQKQE
P159_232 GGSGGSGTSGGSSGGSSSGSTDQKGQTSQSSEKESKSEKEKGKDQQSTQGSEQKQDQKQQ
*****
*************** **********************************.
P159_J
KPKEAEKPAQEKSAQEKPAQEKPAEAPKVAAPVIEPVKKLVFENEKLNQALLETLKDFGG
P159_232 KPKEAEKPAQEK-----PAQEKPAETPKVKAPVIEPVKKLVFENEKLNQALLETLKDFGG
************
********.*** ******************************
P159_J
LKLLAASGLQGLLPNEYTLLPVSSDKSLIKLDIDDQAGTASIHLKLLDKNRKEKNLILPI
P159_232 LKLLAASGLQGLLPNEYTLLPVSSDKSLIKLDIDDQAGTASIHLKLLDKNKKEKNLILPI
**************************************************.*********
P159_J
NGLASIGEIKDKVFSQIFRNQNAYLTIRPQINEYLRKNPRKKIQEVIWSFSREKFDQLRG
P159_232 NGLASIGAIKDKVFSQIFRNQNAYLTIRPQINEYLRKNPRKKIQEVIWSFSREKFDQLRG
******* ****************************************************
P159_J
QNEVEKFLEELYKPSQTSQSPQKSKSSDSGKNNVATIQASPETPPKTPAPTTNSNTEQGS
P159_232 QNEVEKFLEELYNPTQTSQSPQKSKSSDSAKNNVATIQASPETAPKT--TTTNSNTQSSS
************ *.************** ************* ***
******. *
P159_J
TSTNNQSSNGAQQMASPQTESSHSTAKTSEASNSSNESSSETKATQEQANPETNPKTKSQ
P159_232 TSTNNQSSNGSQQMASPQTESSLSTAKTSEASNSSEESSSETKGTKEQANSETNPMGKSQ
**********.*********** ************ ******* *.**** **** ***
P159_J
AKPEAKPEEKPINLEDQAKTELKEILKIHGWNYRTLLKDQNQKVILPDNINFWFDLRNKR
P159_232 AKPEAKPEEKQINLEDQAKTELKEILKIHGWNYRTLLKDQNQKVILPDNINFWFDLRNKR
********** *************************************************
P159_J
SSYENYKLEFDLAKKTGQIQAGDVIDANKIRLNLKISPLANLKLEVDSKNKQYIDAGEIG
P159_232 SSYENYKLEFDLVKKTGQIQAGDVIDANKIRLNLKISPLANLKLEVDSKNKQYIDAGQIG
************ ********************************************.**
P159_J
DYVEFDKQGKKLVEQGKSLDLKVGAAAANSIFSSEIRYSAYELKGWTYPIDIDIKGNPIQ
P159_232 DYVEFDKQGKKLVEQGKSLDLKVGASAANSIFSPEIRYSAYELKGWTYPIDIDIKGNPIQ
*************************.******* **************************
P159_J
QELEKLVGNFHRVGINKNNQYQIYSTDIDKIFAQAKLDKYFELSQEEKQASKKYLQEKLN
P159_232 QELEKLVGNFHKVGINKNNQYQIYSTDIDKIFAQAKLDKYFELSQEEKQASKKYLQEKLN
***********.************************************************
P159_J
PISEITIVKLPPKEEVLPPLEEEKKPEQDEKPQEKQEDKQNQKPQEKQEDKQNQKQQEKQ
P159_232 PISEITIVKLPPKEEVLPPLEEEKKPEQD------------QKAQEKQEDKQNQKQQEKQ
*****************************
** ****************
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P159_J
EDKKEQDQQKHSQSPEQKTETQTQNQEKDKQTSSETSPSNTNESSGTQNTAQNSQTNQAN
P159_232 EDKKEQDQQKHSQSPDQKTETQTHDQEKDKQTSSETSPSNTNESSGTQNTAQNSQTNQAN
***************.*******. ***********************************
P159_J
SGQGQSQQAASSSASYQTHKITTFQDDQKDQTNEQTEKEIEPEKLAFGDYLVKYLDIFET
P159_232 SGQGQSQQAASSSTSYQTHKITTFQDDQKDQTNEQTEKEIEPEKLAFGDYLVKYLDIFET
*************.**********************************************
P159_J
FKVGPDQKLSLSRWYNTPQRTYNVIFRVLDKENIQVAASLFQLHGISATNIALEKSLRYA
P159_232 FKVGPDQKLSIGRWYNAPQRTYNVIFRVLDKENIQVAASLFQLHGISATNIALEKSLRYA
**********. ****.*******************************************
P159_J
PDIFLDGTSGLEYKQDTGDKPYLQGRQFVSAINSINNTKSSYRVHKLFDNLPLSEESSQG
P159_232 PDIFLDGTSGLEYKQDTGDKPYLQGRQFVSAINSINNTKSSYRVHKLFDNLPLSEESSQG
************************************************************
P159_J
LRLKSSLVYDYQKNDPYTFQASKEALRKTALTKGVLYLAFKPEQILGIKGSKTAPGRNYK
P159_232 LRLKSSLVYDYQKNDPYTFQASKEALRKTALTKGVLYLAFKPEQILGIKGSKTAPGRNYK
************************************************************
P159_J
LLSTTNVHFKSLYGLSNLELVKTKYQENLKLVWKLIGAKPVNDDKILPPQVADLPRHKST
P159_232 LLSTTNVHFKSLYGLSNLELVKTKYQENLKLVWKLIGAKPVNDDKILPPQVADLPRHRST
*********************************************************.**
P159_J
EIILLEDSKPGASSSPQTKENSQNKEAETFNLDIRQTKPNQIEPLEHYLGQTWLMEIRID
P159_232 EIILLEDSKPGASSSPQTKENSQNKEAETFNLDIRQTKPNQIEPLEHYLGQTWLMEIRID
************************************************************
P159_J
DESATITIIPEQQEREDSKLKVWKSEIKIKDKNKYQNQDTNWETELASVLGRGFDYGQIG
P159_232 DESATITIIPEQQEREDSKLKVWKSEIKIKDKNKYQNQDTNWETELASVLGRGFDYGQIG
************************************************************
P159_J
DTTPQASNPQDRVGMTFKGFAVFKGDKLLNDKARLNVRKAFMDQYFKNYS
P159_232 DTTPQASNPQDRVGMTFKGFAVFKGDKLLNDKARLNVRKAFMDQY----*********************************************

Fig. 3.8. Eclustalw alignment of the P159 protein sequence from M. hyopneumoniae
strains J and 232. An asterix (*) indicates where the two sequences are identical.
Insertions and deletions are highlighted in green, while conserved amino acid changes are
highlighted in blue and non-conserved in yellow. The various coloured lettering on the
232 strain sequence represents the peptide matches from mass-spectrometry of P27, P110
and P52.
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Fig. 3.9. Whole cell extracts of M. hyopneumoniae strains J and 232 after western blotting
with a pool of anti-P159 sera. The major expression products are highlighted with arrows.
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To further compare the cleavage pattern of P159 between M. hyopneumoniae strains 232
and J an aqueous phase protein preparation from a TX-114 extraction of each strain was
subjected to 2-DGE (Fig. 3.10). Duplicate gels were western transferred and reacted with
a pool of the anti-P159 sera generated from the four recombinant fragments. The protein
loadings are comparable between the two strains as shown in Fig. 3.10A. There are slight
differences in the expression of the P159 products between the two M. hyopneumoniae
strains and a protein appearing to correlate to the 38 kDa protein (it appears to resolve at
approximately 33 kDa) can be seen in both strains, however the size varies slightly
(smaller in strain 232) based on the comparative positions of these spots in the proteome.
This protein also appears to be more highly expressed in strain J based on the relative
intensities of this protein spot on the western blot. In the 2-D blot (Fig. 3.10B) expression
of P110 and the C-terminal P52 protein was detected, but due to the limitations of this
proteomic analysis and the high pI of the N-terminal cleavage product P27, this protein
was not visualised. The protein representing P78 (Fig. 3.5 and 3.9) appears to migrate at a
lower molecular weight during 2-DGE (approximately 70 kDa). Further work is needed
to confirm these spots are the same protein products.
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Fig. 3.10. P159 expression products of M. hyopneumoniae. (A) 2-D gel of M.
hyopneumoniae 232 and J strain separated by a molecular weight marker, highlighting the
P159 cleavage products corresponding to (B) which is a second identical 2D gel western
transferred and blotted with pooled anti-P159 sera generated from the four recombinant
fragments. Highlighted are those spots corresponding to the gel above. The first
dimension of both gels had a non-linear pH range of 3-10 and the second dimension was a
12.5% SDS-PAGE gel.
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3.3.6 P159 reacts with convalescent pig sera
An ELISA assay was conducted using convalescent pig serum attained from pigs in NSW
that had been subjected to the M. hyopneumoniae ELISA assay at EMAI in 2002. The pig
sera were separated into four groups based on their resulting ELISA ratios (indicates
reactivity to a M. hyopneumoniae specific antigen, Djordjevic et al., 1994). Negative
samples were those with an ELISA ratio below 3. Three more groups were analysed,
those with ratios between 5 and 10, 10 and 15, and 15 or above. Any sera between 3 and 5
are considered inconclusive and none of these sera were investigated. Table 3.5 shows the
optical density values obtained when each of the four P159 fragments were coated onto
ELISA plates and then incubated with the different pig sera. The pig sera showing
significant OD values above an arbitrary cut-off value of 0.2 are highlighted. There does
not appear to be a trend between the OD values obtained and the previous ELISA ratio
values.
Table 3.5. P159 reactivity with convalescent pig sera. Average OD values obtained when
F1-F4 were coated onto an ELISA plate and incubated with 16 different pig sera from
EMAI. Highlighted in grey are those with significant OD values (above 0.2).
Pig
Pig 1
Pig 2
Pig 3
Pig 4
Pig 5
Pig 6
Pig 7
Pig 8
Pig 9
Pig 10
Pig 11
Pig 12
Pig 13
Pig 14
Pig 15
Pig 16

M. hyopneumoniae
ELISA ratio
negative
negative
negative
5-10
5-10
5-10
5-10
10-15
10-15
10-15
10-15
≥15
≥15
≥15
≥15
≥15

OD values for
P159F1
0.075
0.161
0.140
0.136
0.133
0.271
0.336
0.095
0.146
1.950
0.231
0.103
0.065
0.071
0.447
0.130
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OD values for
P159F2
0.066
0.100
0.077
0.089
0.256
0.095
0.222
0.128
0.090
0.318
0.111
0.121
0.074
0.082
0.408
0.090

OD values for
P159F3
0.217
0.297
1.105
0.517
0.903
0.830
1.166
4.723
0.682
2.448
0.883
0.594
0.310
0.519
1.206
0.942

OD values for
P159F4
0.332
0.090
0.085
2.012
1.567
0.122
0.172
0.484
0.231
0.349
0.088
0.431
0.286
0.258
0.667
0.227

Chapter 3: P159 is an immunogenic surface antigen of
M. hyopneumoniae that is proteolytically processed

3.4 Discussion
Knowledge of the mechanism by which M. hyopneumoniae cells adhere to the porcine
respiratory tract is currently limited to the cilium adhesin P97. While studies on P97 have
demonstrated that it plays a vital role in adherence it has also been suggested that P97 is
not the only molecule involved in host cell attachment (Zhang et al., 1995). Genome
sequencing studies have identified several paralogs of P97 that are scattered at various
sites around the M. hyopneumoniae genome (Minion et al., 2004). One of these (p216) is
preceded by a novel gene identified here as p159, which together comprise a two-gene
operon. The observations that (i) adhesins of mycoplasmas are often found in multi-gene
operons, (ii) genes in operons often share common functions, and (iii) adherence in
mycoplasmas often involves several gene products acting in concert (Layh-Schmitt et al.,
2000; Papazisi et al., 2002), suggests that the product of the p159 gene may play a role in
adherence of M. hyopneumoniae to swine ciliated respiratory cells.

The p159 gene is predicted to encode a protein of 159 kDa (identified here as P159).
Computational analyses identified a putative N-terminal transmembrane domain within
P159 indicating that this protein may be membrane associated, secreted or on the surface
of M. hyopneumoniae. The predicted conformation suggests that the majority of the
protein is on the outside of the cell with the N-terminus of the protein anchoring it to the
membrane. This conformation would allow P159 to be involved in cellular interactions
such as adhesion or to be processed on the surface of the M. hyopneumoniae cell, possibly
by extracellular proteases. Trypsin digestion studies of whole M. hyopneumoniae cells
77

suggest that P159 is surface exposed. Concentrations of 50 µg/mL of trypsin or above
resulted in loss of all the P159 fragments; a pattern mimicking that of the cilium adhesin,
a molecule that is known to be surface expressed (Djordjevic et al., 2004). Immunogold
studies with F2 and F4 antisera also indicated that P159 is expressed on the surface of M.
hyopneumoniae.

Mycoplasmas are not known to contain components of the secretion apparatus (i.e. SecE,
SecG or SecF along with GroES and GroEL) described in many other bacteria (Burns,
1999; Fath and Kolter, 1993; Hueck, 1998; Sandkvist, 2001). However, the recently
sequenced genome of M. hyopneumoniae strain 232 (Minion et al., 2004) shows the
presence of genes encoding proteins analogous to SecA, SecY, SecD, DnaK/DnaJ, GrpE,
PrsA, LepB (signal peptidase I) and LepA. The presence of these genes suggests that a
potential pathway for the biogenesis of the P159 fragments is Sec-dependent translocation
of P159 then subsequent proteolytic processing of the mature P159 protein external to the
plasma membrane to create the various products. Alternatively, as the nascent protein
emerges from the translating ribosome, P159 may be recognised by the signal recognition
particle (SRP, Ffh) (Luirink and Dobberstein, 1994). SRP in prokaryotes binds the
nascent peptide and slows down or arrests protein synthesis, the SRP then targets the
arrested translational complex to the SRP receptor (FtsY) and eventually to the
translocation machinery. M. hyopneumoniae strain 232 contains Ffh and FtsY
homologues (Minion et al., 2004). Powers and Walter (1997) have found that Ffh and
FtsY of E. coli can function directly in protein targeting. Work by Valent and colleagues
(Valent et al., 1998) shows that while two distinct protein targeting pathways exist in E.
coli, once released from SRP, the targeted nascent protein then inserts into a minimum
translocon containing SecA, SecY and SecG. Thus, it would appear that the SRP and Sec
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targeting pathways converge at the same translocon in the membrane, thereby linking
these two pathways in prokaryotes (Valent et al., 1998).

Proteomic analyses indicated that P159 is cleaved at two distinct sites generating P27 (Nterminal region of P159), the central P110, and a C-terminal fragment P52. However,
subsequent immunoblotting studies detected the presence of a 78 kDa (P78) and a 38 kDa
(P38) product whose cleavage sites and sequence remain to be determined. P38 appears to
be more highly expressed in strain J based on 1-DGE and 2-DGE, however relative
protein concentrations need to be quantified before suggesting that there is a significant
difference between strains with respect to P38. This is the focus of future work. The
determination of the site within P159 that is cleaved to generate P110 and P52 is the focus
of current work. Initial N-terminal sequencing of P110 and P52 was unsuccessful.

Intact P159 is not present in significant quantities in M. hyopneumoniae cells in vitro and
expression of the N-terminal P27 fragment was not readily detected. However, the
cleavage products P52, P78 and P110 were found to be constitutively expressed
throughout the entire growth cycle of M. hyopneumoniae strains 232 and J. The fact that
these products are highly expressed during the entire growth cycle and consistently
cleaved suggests they may play an important role in this pathogen. M. hyopneumoniae
possesses a small genome and therefore limited gene set; cleavage of surface proteins
may allow such proteins to fulfil multiple functions. M. hyopneumoniae, like other
mycoplasmas, contain an unusually large number of lipoproteins (Minion et al., 2004),
with 8.5% of the entire genome coding for lipoproteins (compared to 1.93% for M.
gallisepticum and 5.79% for M. penetrans), but unlike other mycoplasmas these
lipoproteins have not been shown to undergo antigenic and/or size variation. It is possible
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that differential cleavage of surface exposed proteins in M. hyopneumoniae provides this
variation.

The post-translational cleavage of proteins in mycoplasmas has been reported for the
surface lipoprotein MALP-404 of M. fermentans (Davis and Wise, 2002) where MALP404 is cleaved to produce cell-bound MALP-2 and soluble released fragment (RF)
products. The authors suggest that the specific cleavage of some surface proteins may
confer efficient “secretion” of extracellular products by these organisms, with concurrent
changes in the surface phenotype (Davis and Wise, 2002). Post-translational cleavage has
also been reported in the assembly of a complex mycoplasma adhesin organelle (Krause,
1998; Popham et al., 1997). The attachment organelle of M. pneumoniae is a polar
structure that orients mycoplasma binding to host respiratory epithelium and functions in
cell division and gliding motility. The two accessory proteins B (P90) and C (P40) are
post-translational cleavage fragments of the ORF6 gene product, which is encoded by an
ORF of the P1 operon adjacent to the p1 gene (Inamine et al., 1988; Sperker et al., 1991).
These proteins act in concert with others in stabilising and forming the attachment
organelle of M. pneumoniae. Additionally, spontaneously arising mutants of M.
pneumoniae that fail to cytadhere have been found (Krause et al., 1982). The high
molecular weight proteins HMW1-3 are required for the stability and assembly of the
terminal organelle of M. pneumoniae (Krause and Balish, 2004). In class I mutants the
levels of HMW1 and HMW3 are greatly reduced and HMW2 is completely absent
(Popham et al., 1997). This results in the inability of the mutants to cluster the adhesin P1
at the attachment organelle. Loss of HMW1 and HMW3 occurs via post-translational
proteolytic processing and raises the possibility of a role for proteolysis in regulating
components of this attachment organelle in M. pneumoniae. Extensive post-translational
cleavage of the secreted M. hyopneumoniae P97 cilium adhesin has also been observed
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(Djordjevic et al., 2004) and these authors hypothesise that this event provides the
pathogen with a capacity to alter its surface architecture, thereby potentially playing an
important role in the disease process of M. hyopneumoniae. The post-translational
cleavage of P159 may also alter the surface architecture of M. hyopneumoniae and
therefore allow evasion of the host immune system or may have functional implications
for host-pathogen interactions.

An unknown feature of P159 proteolysis is the identity and specificity of the
corresponding protease. Analysis of the M. hyopneumoniae genome identifies five
proteins with aminopeptidase signatures (GenBank accession number AAV27465.1, Map;
AAV27896.1, PepA; AAV27937.1, PepF; AAV27669.1, PepP; and AAV28011.1, Gcp)
and a further two with serine protease signatures (GenBank accession numbers
AAV27500.1 and AAV27502.1). We hypothesise that one or more of these proteases
plays a role in processing of surface proteins such as P159 and the cilium adhesin P97 in
M. hyopneumoniae.

Recombinant poly-histidine fusion protein F4 displayed an ability to form multimers even
when solubilised in 8M urea and after being subjected to reducing SDS-PAGE analysis.
The formation of multimeric forms of proteins has not been previously observed in M.
hyopneumoniae but has been reported elsewhere. For example, Shigella flexineri protein
Wzz has been shown to form multimers of at least six units and the dimeric form is highly
stable even after heating at 100oC in the presence of SDS (Daniels and Morona, 1999).
The role of the multimeric form of F4 (equivalent to P52) is unknown. However, it is
becoming increasingly evident that the formation of bacterial aggregates is an important
step in colonization of some pathogenic bacteria. For example, M protein mediated
aggregation has been reported to contribute to adherence of Streptococcus pyogenes to
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some epithelial cell types (Caparon et al., 1991) and Bordetella pertussis has been shown
to grow in aggregates resulting from homophilic protein-protein interactions within the
lungs of infected mice (Menozzi et al., 1994). Staphylococcus aureus forms aggregates
through fibrinogen-binding surface proteins (McDevitt et al., 1994) and in its aggregated
state S. aureus has been suggested to be protected against phagocytosis (Kapral et al.,
1980). The multimerization of P159 via the F4 domain may allow bacterial aggregation
and thereby contribute to cell-cell adhesion. Another possibility is that the dimer of F4
may be the functional form of this molecule. F4 corresponds to the M. hyopneumoniae Cterminal cleavage product P52 and further study is required to determine whether this
protein forms dimers and the functional consequence of such dimerisation.

ELISA assays with convalescent sera from pigs that had naturally been infected with M.
hyopneumoniae demonstrate the immunogenic properties of P159. F1 reacted with 5/16
(31%) of convalescent pig sera, whereas F2 reacted with 4/16 (25%), F3 reacted with
16/16 (100%) and F4 reacted with 11/16 (69%). This data shows that the various cleavage
products have different immunogenic properties. F3, which represents the P110 cleavage
product, is highly immunogenic and reacted even with those sera showing negative
ELISA values in the M. hyopneumoniae ELISA and may be useful as a diagnostic tool.
These data suggest that F3 is more sensitive in detecting the exposure of a pig to M.
hyopneumoniae than the antigen currently in use in this diagnostic assay. The fact that
P159 is immunogenic means it may be a good target for vaccine development and as it is
surface exposed it is freely available as a target of the swine humoral immune response.
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Chapter 4: M. hyopneumoniae surface antigen P159 binds heparin and
promotes adhesion to and internalization of eukaryotic (PK15) cells

4.1

Introduction

The p159 gene resides in a two gene operon with a paralog of p97 (p216) but it has no
significant homology to p102, the second gene found in the two gene operon with p97. As
shown for the cilium adhesin P97 (Djordjevic et al., 2004), P159 also seems to undergo
post-translational modification generating various sized products ranging from 27 to 110
kDa. The cleavage and expression pattern appears to vary between the pathogenic strain
232 and the non-pathogenic J strain and at least parts of this molecule are found to be
expressed on the surface of M. hyopneumoniae, as presented in Chapter 3. It is thought
that adherence in M. hyopneumoniae is multi-factorial involving other adhesins, possibly
working in combination with the cilium adhesin P97. This idea evolved from the work of
Zhang and colleagues (Zhang et al., 1995) who showed that MAbs F1B6 and F2G5,
which recognise P97 in immunoblots, reduce adherence (in vitro) to purified cilia and to
ciliated cells by only 67%. These authors proposed the idea that other molecules must be
involved in adherence.

Recent studies on pathogenic mechanisms of bacteria have focused on the ability of
bacteria to bind to components of the extracellular matrix (ECM) as a mechanism to
adhere to host cells and tissue. Zhang and colleagues had also shown that
glycosaminoglycans and ECM components, namely dextran sulfate, heparin, chondroitin
sulfate, laminin, mucin and fucoidan inhibit the binding of M. hyopneumoniae to tracheal
cilia (Zhang et al., 1994b). The P159 antigen was therefore screened for its ability to bind
to a range of ECM components and glycosaminoglycans, namely fibronectin, laminin,
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fibrinogen, type IV collagen, keratin and heparin. Finally, the ability of this protein to
adhere to a porcine epithelial-like cell line was investigated.
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Chapter 4: M. hyopneumoniae surface antigen P159 binds heparin and
promotes adhesion to and internalization of eukaryotic (PK15) cells

4.2

Methods

4.2.1 Ligand blots
Samples of purified recombinant P159 proteins (generated in Chapter 3) were equally
loaded onto multiple 15% SDS-PAGE gels and western transferred onto PVDF at 20 V
overnight as described in 2.9. Blots were subjected to western blotting as described in
section 2.9, incubating with human fibronectin (40 µg/ml), laminin (30 µg/ml), human
fibrinogen (50 µg/ml), chondroitin sulphate A (40 µg/ml) and biotinylated heparin (10
µg/ml). The membranes were then incubated with the appropriate primary antibody: antifibronectin at 1:500, anti-laminin at 1:500, anti-fibrinogen at 50 µg/ml, and antichondroitin sulphate at 1:500. Then the membranes were incubated with the appropriate
HRP-conjugated secondary antibody: sheep anti-rabbit at 1:1000, anti-mouse at 1:1000
for the chondroitin sulphate blot and streptavidin-peroxidase (1:3000) for the biotinylated
heparin blot. Control blots were also conducted with the ECM components which
involved exactly the same method as above but without incubating the membranes with
the ECM ligand.

4.2.2 Fibronectin and Fibrinogen ELISA
This method is described in detail in 2.10. Aliquots (100 µl) of F1-F4 (5 µg/ml) were
applied to ELISA trays (Linbro/Titretek; ICN Biochemicals) and allowed to adsorb
overnight at RT. The wells were then blocked for 1 h at RT. Fibronectin and fibrinogen in
PBS containing 1% skim milk were next applied to the wells in 100 µl aliquots and
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incubated for 1.5 h at RT. The primary antibodies, anti-fibronectin or anti-fibrinogen
diluted 1:3000, were added and incubated for 1 h at RT. The secondary antibodies of
HRP conjugated anti-rabbit Ig (Silenus) at 1:1000 for those wells with fibronectin and
HRP conjugated anti-goat Ig (KPL) diluted 1:1000 for fibrinogen were then added. The
wells were washed 3 times with 0.05% (v/v) Tween20 in PBS between each of the above
steps. The substrate solution used was 100 µl aliquots of ABTS solution (Appendix A).
The absorbance of the product formed was measured at 414 nm using a Multiskan Ascent
ELISA plate reader (Thermo Labsystems).

4.2.3 Radioactive pull-downs and western blots
4.2.3.1 Radioactively labelling ECM proteins
To determine whether P159 recombinant fragments could bind ECM components
radioactive labelling of the ECM proteins was performed and these were then subjected to
pull-down experiments and western blotting. The following ECM components were used:
fibronectin (whole [ICN], alpha-chymotryptic 120kDa fragment [Chemicon], and the
proteolytic fragments 70, 45 and 30kDa [Sigma-Aldrich]), type IV collagen (SigmaAldrich), laminin (Calbiochem), fibrinogen (Calbiochem) and keratin (Sigma-Aldrich),
see Appendix B. 100 µg aliquots of each protein solution were transferred into silicon
coated glass tubes. 3 µl of radioactive I125 (Amersham Pharmacia Biotech) and 20 µg of
Chloramin T (Sigma; made in PB buffer, Appendix A) were added to each tube. After 1
min the labelling reaction was stopped by the addition of 20 µg of sodium metabisulphite
(Sigma; made in PB buffer, Appendix A). The binding efficiency was then calculated by
adding 1 µl of the newly labelled protein to a microcentrifuge tube containing 20 µl of
foetal calf serum (FCS) and the counts per minute (CPM) determined over 30 sec. The
labelled protein was then precipitated by addition of 1 ml of a 10% tricarboxylic acid
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(TCA) solution and centrifuged at 12,000 g for 3 min. The supernatant was removed and
the CPM of the resulting pellet was determined. A binding efficiency of 60% or greater
was considered adequate. The unbound I125 was removed from the remaining labelled mix
by adding PBST (PBS with 0.5% tween 20) to a total volume of 2.5 ml to each labelled
protein mix. This solution was put onto a PBST equilibrated PD10 column (Pharmacia).
The void volume was discarded and the labelled protein was eluted in a further 3.5 ml of
PBST. The labelled protein was aliquoted into microcentrifuge tubes and stored at 4oC.

4.2.3.2 Radioactivity pull-down experiments
The P159 recombinant fragments were subsequently screened for their ability to bind the
radioactively labelled ECM compounds by a pull-down assay which allowed any proteins
binding to the radioactive ECM compounds to be isolated by nickel affinity
chromatography due to the presence of the His-tag on the recombinant proteins.
Subsequently these would be detected due to the presence of radioactivity on the ECM
compound bound to the P159 protein. The method was as follows: 50 µg of protein (in
PBS or PBS with 0.1% SDS) were aliquoted into microcentrifuge tubes. A volume of 50
µl of PBS was added to another microcentrifuge tube as a negative control. A “total
counts” control tube containing the total CPM values possible for the particular labelled
ECM component was set up in duplicate containing 20 µl of FCS due to its ability to bind
the radioactively labelled compounds and be precipitated with TCA. A volume of 20 µl of
each I125-labelled ECM component was added to the P159 protein (F1-F4), PBS or FCS
in the microcentrifuge tubes. These were left rotating at RT for 45 min. The protein
mixtures and negative (PBS) control were added to a microcentrifuge tube containing a
pellet from 100 µl of a 50:50 solution of Ni-NTA sepharose (washed 2 times in PBS + 20
mM imidazole, centrifuged at 500 g for 5 min; Qiagen). These were again left rotating at
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RT for 45 min, the total counts control tubes were left standing (no resin). After this time
the microcentrifuge tubes were centrifuged at 12,000 g for 25 sec. The supernatant was
removed and 1 ml of PBS + 20 mM imidazole was added to remove any unbound protein.
The tube was then centrifuged as above. This was repeated again for a total of two
washes. The CPM of the resin pellets were determined. A total of 1 ml of a 10% TCA
solution was added to the “total counts” tubes. The tubes were centrifuged at 12,000 g for
3 min, upon which the CPM of the pellet was determined.

4.2.3.3 Radioactivity western blots
A total of 10 µg of each purified F1-F4 protein was loaded onto a 15% SDS-PAGE gel
and western transferred onto PVDF at 90 V for 1.5 h. The membranes were blocked
overnight with 5% w/v skim milk in PBS at 4oC and subsequently washed in PBST for
20-30 min. The I125–labelled ECM components (diluted 1:30) were added and the
membranes incubated for 1 h at RT with shaking. The membranes were subsequently
washed in PBST and the washes transferred to a clean container and the radioactivity
detected with a gamma-counter. Washing was continued until the radioactivity in the
wash had stabilised and reached background level (approximately 10 x 10 min washes).
The membranes were then placed in an X-ray cassette sealed between two sheets of
plastic. A piece of x-ray film (Kodak) was then placed over the membrane and the
cassette sealed for 1-7 days and the film developed.

4.2.4

Heparin binding assays

Aliquots (100 µl) of F1-F4 (5 µg/ml) were applied to ELISA trays and allowed to adsorb
overnight at RT as described in 2.10. The wells were then blocked with 100 µl aliquots of
PBS containing 2% (w/v) skim milk for 1 h at RT. Biotinylated heparin (Sigma-Aldrich)
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in PBS containing 1% skim milk was next applied to the wells in 100 µl aliquots and
incubated for 1.5 h at RT. Bound biotinylated heparin was detected using 100 µl aliquots
of peroxidase conjugated streptavidin (Roche) diluted 1:3000 with a 1 h incubation at RT.
The wells were washed 3 times with 0.05% (v/v) Tween20 in PBS between each of the
above steps. The substrate solution used was 100 µl aliquots of ABTS solution, Appendix
A. The absorbance of the product formed was measured at 414 nm using a Multiskan
Ascent ELISA plate reader (Thermo Labsystems). In other experiments, a competition
binding assay was used in which unlabeled glycosaminoglycans: heparin, fucoidan,
heparan sulfate, chondroitin sulphate A and chondroitin sulfate B (all from SigmaAldrich) were pre-incubated with biotinylated heparin before the addition of 100 µl
aliquots of the mixture to coated and blocked wells. Control experiments showed that
none of the P159 fragments could bind to streptavidin-peroxidase or the ABTS solution,
establishing that the heparin binding is not an artifact of binding to a compound used in
the detection system. Graph construction and non-linear regression with one-site binding
and one-site competition analysis was performed using GraphPad Prism version 4
(GraphPad Software).

4.2.5 Adherence/invasion assay of P159 fragments with PK15 cells
4.2.5.1 Coating latex beads with F1-F4 and incubation with PK15 cells
As per previously published methods (Dombek et al., 1999; Molinari et al., 1997), latex
beads (3 µm; Sigma-Aldrich) were coated with purified recombinant P159 fragments F1F4. Briefly, 108 bead particles in 20 µl PBS were incubated with 5 µg of purified proteins
in PBS overnight at 4oC. After washing steps, free binding sites on the bead surface were
blocked by incubation with 200 µl of PBS with 10 mg/ml BSA for 1 h at RT. The
efficiency of particle loading was verified by fluorescence-activated cell sorter (FACS)
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analysis with anti-F1-F4 rabbit serum (results not shown). Beads were washed and the
volume adjusted to 2.5 ml with Dulbecco modified Eagle medium (Invitrogen GmbH)
with HEPES and 1% foetal calf serum. PK15 cells (American type culture collection
certified cell line 33) were seeded on 12-mm-diamater glass coverslips (Nunc Gmbh and
Co.) placed on the bottom of 24-well tissue culture plates (Nunc Gmbh and Co.) at 1.5 x
105 cells per well and allowed to grow to semiconfluent monolayers at 37oC under a 5%
CO2 atmosphere. After addition of 250 µl of the bead suspension, the cells were incubated
for 2, 4, 7 and 22 h at 37oC under a 5% CO2 atmosphere. Cells were washed three times
with PBS to remove unbound beads. Cells were either processed for scanning electron
microscopy (Molinari et al., 1997, outlined in section 4.2.6) or for double
immunofluorescence as described below.

4.2.5.2 Double immunofluorescence detection of F1-F4 beads
PK15 cells (after incubation with the coated latex beads) were washed with PBS and then
fixed by the addition of 0.5 ml/well of pre-cooled fixation buffer (1% paraformaldehyde
in PBS), the tray was placed on ice for 1 h and then stored at 4oC overnight. The PK15
cells were blocked by the addition of 200 µl/well of PBS with 10% FCS and incubated for
30 min at RT. The blocking solution was then removed and the cells incubated separately
with 200 µl/well of the anti-F1-F4 rabbit polyclonal antibodies (40-50 µg/ml) for 45 min
at RT. Cells were incubated with goat anti-rabbit Alexa 488 (green) (Molecular Probes)
for 1 h at RT and subsequently washed with PBS. Cells were permeabilized with Triton
X-100 (200 µl/well of a 0.1% triton X-100 in PBS solution) for 5 min at RT, washed in
PBS, followed by incubation with 200 µl/well of the anti-F1-F4 rabbit polyclonal
antibodies (40-50 µg/ml) for 45 min at RT. After washing, cells were treated with goat
anti-rabbit Alexa 568 (red) (Molecular Probes) for 1 h, washed three times in PBS and
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then mounted onto glass slides. After this labelling procedure, extracellular beads appear
yellow/green whereas intracellular beads are stained orange/red. Images were recorded
using a Zeiss inverted microscope 100 M with an attached Zeiss Axiocam HRc digital
camera.

4.2.6 Incubation of PK15 cells with M. hyopneumoniae
A M. hyopneumoniae J strain culture was kindly supplied by the Microbiology Institute
(Hannover). A 5 ml fresh M. hyopneumoniae culture was centrifuged at 10,000 g and
resuspended in 100 µl of infection medium. 10 µl of M. hyopneumoniae suspension per
well was added to 0.5 ml PK15 cell culture infection medium in a 24 well tray and
incubated at 37oC for 5 and 24 h. The wells were washed 3 times with cacodylate buffer
(Appendix A) and the cells fixed in 2% formaldehyde and 3% glutaraldehyde in
cacodylate buffer for 1 h on ice. The wells were then washed three times in cacodylate
buffer and then in TE buffer (20 mM Tris, 2 mM EDTA, pH 6.9). The cells were
dehydrated with a graded series of acetone (10, 30, 50, 70, 90, 100%) with each step
being for 15 min on ice, the 100% step was conducted at RT. Critical point drying was
carried out using liquid CO2 and the samples examined in a Zeiss DSM982 field emission
electron microscope at an acceleration voltage of 5 kV.
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4.3

Results

4.3.1 Recombinant P159 proteins bind heparin
Parts of the P159 molecule were shown to bind laminin and fibronectin using affinity
chromatography (results not shown). This binding to laminin and fibronectin along with
other ECM components was investigated further using the P159 recombinant fragments
generated in Chapter 3. Western blots were conducted with fibronectin, fibrinogen,
laminin, chondroitin sulphate A and biotinylated heparin. From these blots it was found
that recombinant fragment F2 reacts non-specifically by binding to secondary antibodies
and to streptavidin-peroxidase (results not shown). F1, F3 and F4 did not bind
significantly to any of these compounds under these conditions. Experiments using
radioactively labeled ECM components showed that the P159 fragments did not bind to
type IV collagen, laminin, fibrinogen, keratin, whole fibronectin or proteolytic fragments
of fibronectin. This was found when using either radioactive pull-down experiments or
when using radioactive proteins for western blot detection (results not shown).

ELISA assays showed no significant binding of any of the four P159 recombinant
fragments to fibronectin or fibrinogen (results not shown), however, F3 and F4 were
shown to bind biotinylated heparin in a saturable and dose-dependent manner with
saturation occurring at 15-20 µg/ml of biotinylated heparin. A 50-fold excess of
unlabelled heparin was found to extinguish the majority of the signal by competitively
inhibiting biotinylated heparin binding (Fig. 4.1), thus indicating that heparin occupies
specific binding sites on the F3 and F4 proteins. Non-linear regression and one-site
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binding analysis was performed on the specific binding data which gave an estimate of
the apparent dissociation constants for F3–biotinylated heparin complexes (142.37 +
22.01 nM) and F4–biotinylated heparin complexes (75.37 + 7.34 nM). The specificity of
the biotinylated heparin binding of F3 and F4 was verified by inhibition experiments
using unlabeled heparin (Fig. 4.2A). F1 and F2 were also included as non-biotinylated
heparin binding P159 controls. With increasing concentration of unlabeled heparin there
was a decrease in binding of biotinylated heparin to F3 and F4 (Fig. 4.2A). This data was
subjected to non-linear regression with one-site competition and the 50% inhibitory
concentration (IC50) for F3 (52.92 + 1.03 µg/ml) and F4 (66.63 + 1.02 µg/ml) determined.
The potent competition obtained with unlabeled heparin confirms that binding is due to
interaction with heparin and not the biotin label. To examine the specificity of the
interaction between F3 and F4 and heparin, we employed various glycosaminoglycans as
soluble competitors of the heparin-P159 interaction (Fig. 4.2B and C). In addition to
heparin, fucoidan, a highly sulfated fucose polymer, is an effective inhibitor of the
binding of both F3 and F4 to biotinylated heparin giving IC50 values of 96.28 + 1.19
µg/ml and 36.23 + 1.14 µg/ml. By contrast, heparan sulfate, chondroitin sulfate A or
chondroitin sulfate B did not show significant inhibition.
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Fig. 4.1. Binding of P159 fragments to biotinylated heparin. Increasing concentrations of
biotinylated heparin were added to ELISA plate wells coated with 5 µg/ml of each of the
four P159 fragments. □ represents the total binding and ∆ represents non-specific binding
measured by mixing the biotinylated heparin with a 50 fold excess (2.4 mg/ml) of nonlabeled heparin prior to incubation with the P159 fragments. The non-specific binding
subtracted from the total binding generated the specific binding curve ○. Figures shown
are means + SEM of triplicate determinations, indicated by error bars where they are
larger than the symbol size.
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Fig. 4.2. Effect of inhibitors on P159 fragments binding to biotinylated heparin. (A)
displays the results of unlabeled heparin inhibition on F1 (□), F2 (∆), F3 (○) and F4 (◊)
binding, while (B) and (C) shows the results of fucoidan ■, heparan sulfate ▲,
chondroitin sulfate A ● and chondroitin sulfate B ♦ inhibition on F3 and F4 binding,
respectively. Varying concentrations of inhibitor 0 to 40 times the saturating
concentration of 60 µg/ml were pre-incubated with biotinylated heparin at 60 µg/ml and
then added to ELISA plate wells coated in 5 µg/ml of F1-F4 before incubation with
streptavidin-peroxidase and development with substrate. The data represents mean values
+ SEM from triplicate determinations, shown by error bars where they are larger than the
symbol size.
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4.3.2 Mycoplasma hyopnemoniae adheres to porcine epithelial cells
Due to the procedural difficulties and unavailability of working with the natural cells in a
M. hyopneumoniae infection, porcine respiratory cilia, a cell line from the American Type
Culture Collection was chosen. This was a porcine kidney epithelial-like cell line (PK15)
and Zielinski and Ross (1990) demonstrated the ability of M. hyopneumoniae to adhere to
this cell line. However through this work it appeared that they did not investigate whether
the bacterial cells had the ability to invade the PK15 cells and all data was numerical. We
therefore infected PK15 cell monolayers with M. hyopneumoniae and looked for the
adherence or invasive capabilities of the bacteria at 5 and 24 h of incubation. This
involved incubating M. hyopneumoniae strain J (kindly supplied by the Institute for
Microbiology, Hannover) with a monolayer of PK15 cells. Using electron microscopy it
was found that the bacteria could adhere to these cells after 5 h of incubation (Fig. 4.3)
but were not able to invade the cells even after a period of 24 h. Electron microscopic
analysis of sections of the PK15 cells infected with M. hyopneumoniae shows the
accumulation of flask or omega-shape like structures in the PK15 cell membrane (Fig.
4.3B) in the near vicinity to attached bacteria which resemble caveolae (flask- or omegashaped non-coated invaginations, mainly 50-100 nm in size, of the plasma membrane;
Rohde et al., 2003).
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A

2 µm

B

500 nm

Fig. 4.3. Electron micrographs of M. hyopneumoniae J strain bacterial cells adhering to
PK15 cells. The scale bar can be seen at the bottom of both images. (A) Bacterial cells
adhering to the surface of a PK15 cell. (B) An enlargement of a small area of a PK15 cell
showing the apparent pore formation on the surface of the PK15 cell at the site of
bacterial adherence.
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4.3.3 P159 fragments adhere to porcine epithelial cells
M. hyopneumoniae has previously been shown to adhere to the porcine kidney epitheliallike (PK15) cell line (Zielinski and Ross, 1990) and this was verified in this current study,
Fig. 4.3. A coated latex bead binding assay was used to examine whether P159 adheres to
PK15 cells. Latex beads and latex beads coated with each of the four purified
recombinant P159 protein fragments were incubated with monolayers of PK15 cells.
Scanning electron microscopy, in conjunction with double-immunofluorescence of intact
and then Triton X-100 treated PK15 cells, was used to differentiate between beads
adhering to the surface of the cells and those able to penetrate inside the cells. Latex
beads not coated with P159 fragments neither adhered to cells nor were internalized
(results not shown). Beads coated with F1 protein were unable to either adhere to or
penetrate into the PK15 cells. F3 coated beads were found to adhere to PK15 cells 2 h
post-incubation but were not found to penetrate cells even after 22 h. Both F2 and F4
coated beads were found to adhere to PK15 cells 2 h post-incubation and were detected
inside PK15 cells from 2-22 h post-incubation. Increasing numbers of internalized beads
were detected over this time course (Fig. 4.4 and Fig. 4.5; results not shown).

.
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Fig. 4.4. Double immunofluorescence analysis of the adherence of P159 F1-F4 coated
latex beads to PK15 cells. Intracellular beads are highlighted with white arrows. (A)
PK15 cells as they appear on the glass coverslip. These cells were incubated with F1
coated latex beads for 22 h but the beads did not adhere or penetrate these cells. (B)
Extracellular F2 coated latex beads (yellow/green) adhering to the PK15 cells and the
intracellular F2 coated latex beads (orange/red) that have been taken up by the PK15 cells
after 7 h of incubation. (C) F2 coated beads interacting with the PK15 cells after 7 h of
incubation with the nucleus of the PK15 cells stained with Hoerst for orientation. (D) The
same image as in C but with a different exposure time showing the extracellular
(yellow/green) beads and the intracellular (orange/red) beads. (E) F3 coated beads
interacting with a cluster of PK15 cells after 4 h of incubation (F) F4 coated beads
interacting with PK15 cells 7 h post-incubation, highlighting the extracellular
(yellow/green) beads and intracellular (orange/red) beads.
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Chapter 4: M. hyopneumoniae surface antigen P159 binds heparin and
promotes adhesion to and internalization of eukaryotic (PK15) cells

4.4

Discussion

The ability of pathogenic bacteria to bind components of the extracellular matrix and the
role this may play in pathogenesis has been the focus of intense research in recent years.
Preliminary experiments identifying ECM binding proteins in M. hyopneumoniae (results
not shown) identified regions within P159 that were found binding to a fibronectin and
laminin affinity column. Recombinant P159 fragments were screened for their ability to
bind a number of ECM components by western analysis, radioactive pull-downs,
radioactive western blots and finally by ELISA and all results showed the inability of any
fragment of P159 to bind to fibronectin, laminin, fibrinogen, chondroitin sulphate A, type
IV collagen and keratin.

Experiments using biotinylated heparin showed that the C-terminal half of the P159
molecule, represented by recombinant fragments F3 and F4, had the ability to bind to
heparin in a dose-dependent saturable manner. The six histidines added at the N-terminus
of the proteins during the cloning process are not playing a role in the binding ability, as
other proteins containing this tag such as F1 and F2 are not able to interact with heparin.
The M. hyopneumoniae recombinant protein RpL7/L12 (Chapter 5) was also used as a
non-P159 protein 6x His-tag control due to its inability to bind to any of the ECM
molecules investigated (results not shown).

The binding of heparin to F3 and F4 displays an apparent dissociation constant of 142.37
+ 22.01 nM and 75.37 + 7.34 nM, respectively. This value is comparable to that (60 nM)
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reported for the binding of clusterin to heparin (Pankhurst et al., 1998), to that (20 nM) of
heparin binding to antithrombin (Barrow et al., 1994), to that of M. tuberculosis DNAbinding protein 1 to heparin (0.35 nM) and heparan sulfate (15.4 nM) (Aoki et al., 2004),
to that (26 nM) of M. tuberculosis heparin-binding hemagglutinin adhesin binding to
heparin (Pethe et al., 2000), to that (500 nM) of human IL-12 binding to heparin (Hasan
et al., 1999) and falls in the midrange of other reported constants for heparin-protein
interactions. These values range from 0.3 nM for heparin binding to the Alzheimer’s
disease amyloid precursor protein (Multhaup et al., 1995) to 400 nM for binding of
heparin to low-density lipoproteins (Gigli et al., 1992).

Heparan sulfate was only a weak competitive inhibitor of heparin binding by P159
fragments and this may be due to heparin having a higher ratio of iduronate:glucuronate
residues and higher sulfation than heparan sulfate. Najjam and colleagues had previously
shown that only a highly sulfated form of heparan sulfate was an effective inhibitor of the
binding of recombinant interleukin 2 (IL-2) to heparin (Najjam et al., 1997). Frick and
colleagues demonstrated that only a highly sulfated form of heparan sulfate inhibited the
interaction of Streptococcus pyogenes strain AP1 to chondroitin sulfate B (Frick et al.,
2003). Fucoidan, a sulfated polysaccharide of non-mammalian origin, is shown here to be
a strong competitor of the interaction between heparin and F3 and F4. It is generally the
case that heparin-binding proteins also interact with fucoidan due to its high sulfate
density and branched, comb-like structure, which contrasts with the linear structure of
mammalian glycosaminoglycans (Patankar et al., 1993). Chondroitin sulfate A,
chondroitin sulfate B and mucin did not show an ability to competitively inhibit the
heparin binding of the P159 fragments F3 and F4. The B variant of chondroitin sulfate
contains iduronate residues, similar to heparin and heparan sulfate, which shows that
inhibition is not due to the presence of iduronate, as had been found for the streptococcal
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M protein (Frick et al., 2003), but more likely due to the high degree of sulfation of
heparin and fucoidan.

It is assumed that binding of proteins to various glycosaminoglycans (GAGs) depends on
electrostatic interactions between the negatively charged sulfate groups of the GAG
chains and positively charged regions of the protein. Typically, heparin-binding proteins
are rich in basic amino acids that are usually clustered. There is a lack of agreement on
consensus sequences found in proteins showing an ability to bind to heparin. Cardin and
Weintraub (1989) proposed two heparin-binding motifs, XBBXBX and XBBBXXBX,
where B represent basic amino acids and X any other amino acids. Aoki and colleagues
have since shown that repeats of the residues PAKK are key residues for binding to
GAGs in M. tuberculosis (Aoki et al., 2004). P159 does not possess these motifs but has a
high density of lysine (K) and arginine (R) residues in F3 (15.6% of the total sequence is
K and R) and F4 (13.9% of the total sequence is K and R) which is consistent with their
role as basic amino acids interacting with the negatively charged sulfate groups on the
GAGs.

Pathogenic bacteria may also bind heparin which then binds to tertiary heparin binding
proteins, allowing adherence to the host cells (Duensing et al., 1999; van Putten et al.,
1998). It is known that mast cells, the primary cellular source of heparin, can be
chemotactically recruited to sites of tissue damage or repair, where heparin-containing
granules are released (Hamawy et al., 1994). Potentially M. hyopneumoniae, through
P159, may attach to heparin preventing it from taking part in wound healing.
Furthermore, because of the multiple binding activities of GAGs, it is also possible that
GAGs bound to the M. hyopneumoniae surface mediate binding to proteins involved in
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host defense. Known relevant ligands for GAGs include growth factors, cytokines and
other mediators of inflammation (Bernfield et al., 1999). Trapping of these mediators
could potentially provide the bacteria with means to modulate the local response to the
pathogen.

Heparin was one of the molecules shown by Zhang and colleagues in 1994 to inhibit the
binding of M. hyopneumoniae to purified porcine tracheal cilia. The results suggested that
heparin interacted with the adhesive molecules on the surface of M. hyopneumoniae.
P159 may be one of these surface molecules which bound heparin. The fact that heparin
inhibited adherence may be due to the surface molecules once bound to heparin were no
longer able to bind the heparin molecules present on the tracheal cilia, thereby preventing
adherence. Whether or not heparin is freely available on these cells requires further
investigation.

In vitro models used for investigation of mycoplasma-host cell interactions have included
a model using suspensions of porcine respiratory tract ciliated epithelial cells (Zielinski
and Ross, 1993) and a microtiter plate adherence assay for M. hyopneumoniae using
purified swine tracheal cilia (Zhang et al., 1994b). A porcine kidney epithelial-like cell
line (PK15) was used by Zielinski and Ross (1990) where the ability of M.
hyopneumoniae to adhere to this cell line was demonstrated and confirmed in this study.
P97 has been established as an important adhesin in M. hyopneumoniae due to its ability
to adhere to swine ciliated cells. However, monoclonal antibodies directed against P97
were only able to reduce up to 67% of adherence of M. hyopneumoniae to swine ciliated
cells. Therefore, it was hypothesised that other molecules may be involved in adherence.
F2, F3 and F4 were found to mediate the adherence of latex beads to PK15 cells.
Additionally, F2 and F4 coated beads penetrated PK15 cells. This same methodology has
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been used to demonstrate serum opacity factor (SOF) involvement in the fibronectinmediated adherence of Streptococcus pyogenes to epithelial cells (Oehmcke et al., 2004)
and the fibronectin binding protein (SfbI) of S. pyogenes involvement in the
internalization of group A streptococci by epithelial cells (Molinari et al., 1997).
Ectodomains 3 and 4 of human polymeric immunoglobulin receptor were shown to
mediate invasion of Streptococcus pneumoniae into the epithelium using this same
methodology (Elm et al., 2004) and aromatic amino acids at the surface of InlB were
found to be essential for host cell invasion by Listeria monocytogenes using this method
(Machner et al., 2003). The data generated in this study suggest the function of P159 as
an adhesin. As whole M. hyopneumoniae cells were not able to invade the PK15 cells
while parts of the P159 molecule were suggests that the P159 molecules are secreted from
the bacteria where they invade and disturb the function of the PK15 cells, although this
remains to be determined.

In conclusion the data indicating P159 as an adhesin is substantial. The gene p159 is
found in a two-gene operon with a p97 paralog, p216, as one of the adhesin operon
families. P159 fragments F3 and F4 exhibit the ability to bind heparin and other
pathogenic bacteria have been shown to bind heparin as a potential mechanism of
adherence. Inert latex beads coated with F2, F3 and F4 were able to adhere to PK15 cells
whereas F2 and F4 coated beads were able to penetrate the PK15 cells. Collectively this
data suggests that P159 is a good candidate for an adhesin of M. hyopneumoniae and thus
may play a role in the colonization of the respiratory tract of swine.

105

Chapter 5: Characterization of M. hyopneumoniae ribosomal protein
L7/L12

5.1

Introduction

The structure and function of ribosomal proteins, such as L7/L12 has been extensively
explored. The rplL gene codes for a protein core, L12 which can also undergo acetylation
producing L7. Within the ribosomal complex, these two ribosomal proteins are unique in
their acidic nature and exist in a 4:1 ratio. The protein L7/L12 is central to the
translocation step of translation, that is, the step where the peptidyl-tRNA is moved
(translocated) to the next codon to continue protein synthesis. The monomer of L7/L12
has a molecular mass of 12 kDa and is organized in the ribosome as two dimers bound to
one copy of protein L10, which anchors the pentamer to the large ribosomal subunit.
L7/L12 was one of the first proteins isolated from 50S ribosomal particles (Moller and
Castleman, 1967).

The tertiary structure model of the L7/L12 dimer (Fig. 5.1) has 3 domains. The N-termini
of both monomers, comprising residues 1-37, form a four-helix bundle. This domain is
responsible for dimer formation and binding to L10. The C-terminal domain (residues 50120) consists of two associated globules that are responsible for interaction with
elongation factors. The N- and C-terminal domains are connected via flexible strings
(residues 38-49). The L7/L12 dimer forms a clearly defined morphological feature in the
E. coli 50S ribosomal subunit which is called the L7/L12 stalk or protuberance (Strycharz
et al., 1978).
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Fig. 5.1. Secondary structure of the L7/L12 dimer. N-domain comprising residues 1-37
form a four-helix bundle (αD-αE), the C-terminal domain forms two associated globules
(residues 50-120), and the N- and C-terminal domains are connected with flexible strings
of residues 38-49 representing a hinge region. The C-terminal domain consists of three
anti-parallel β–strands (βB-βA-βC) in one layer and three α–helices (αB-αA-αC) in
another (Bocharov et al., 1996).

In E. coli it has been found that a significant amount of L7/L12 exists in a non-ribosomal
pool (Morrissey et al., 1975 and 1976). The non-ribosomal L7/L12 molecules share
identical amino acid composition and electrophoretic characteristics and are
immunologically identical to ribosomal L7/L12 (Morrissey et al., 1975) but are not able
to interact with protein-stripped ribosomes, show different gel filtration profiles, and
present a different trypsin digestion profile than ribosomal L7/L12. The authors
postulated that the differences might be due to modification of non-ribosomal L7/L12 to
inactivate excess L7/L12 or to convert it into a form with other biological activities in
some organisms (Morrissey et al., 1975 and 1976). Spence and Clarke (2000) have also
shown that L12 is membrane associated and surface exposed in Neisseria gonorrhoeae.
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Vaccines based on ribosomal preparations have been described for over 35 years
(Gregory, 1986; Thompson and Snyder, 1971; Venneman and Bigley, 1969). The use of
such vaccines has been controversial, mainly due to the lack of a common mechanism
explaining the protection achieved by the various ribosomal components (Gregory, 1986).
Nevertheless, ribosomal preparations derived from intracellular pathogens have been
shown to induce a delayed-type hypersensitivity (DTH) reaction in animals sensitized
with the pathogen (Baker et al., 1973; Corbel, 1976; Loge et al., 1974; Ortiz-Ortiz et al.,
1971). Tantimavanich et al. (1993) found that among all of the ribosomal proteins,
L7/L12 was the only protein able to reveal a DTH reaction in guinea pigs sensitised by
live BCG or killed Mycobacterium tuberculosis. Bachrach et al. (1994) found that the
Brucella melitensis L7/L12 ribosomal protein was the main immunogenic protein in the
commercial protein preparation Brucellergen responsible for DTH activity. Furthermore,
Bachrach et al. (1997) showed that acetylation of the B. melitensis L7/L12 protein is
crucial for the recognition of the protein by the host cells triggering the DTH reaction.

The Brucella abortus L7/L12 ribosomal protein has also been identified as an
immunodominant antigen (Brooks-Worrell and Splitter, 1992). B. abortus L7/L12
ribosomal protein fused to a maltose binding protein (MBP) conferred a significant
degree of protection, when compared to mice vaccinated with adjuvant alone, adjuvant
plus MBP or with the B. abortus live attenuated vaccine strain 19 (Oliveira and Splitter,
1996). Further evidence of the immunogenicity of L7/L12 proteins come from studies of
Chlamydia trachomatis, in which western blots of two-dimensional electrophoretic maps
of proteins from this organism were probed with sera from 17 seropositive patients with
genital inflammatory disease. Seven sera (41%) recognized the ribosomal protein L7/L12
(Sanchez-Campillo et al., 1999). Finally, Spence and Clarke (2000) have shown that preincubation of low invasive N. gonorrhoeae with micromolar amounts of purified
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recombinant L12 lead to a five- to eight-fold increase in invasion of the human
endometrial cell line, Hec1B. In addition, nanomolar concentrations of exogenous L12
inhibits N. gonorrhoeae invasion to approximately 70% of the level in controls. Thus it
has been found that L7/L12 is immunogenic and surface exposed in some pathogens and
in at least one case is able to increase the invasive capabilities of the pathogen.

Based on these data an investigation was commenced to determine whether the M.
hyopneumoniae ribosomal protein L7/L12 (rpL7/L12) is expressed on the surface of the
bacterial cell and whether it is an immunogenic antigen and therefore a possible target for
vaccine development.
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Chapter 5: Characterization of M. hyopneumoniae ribosomal protein
L7/L12

5.2

Methods

5.2.1 Microbial rpL7/L12 gene similarity analysis
A database search was conducted to obtain the gene sequence of rpL7/L12 genes from
various bacterial species (National Centre for Biotechnology Information website:
www.ncbi.nlm.nih.gov). An alignment of the complete amino acid sequences available
for these 27 different bacterial species was generated using the ClustalW program
available

on

the

European

Molecular

Biology

(EMBnet)

website

(www.ch.embnet.org/software/ClustalW.html). A similarity matrix was generated for this
data using GeneDoc, available from the Pittsburgh Super Computing Centre website
(www.psc.edu/biomed/genedoc/). A phylogenetic tree was constructed from the aligned
sequences using the Phylip 3.6 package available through The University of Washington
website (evolution.genetics.washington.edu/ phylip) and the Treeview program available
through the University of Glasgow website (taxonomy.zoology.gla.ac.uk/rod/treeview.
html). The Phylip 3.6 package consisted of: the aligned sequences were subjected to 100
bootstrap replications using Seqboot. This data was used to generate a distance matrix
with the Protdist program which was run using the default parameters. A consensus tree
was then constructed using the neighbour-joining method from the programs Neighbour
and Consense. Treeview was used to view the resulting tree.
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5.2.2 Genetic Techniques
5.2.2.1 PCR amplification of the M. hyopneumoniae strain 232 rpL7/L12 gene
The M. hyopneumoniae rpL7/L12 nucleotide sequence was obtained from genome
sequence data generated by F.C. Minion (Minion et al., 2004). Primers rpL7L12 forward
and rpL7L12 reverse (Fig. 5.2) were used to PCR amplify the entire 363 bp rpL7/L12
gene from M. hyopneumoniae strain 232 chromosomal DNA. BamH1 and HinDIII
restriction enzyme sites were incorporated into the forward and reverse primers
respectively to facilitate directional cloning.

5’

rpL7/L12 forward

3’

GG GGATCC ATG GCT AAA ATT ACA AAA GAA
BamH1
5’

rpL7/L12 reverse

3’

GG AAGCTT TCA GTC AAT CGA AAC TTC TGC
HinDIII

Fig. 5.2. Primers designed to amplify the entire rpL7/L12 gene from M. hyopneumoniae,
rpL7/L12 forward and reverse. The incorporated restriction sites for BamH1 and HinDIII
are underscored.
An initial gradient PCR was undertaken to establish the optimal PCR conditions. The
reaction mix was the same as described in 2.2.1 and the reaction conditions are shown in
Table 5.1.
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Table 5.1. Reaction conditions for the rpL7/L12 PCR. Each PCR reaction began with an
initial denaturation step at 94oC for 5 min and completed by a final extension at 72oC for
5 min.
Primer pair

Amplified product

PCR cycle protocol x 30

rpL7L12F
rpL7L12R

rpL7/L12 363 bp

94oC 60 sec, 68oC 30 sec, 72oC 60 sec

For electrophoresis of PCR products, a 2.5% agarose (w/v) gel was prepared and run as
described in 2.2.2. GeneRuler™ 100 bp DNA Ladder Plus (1.5 µg; Progen) was used for
sizing the resolved fragments.

5.2.2.2 Purification of the rpL7/L12 PCR product
PCR products were purified using a QIAquick PCR Purification Kit (Qiagen) to remove
any unbound dNTPs and PCR reagents essentially as described below. Products from
PCR reactions were pooled into a microcentrifuge tube and a 5X volume of buffer PB
(Appendix A) was added and mixed. The sample was then applied to a QIAquick spin
column and centrifuged at 13,000 rpm for 1 min at RT (Biofuge Pico centrifuge,
Heraeus). The flow through was discarded and 0.75 ml of buffer PE (Appendix A) was
added to the spin column to wash. The column was centrifuged as above, the flowthrough
discarded and then further centrifuged for 1 min to remove any residual PE buffer. The
spin columns were then placed into new microcentrifuge tubes and a volume of 50 µl of
sterile MilliQ water was added to the centre of the spin column and left to stand for 1-5
min. The column was then centrifuged as above and the flow through containing the
purified PCR product was retained and stored at -20oC. The purified PCR product was
examined on an agarose gel as described in section 2.2.2.
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5.2.3 Expression of rpL7/L12 in pQE-9
5.2.3.1 Plasmid DNA extraction
A culture of E. coli JM109 (pQE-9) was harvested and the plasmid extracted using a
Maxi Prep Kit (Qiagen) as described in section 2.2.7.
5.2.3.2 Restriction enzyme digestion and gel extraction
The purified PCR product and the pQE-9 plasmid were digested for 2 h at 37oC using a
dry block heater (Thermoline) with restriction enzymes BamH1 and HinDIII (New
England Biolabs) according to the manufacturers’ instructions. The digested products (60
µl of each) were electrophoresed on a 2% agarose gel in 1X TAE and stained with
ethidium bromide. The bands were excised from the agarose gel using a clean scalpel
blade and transferred to pre-weighed microcentrifuge tubes. Gel extraction of these
products was performed using the GenElute™ Gel Extraction Kit (Sigma) as follows: a
3X gel volume of gel solubilisation solution was added to each gel slice. The tubes were
incubated at 60oC until the gel had completely dissolved (approximately 10 min).
Afterwards, 1X gel volume of isopropanol was added and mixed. The entire sample was
loaded onto a GenElute miniprep binding column placed in a collection tube and
centrifuged at 14,000 rpm for 1 min using a bench-top microcentrifuge (Biofuge Pico,
Heraeus). The column was washed with 0.6 ml of wash solution, centrifuged as above
and then further centrifuged for 2 min to remove excess wash solution (ethanol). The
DNA was eluted by transferring the column to a new microcentrifuge tube, adding 50 µl
of MilliQ water to the column, incubating for 1 min and subsequently centrifuging for 1
min. The eluted DNA was stored at -20oC.
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5.2.3.3 Ligation and transformation
The gel extracted products (PCR and plasmid) were then mixed together in a 1:1 ratio
(3:3 µl and 5:5 µl) and ligated together overnight as outlined in 2.2.4. The ligation mixes
(20 µl) were then transformed into 300 µl of chemically competent E. coli M15 (pREP4)
cells as discussed in 2.2.4.

5.2.3.4 Screening recombinant plasmids and plasmid DNA extraction
Recombinant plasmids were screened through small-scale plasmid preparations using the
FlexiPrep™ Kit (Amersham Pharmacia Biotech) as described in 2.2.6. Plasmid
preparations were digested for 4 h at 37oC with BamH1 and HinDIII according to the
manufacturer's instructions and analysed by agarose gel electrophoresis on a 0.8% gel for
detection of the rpL7/L12 gene insert.

5.2.3.5 DNA sequence analysis of M. hyopneumoniae rpL7/L12 genes
The

primers

pQEF

(5’-CGGATAACAATTTCACACAG-3’)

and

pQER

(5’-

GTTCTGAGGTCATTACTGG-3’) were used to sequence the M. hyopneumoniae (strain
232) rpL7/L12 gene insert in the pQE-9 vector as described in 2.2.5. The rpL7/L12 gene
from M. hyopneumoniae J strain was also sequenced (using primers rpL7L12 forward and
rpL7L12 reverse). The PCR product was generated as described in 5.2.2.1 with M.
hyopneumoniae J strain chromosomal DNA as the template. After PCR, the product was
purified using the QIAquick PCR Purification Kit (Qiagen) (section 5.2.2.2) and then
subjected to a polyethylene glycol (PEG) precipitation. This involved adding an equal
amount of PEG8000 solution (Appendix A) to a microcentrifuge tube containing the PCR
product. The sample was incubated at 4oC for 24-40 h. The microcentrifuge tube was
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centrifuged at 13,000 rpm for 30 min at RT using a bench-top microcentrifuge (Biofuge
Pico, Heraeus). The sample was washed with 0.1 ml of 70% ethanol and centrifuged at
13,000 rpm for 10 min at RT. This was repeated with 0.1 ml of 95% ethanol. The pellet
was air-dried for approximately 30 min at RT and then resuspended in sterile MilliQ
water back to the initial PCR volume. PCR sequencing reaction mixes containing either
10 µl of the PEG precipitated DNA or 5 µl MilliQ water and 5 µl of pQE-9 clone DNA
(pTB1), with 8 µL DTCS Quickstart Master Mix (Beckman Coulter) and 2 µl of primer
(1 pmol/µl) were prepared. The reaction mixes were then thermocycled at 96oC, 20 sec;
50oC, 20 sec; 60oC, 4 min (30 cycles) (FTS-960 Thermal Sequencer, Corbett Research).
The reaction products were then purified using ethanol precipitation and analysed on a
CEQ8000 Genetic Analyser (Beckman Coulter) as described in 2.2.5.

5.2.4 Protein techniques
5.2.4.1 RpL7/L12 protein expression
A 250 ml E. coli M15 (pREP4) culture containing the pQE-9-based isopropyl-β-Dthiogalactopyranosidase (IPTG) inducible L7/L12 expression plasmid (pTB1) was grown
to an optical density (at 600 nm) of 0.6 (Ultraspec 3300 Pro spectrophotometer,
Amersham) and induced with a final concentration of 1 mM IPTG as outlined in section
2.3. The culture was incubated at 37oC with shaking at 200 rpm overnight (Certomat® R,
B-Braun).

The overnight culture was then subjected to protein purification under

denaturing conditions in a buffer containing 8M urea as described in 2.4.
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5.2.4.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
Whole-cell protein extracts of E. coli M15 (pREP4 pQE-9 L7/L12) before and after
induction were prepared by resuspending cells (obtained in section 5.2.4.1) in SDS-PAGE
reducing solution (Appendix A) and boiling for 5 min. Samples of the denatured
rpL7/L12 purified protein in urea buffer (from section 5.2.4.1) were prepared by
combining 25 µl of the protein with 5 µl of bromophenol blue loading dye (Appendix A).
Samples were electrophoresed through a 15% SDS-PAGE gel (Appendix A) as described
in 2.7.

5.2.5 Generation of polyclonal antiserum to recombinant rpL7/L12
20 ml of purified rpL7/L12 protein in urea buffer (from section 5.2.4.1) was ultrafiltered
with sterile PBS (as described in 2.4) to a final volume of approximately 18 ml and this
was used to inject a New Zealand White rabbit as described in 2.6. To verify reactivity of
the antiserum, purified protein was transferred from polyacrylamide gels onto
polyvinylidene difluoride membrane (PVDF) as described in 2.9. The membrane was
then subjected to western blotting as described in 2.9 which included incubation with
primary antibody (pre-immune sera diluted 1:200, or anti-rpL7/L12 sera diluted 1:2001:500 in wash solution), followed by sheep anti-rabbit HRP conjugated secondary
antibody (Silenus) at 1:1000 and developed in a DAB solution.

5.2.6 Mass spectrometry analysis of recombinant rpL7L12
A sample of rpL7L12 purified protein in PBS (from 5.2.5) was reduced and
electrophoresed on a 15% SDS-PAGE gel as described in 2.7. The resulting band of
rpL7/L12 was excised from the gel and subjected to MALDI-TOF mass spectrometry
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analysis, as described in 2.8. This technique was used to confirm the identity of the
protein.

5.2.7 Expression patterns of rpL7/L12 by M. hyopneumoniae J and 232
Samples from in vitro grown cultures of M. hyopneumoniae strains 232 and J were
prepared as in 2.1, separated by electrophoresis through 15% SDS PAGE gels and
transferred to PVDF, as described in 2.9. Blots were exposed to anti-rpL7/L12 rabbit sera
diluted 1:200, followed by anti-rabbit HRP conjugated antibody (Silenus) at 1:1000 and
developed in a DAB solution as outlined in 2.9.

5.2.8 FACScan analysis of M. hyopneumoniae with anti-rpL7/L12 sera
The location of rpL7/L12 protein in M. hyopneumoniae was explored using fluorescent
techniques and flow cytometry as follows. The cell surface assay involved growing a 6 ml
culture of M. hyopneumoniae strain 232. The absorbance of the culture at 600 nm was
determined to ensure that the same numbers of bacterial cells were used in all
experiments. The culture was divided into 1 ml aliquots which were centrifuged at 8,000
g for 3 min at 4oC and washed once in 1 ml of PBS. The bacterial pellets were
resuspended in PBS with 0.1% BSA and based on the absorbance values an aliquot of
cells (e.g. 100 µl of a culture with an OD of 0.1) was added to sterile microcentrifuge
tubes (this was based on initial experiments optimising the number of cells necessary for
the assay). Volumes of 50 µl of the primary antibodies at a concentration of 1:20 (diluted
in PBS with 0.1% BSA) were added to an aliquot of cells. These antibodies were the antirpL7/L12 rabbit serum and normal rabbit serum (Zymed). A control tube with no primary
antibody was also prepared. The tubes were incubated on ice for 30 min after which the
pellets were washed twice with chilled PBS by centrifugation as above. The pellets were
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resuspended in 50 µl of the secondary antibody, (FITC conjugated sheep anti-rabbit
[Silenus] diluted at 1:50 in PBS with 0.1% BSA) and incubated on ice for 30 min. The
pellets were washed twice in PBS and resuspended in 0.5 ml of chilled 1%
paraformaldehyde in PBS. The samples were then transferred to flow cytometry tubes and
analysed on a Becton Dickinson FACScan, counting at least 10,000 events per sample.

The assay to determine whether the rpL7/L12 protein was located intracellularly involved
the same strategy although saponin was added to introduce holes in the cell membrane to
allow the antibodies to reach any internal proteins. The method used was as follows. The
culture was washed twice with PBS before being fixed with 4% paraformaldehyde in PBS
and being placed on ice for 2 h. The cells were washed twice with 1 ml of 0.1% saponin
containing 1% FCS in PBS. The primary antibodies were the same as for the cell-surface
assay although they were diluted in 0.3% saponin with 1% FCS in PBS and the cells were
incubated at RT for 2 h. The cells were then washed twice as before and the secondary
antibody added as in the cell-surface assay but diluted in 0.3% saponin with 1% FCS in
PBS and incubated at RT for 1 h. Lastly the cells were washed once, resuspended in 1 ml
PBS, transferred to flow cytometry tubes and subjected to FACScan analysis (Becton
Dickinson).

5.2.9 Convalescent pig sera ELISA
To test the immunogenicity of rpL7/L12 this protein was reacted with convalescent pig
sera as follows: wells of a 96 well ELISA plate (Nunc) were coated with 100 µl of a 10
µg/ml solution of recombinant rpL7/L12 protein (in PBS from section 5.2.5) in carbonate
coating buffer. The plate was then incubated overnight at RT in a humidifying chamber
for the protein to coat to the plate, washed and blocked as described previously (2.10). A
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total of 16 different pig sera were chosen from a collection held at EMAI. Sera from pigs
that had been tested for M. hyopneumoniae (using the M. hyopneumoniae ELISA
diagnostic test used at EMAI) were selected. Pigs with various ELISA ratios (which
indicate a positive or negative reaction; Djordjevic et al., 1994), ranging from 0-3
(negative), 5-10, 10-15 and 15 or above were chosen. These sera were diluted 1:100 with
1% w/v skim milk in PBS after which 100 µl of each was added to the wells of the ELISA
plate. Wells not coated with rpL7/L12 were also incubated with each pig serum to ensure
that serum antibodies were not non-specifically binding to the plate. After washing, goat
anti-swine HRP conjugated antibody diluted 1:1000 in 1% w/v skim milk in PBS was
then added to the ELISA plate. Wells with no rpL7/L12 or pig serum were also incubated
with the goat anti-swine sera to check that these antibodies were not binding to the plate.
Reactivity was detected with an ABTS solution as described previously (section 2.10).
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Chapter 5: Characterization of M. hyopneumoniae ribosomal protein
L7/L12

5.3

Results

5.3.1 Sequence similarity of L7/L12 between bacterial species
A similarity matrix generated from a ClustalW alignment showed that the M.
hyopneumoniae L7/L12 protein sequence has greatest homology to those from other
Mycoplasma species. The M. hyopneumoniae L7/L12 protein sequence displayed 57%,
43% and 45% identity and 76%, 65% and 65% similarity to sequences from M. pulmonis,
M. genitalium and M. pneumoniae, respectively.

Ribosomal proteins belonging to the L7/L12 family of bacteria share strong amino acid
sequence identity (Kolberg et al., 1997). Alignment of the complete amino acid
sequences available for L7/L12 ribosomal proteins from 27 different bacterial species is
shown in Fig. 5.3. The C-terminus contains the highly conserved regions, whereas there is
less sequence conservation at the N-terminus. A consensus tree containing 27 sequences
from pylogenetically diverse bacteria was also constructed from this data using Phylip
(Fig. 5.4).
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Fig. 5.3. ClustalW alignment of the complete amino acid sequences available for L7/L12
ribosomal proteins from 27 diverse bacterial species. Black shading indicates areas where
all (100%) species show conservation, dark grey highlights the areas that are 80%
conserved among species and light grey shading shows the areas where 60% of all
bacterial species show conservation.
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Fig. 5.4. A phylogenetic tree showing the relationship between rpL7/L12 proteins of
various bacterial species. The numbers on the nodes represent bootstrap values from 100
replicates.
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5.3.2 Cloning and expression of rpL7/L12 in Escherichia coli
The rpL7/L12 gene of M. hyopneumoniae strain 232 was cloned into E. coli strain M15,
the gene contains 363 nucleotides encoding a protein of 121 amino acids and the
sequence of the gene is displayed in Fig. 5.5.
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Fig. 5.5. The sequence of the rpL7/L12 gene from M. hyopneumoniae. The primer
sequences (rpL7/L12 forward and rpL7/L12 reverse) used for PCR amplification are
shaded in grey.
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Following PCR, the 363 bp product and the pQE-9 vector were digested with the
restriction enzymes BamH1 and HinDIII and then ligated together. The construct is
shown in Fig. 5.6. The ligated vector was then transformed into competent E. coli M15
[pREP4] cells which were plated onto selective media and the colonies screened for
recombinants. Positive clones contained both the pQE-9 and rpL7/L12 bands following
restriction enzyme digestion (Fig. 5.6B).
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pQE-9
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Fig. 5.6. (A) pQE-9 cloning vector showing the multiple cloning site (MCS) and the
rpL7/L12 gene inserted between the BamH1 and HinDIII sites. Also depicted is the
ColE1origin of replication, an ampicillin resistance gene (bla, to aid in screening for
recombinants), the phage T5 promoter (PT5), two lac operator sequences which increase
lac repressor binding, ribosome binding site (RBS) for high translation rates, ATG
translation start codon, the 6x Histidine-tag, the multiple cloning site (MCS) and a cluster
of translational stop codons in all reading frames. (B) BamH1 and HinDIII restriction
digest of M. hyopneumoniae 232 rpL7/L12 pQE-9 clones on an agarose gel. Lane 1
shows a vector only control, whereas lanes 2 and 3 contain the rpL7/L12 insert and are
designated pTB1 and pTB2. The 100 bp DNA ladder plus marker is included in lane 4
and the values of bands in bp are given.
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5.3.3 Verifying recombinant rpL7/L12 expression and the production of
rabbit polyclonal antiserum
DNA sequence analysis confirmed the identity and integrity of the rpL7/L12 gene within
the pTB1 plasmid. PCR amplification of the rpL7/L12 gene from M. hyopneumoniae
strain J using primers rpL7/L12 forward and reverse generated a 363 bp fragment as
expected. DNA sequence analysis confirmed that rpL7/L12 from both strains were
identical (results not shown).

Fig. 5.7 shows the purified rpL7/L12 as it appears on a reducing 15% SDS-PAGE gel,
and after western analysis with the anti-rpL7/L12 rabbit serum that was raised using the
purified rpL7/L12 protein. The antiserum also reacts with two higher molecular weight
bands. These bands may represent multimers of the rpL7/L12 molecule although this
would need further verification. The identity of the protein expressed from pTB1 was
examined using MALDI-TOF mass-spectrometry. Fig. 5.8 below shows the results of the
peptide matches obtained in this analysis after excision of the rpL7/L12 band in Fig. 5.7
(circled).

5.3.4 Expression pattern of M. hyopneumoniae rpL7/L12 in strains 232
and J
Whole cell protein samples from in vitro cultures of the pathogenic M. hyopneumoniae
strain 232 and non-pathogenic J strain were analyzed for the expression of rpL7/L12.
RpL7/L12 is expressed by both strains at an apparent molecular weight of 14 kDa, Fig.
5.9. The higher band of approximately 30 kDa detected by the antiserum is expressed by
both strains although to a greater extent in strain J and may possibly represent a
multimeric form of rpL7/L12.
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Fig. 5.7. SDS-PAGE and immunoblot analyses of rpL7/L12. 15% polyacrylamide gel
containing purified rpL7/L12 (lane 1), and purified rpL7/L12 reacted with rabbit antisera
to rpL7/L12 (lane 2). Lane 3 contains the molecular weight marker.

1 MAKITKEQFIESLKEMTIKEVMEFVDALKEEFGVDPSAVAVAATPVATEEVKTEVKLTLKAA
GQQKVAVIKVVKDLLGLSLMDAKKLVDAAPSVLKEAIKPEEAEEYKAKLVAAGAEVSID 121

Fig. 5.8. Peptide matches (underlined) as they align on the entire sequence of rpL7/L12
from MALDI-TOF mass-spectrometry analysis of the recombinant rpL7/L12 expression
product from E. coli, circled in Fig. 5.7.
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Fig. 5.9. Western blot images of whole cell protein preparations of M. hyopneumoniae
232 and M. hyopneumoniae J reacted with anti-rpL7/L12 rabbit sera. (A) Whole cell
lysate protein preparations of M. hyopneumoniae strains 232 (lane 2) and J (lane 4) on
SDS-PAGE gels stained in Coomassie. (B) Western blot images of whole cell protein
preparations of M. hyopneumoniae 232 (lane 2) and M. hyopneumoniae J (lane 4) reacted
with anti-rpL7/L12 rabbit sera. The markers are the same for all images and the sizes are
as indicated, in kilodaltons.

5.3.5 rpL7/L12 is expressed inside the M. hyopneumoniae cell
Figure 5.10 displays the results of FACScan analysis with anti-rpL7/L12 rabbit serum.
After analyzing the external surface of M. hyopneumoniae using intact cells and being
unable to detect the presence of rpL7/L12 (Fig. 5.10A), an assay using saponin treated
cells was conducted which perforated the M. hyopneumoniae cells. Saponin treated cells
were found to react with the antisera resulting in a shift in fluorescence intensity of the
peak, indicating rpL7/L12 is expressed inside the M. hyopneumoniae cell (Fig. 5.10B).
Purified normal rabbit serum (Zymed) failed to react with M. hyopneumoniae cells, either
without (Fig. 5.10C) or with (Fig. 5.10D) saponin treatment.
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A. Intact cells with anti-rpL7/L12
serum

B. Saponin treated cells with antirpL7/L12 serum

M1

M1

C. Intact cells with normal rabbit
serum

D. Saponin treated cells with
normal rabbit serum

M1

M1

Fig. 5.10. FACScan analysis with anti-rpL7/L12 rabbit serum and normal rabbit serum. A
and C represent intact M. hyopneumoniae cells whereas B and D represent saponin treated
cells. A and B were reacted with anti-rpL7/L12 serum whilst C and D were reacted with
commercial normal rabbit serum. Highlighted with a bar is the area of interest (M1) in the
histograms with a peak present in B but not in A, C or D. The x-axis is a logarithmic scale
while the y-axis is a numerical scale of fluorescent counts.

The data generated from the FACScan histograms are presented in Table 5.2. From this
table we see a distinct positive reaction with the anti-rpL7/L12 sera, when analyzing
saponin treated M. hyopneumoniae cells (highlighted).
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Table 5.2. FACScan analysis of M. hyopneumoniae intact cells and saponin-treated cells
with anti-rpL7/L12 serum and normal rabbit serum. Positive results are highlighted.

Intact M. hyopneumoniae cells
Normal rabbit Anti-rpL7/L12
serum
serum
% Gateda
10.05
12.44
Median of
850.53
809.47
M1 regionb
Saponin treated M. hyopneumoniae cells
Normal rabbit Anti-rpL7/L12
serum
serum
a
% Gated
1.58
60.94
Median of
120.79
61.53
M1 regionb
a

represents the percentage that the M1 region represents of the entire histogram. The
higher the value indicates a more positive result due to the presence of a peak in the M1
region.
b
the middle fluorescent value for the M1 region only, once again the higher the value the
more positive the result.
These results are based on comparison with the normal rabbit serum control as this
represents the fluorescence detected when normal serum from rabbits is incubated with
M. hyopneumoniae cells.

5.3.6 rpL7/L12 is recognized by convalescent pig sera
A selection of porcine sera previously tested using an accredited enzyme-linked
immunosorbent assay (Djordjevic et al., 1994) were used to determine if swine with a
history of exposure to M. hyopneumoniae generate antibodies to rpL7/L12. The pig sera
were separated into four groups based on their ELISA ratios. Negative samples are those
with an ELISA ratio below 3, sera with ratios between 5 and 10, 10 and 15, and 15 or
above were also tested. Table 5.4 shows the ELISA ratio obtained in the M.
hyopneumoniae ELISA (conducted by J. Gonsalves, EMAI). The pig sera showing
significant OD’s (above an arbitrary 0.2 cut-off) when reacted with rpL7/L12 are
highlighted.
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Table 5.3. M. hyopneumoniae (EMAI) ELISA ratios for each of the 16 pig sera used in
the rpL7/L12 ELISA. The ELISA grouping of each is also shown based on these ratios.
Highlighted are those pig sera that gave significant OD values (above 0.2) when reacted
with rpL7/L12.

Pig
Pig 1
Pig 2
Pig 3
Pig 4
Pig 5
Pig 6
Pig 7
Pig 8
Pig 9
Pig 10
Pig 11
Pig 12
Pig 13
Pig 14
Pig 15
Pig 16

Actual
ELISA ratio
Less than 3
Less than 3
Less than 3
9.12
7.77
8.39
8.79
13.53
12.22
10.65
13.75
22.77
19.02
15.14
18.17
17.66

ELISA
status
negative
negative
negative
5-10
5-10
5-10
5-10
10-15
10-15
10-15
10-15
≥15
≥15
≥15
≥15
≥15

Fig. 5.11 below shows the results when recombinant rpL7/L12 was reacted with each of
the 16 pig sera from table 5.3 above. Six serum samples reacted (OD > 0.2) with
rpL7/L12, these were sera 5, 6, 8, 10, 11 and 15.
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1.6
1.4
Average OD

1.2
1
0.8
0.6
0.4
0.2
negative
negative
negative
5--10
5--10
5--10
5--10
10--15
10--15
10--15
10--15
≥15
≥15
≥15
≥15
≥15

0

M. hyopneumoniae
ELISA ratio

1 2 3 4 5 6 7 8 9 10 1112 13 1415 16

Pig sera

Fig. 5.11. Reactivity of rpL7/L12 with 16 different convalescent pig sera. These are the
average OD values obtained from duplicate samples.
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Chapter 5: Characterization of M. hyopneumoniae ribosomal protein
L7/L12

5.4

Discussion

Ribosomal protein L7/L12 has been shown to play a role in the pathogenesis of a number
of bacterial pathogens in vitro. For example in Neisseria gonorrhoeae, rpL12 plays a role
in the invasion of human reproductive cells (human endometrial cell line, Hec1B). The
observation that the rpL7/L12 protein of M. hyopneumoniae did react with a subset of
convalescent pig sera indicates that this protein is immunogenic and expressed during the
course of infection. Flow cytometry experiments did not detect rpL7/L12 expression on
the surface of intact M. hyopneumoniae cells as had been previously described for N.
gonorrhoeae (Spence and Clarke, 2000).

The consensus tree constructed from rpL7/L12 protein sequences from 27
phylogenetically diverse bacteria showed M. hyopneumoniae clustered together with the
other Mycoplasma species. The Mycoplasma species were found to be most closely
related to other members of the firmicutes, such as the Bacillus species, Clostridium
perfringens and Staphylococcus aureus.

The fact that both strains of Mycoplasma hyopneumoniae (232 and J) expressed the
rpL7/L12 molecule is likely attributed to its important function in the translocation step of
translation and was not unexpected. A sequence alignment and phylogenetic tree from
these sequences demonstrate the highly conserved nature of this protein. DNA sequencing
data demonstrated this molecule to be identical in both M. hyopneumoniae strains. The 14
kDa rpL7/L12 band was detected in both strains of M. hyopneumoniae when reacted with
anti-rpL7/L12 serum, representing the monomer of this protein. However, a second band
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of approximately 30 kDa was also detected which might represent a SDS-stable dimer of
rpL7/L12. The polyhistidine fusion protein expressed in E. coli also showed the
possibility of multimer formation due to the production of extra bands at approximately
26 kDa and 30 kDa during the purification process. These bands remained even after the
protein sample was reduced in a buffer containing β-mercaptoethanol and SDS and heat
treatment at 100oC for 5 min. The samples from the purification and in the M.
hyopneumoniae whole cell extracts were not produced in sufficient quantities to allow
identification by MALDI-TOF mass spectrometry. However identification of these
protein bands is required to verify the hypothesis that these higher molecular weight
bands consist of rpL7/L12.

Bachrach et al. (1997) showed that the ribosomal protein L7/L12 isolated from Brucella
melitensis induces a DTH reaction in Brucella-sensitised guinea pigs. Surprisingly, the
recombinant Brucella L7/L12 protein expressed in E. coli as a fusion protein with a sixHistidine tag cannot elicit such a reaction. The histidine tag on the recombinant L7/L12
protein was removed enzymatically, but the resulting protein did not induce a DTH
reaction in sensitized animals (Bachrach et al., 1997). Incubation of the recombinant
L7/L12 fusion protein in a B. melitensis lysate endowed the recombinant protein with a
DTH activity, suggesting that the recombinant protein was modified by this treatment. It
was shown that acetylation of the Brucella L7/L12 protein is crucial for the proteins
recognition by the host cells that trigger the DTH reaction (Bachrach et al., 1997). This
could also be true for the M. hyopneumoniae L7/L12 protein, where post-translational
modification that might occur in M. hyopneumoniae may not occur in the E. coli
expression strain.
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In conclusion, rpL7/L12 is recognised by a subset of convalescent pig sera and this
protein appears to be highly conserved within M. hyopneumoniae strains. Further work is
required to examine the immunological status of swine to this antigen, however this
recombinant poly-histidine fusion protein represents an excellent negative control of a M.
hyopneumoniae derived protein for ligand binding studies.
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Chapter 6: General Discussion and Future Studies

M. hyopneumoniae is the etiological agent of porcine enzootic pneumonia and
significantly impacts swine production (Ross, 1992). M. hyopneumoniae adheres
exclusively to ciliated cells of the respiratory tract and this colonization disrupts the
normal function of the mucociliary escalator through ciliostasis, loss of cilia and acute
inflammation. The disease can be resolved after a long period but M. hyopneumoniae
colonization predisposes the host to secondary infections and more severe and longer
lasting diseases (Frey et al., 1994; Ross, 1992). Current vaccines are unsatisfactory as
they do not protect against colonization and vaccinated herds can still develop disease
(Thacker et al., 1998).

For cilial damage to occur, M. hyopneumoniae must attach to the swine respiratory
epithelial cells (Zielinski and Ross, 1990; DeBey and Ross 1994). Non-pathogenic M.
hyopneumoniae and excessively in vitro passaged M. hyopneumoniae do not adhere to
ciliated cells (Zielinski and Ross, 1990), and are therefore unable to colonize the
respiratory epithelium and establish infection. It is therefore important to identify the
adhesins associated with attachment of pathogenic M. hyopneumoniae in vivo for
production of vaccines that prevent infection in the pig (DeBey and Ross, 1994).

Ribosomal protein L7/L12 has been shown to play a role in the pathogenesis of a number
of bacterial pathogens in vitro and has been identified as one of the dominant
immunoreactive proteins in pathogens such as Chlamydia trachomatis (Sanchez-Campillo
et al., 1999), Brucella abortus (Oliveira and Splitter, 1996) and Brucella melitensis
(Bachrach et al., 1997). This protein has been found to be expressed on the cell surface of
some pathogenic bacteria, including Neisseria gonorrhoeae (Spence and Clarke, 2000).
136

Further work has shown this molecule to be internally expressed in M. hyopneumoniae
and that this protein has immunogenic properties due to its reactivity with convalescent
pig serum. This protein may be a good target for antimicrobial therapy and vaccine
development because of its immunogenic properties and has been useful in this study as
an E. coli expressed His-tagged protein control for adherence assays, including
radioactive experiments and ELISAs (results not shown), due to its inability to adhere to
the ECM components analysed.

Pre-incubation of M. hyopneumoniae cells with periodate and trypsin abolished
attachment of M. hyopneumoniae to ciliated respiratory tract cells (Zielinski and Ross,
1993), indicating that adherence is mediated by carbohydrates and proteins on the surface
of the organism. A 97 kDa surface protein of M. hyopneumoniae, P97, has been
implicated as playing a role in host cell adhesion. However, monoclonal antibodies F1B6
and F2G5, which recognise P97 in immunoblots, reduce adherence of M. hyopneumoniae
(in vitro) to purified cilia and to ciliated cells by only 67% (Zhang et al., 1995). These
authors proposed that other molecules must be involved in adherence.

Analysis of the M. hyopneumoniae genome for paralogs of the gene for the P97 cilium
adhesin and the adjacent locus p102, revealed the presence of six adhesin parolog
operons. The p159 gene is found in one of these operons adjacent to a p97 paralog but
shows no resemblance to p97 or p102. Two-dimensional gel electrophoresis revealed that
P159 is cleaved into distinct fragments. Cleavage of surface proteins has been reported
for other Mycoplasma species (Davis and Wise, 2002) and for the P97 cilium adhesin of
M. hyopneumoniae (Djordjevic et al., 2004). The protease(s) involved in the cleavage of
P159 and P97 remain to be determined and is the focus of further research.
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This study has shown that at least regions of P159 are surface expressed in vitro and that
this molecule is highly immunogenic. P159 may therefore be a candidate for
antimicrobial therapy against M. hyopneumoniae, such as in a multi-subunit vaccine. The
C-terminal half of the P159 molecule was shown to bind to heparin which may play a role
in the adherence of M. hyopneumoniae to swine respiratory cilia. Some pathogenic
bacteria have been shown to bind heparin which can then bind to further components on
the surface of cells, thereby acting as a bridging molecule (Duensing et al., 1999; Ljungh
et al., 1996; Van Putten et al., 1998). Future work will aim at determining whether,
through molecules such as P159 and P97 (also a heparin binding protein, Djordjevic et
al., 2004 IOM), M. hyopneumoniae may be binding directly to heparin on the swine
ciliated cells or to heparin as a bridging molecule.

Portions of the P159 molecule were shown to have the ability to adhere to a porcine
kidney epithelial cell line (PK15). Whole M. hyopneumoniae cells also showed the ability
to adhere to these cells and it is possible that the surface exposed P159 molecules are
involved in the adherence of the bacteria to the PK15 cells. Parts of the P159 protein also
showed the ability to cross the PK15 cell membrane, although the mechanism utilized for
this is unknown. As whole Mycoplasma cells were not able to invade PK15 cells it could
be that P159 molecules are released from the bacteria and are able to invade the PK15
cells, although this remains to be determined. The accumulation of flask or omega-shape
like structures in the PK15 cell membrane in the near vicinity to attached bacteria which
resemble caveolae may represent a mode for entry of the secreted proteins. Caveolae
(which are found in a variety of mammalian cells; Anderson, 1998) represent an entry
port for pathogenic agents such as viruses, bacteria and parasites (Couet et al., 2001;
Norkin, 2001; Marjomäki et al., 2002; Shin and Abraham, 2001a,b,c,d; Shin et al., 2000).
For example, caveolae have been shown to act as an entry port for group A streptococci
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into epithelial and endothelial cells (Rohde et al., 2003). Incubation of cells with SfbI
protein also triggered accumulation of caveolae showing that SfbI is the triggering factor
that activates the caveolae-mediated endocytic pathway (Rohde et al., 2003). Future work
will be aimed at determining whether these structures are caveolae and whether or not
proteins, including P159, secreted from M. hyopneumoniae cells utilize these caveolae to
enter PK15 cells.

P159 can bind heparin; whether this ability is utilized in the adherence to PK15 cells
remains to be determined. That is, heparin molecules may be produced by PK15 cells or
supplied by the media. M. hyopneumoniae may bind to these heparin molecules on the
PK15 cells through the P159 molecule or other heparin binding proteins on the surface of
M. hyopneumoniae.

P159 cleavage fragments are found on the surface of M. hyopneumoniae however, it is
not clear from these studies how P159 cleavage fragments that lack a putative
transmembrane domain(s) remain associated with the cell surface after cells are harvested
from culture and washed several times with PBS. The N-terminal protein P27 is the only
cleavage fragment that possesses a hydrophobic stretch of amino acids that would be
predicted to span the cell membrane. It is possible that this transmembrane domain allows
transfer of the entire P159 molecule to the surface of the M. hyopneumoniae cell where it
is further processed and cleaved. Similar to P159, the cilium adhesin P97 only possesses
a single putative N-terminal leader peptide that is capable of spanning the cell membrane
(Djordjevic et al., 2004). Recently Djordjevic and colleagues have demonstrated that the
C-terminal third of P97, the region that contains the cilium binding domain R1 (Minion et
al., 2000) is found associated with the cell surface (Djordjevic et al., 2004). This portion
of the molecule binds strongly to porcine and human fibronectin and like P159, to the
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glycosaminoglycan heparin (Djordjevic et al., 2004 IOM). P159 fragments possess the
ability to remain attached to the cell surface either by protein-protein interactions with
other surface anchored membrane proteins or sequestering ECM and other medium
components to the surface, such as heparin. ECM components can be found on epithelial
surfaces, including those that line the respiratory tract and we propose that the ability to
sequester ECM components to the surface of the M. hyopneumoniae cell may play a role
in facilitating adherence and colonisation and possibly immune evasion in the porcine
respiratory tract.

In conclusion, the P159 protein of M. hyopneumoniae was shown to be posttranslationally cleaved and parts of this molecule were found to be expressed on the
surface of M. hyopneumoniae. P159 also reacted with convalescent pig serum and the Cterminal half of the molecule bound to the glycosaminoglycan heparin. Parts of the
molecule were also shown to bind to and cross the cell membrane of porcine epithelial
(PK15) cells. This data collectively indicates the potential of P159 as a M.
hyopneumoniae adhesin and future work will aim at verifying this hypothesis and
determining the adhesive mechanism utilised to further understand the pathogenic
mechanisms of M. hyopneumoniae and to control infections in swine.
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Appendix A: General Buffers and Reagents

Commonly used buffer solutions
1X Phosphate buffered saline (PBS) pH 7.2
0.5 M K2HPO4
71.7 ml/l
0.5 M KH2PO4
28.3 ml/l
NaCl
8.57 g/l
Phosphate buffer (PB) pH 7.2
0.5 M K2HPO4
0.5 M KH2PO4

71.7 ml/l
28.3 ml/l

1.5 M Tris pH 8.8
Tris

181.71g/l

1 M Tris pH 6.8
Tris

121.14 g/l

1% Triton X-114 buffer
Triton X-114
Tris
NaCl
0.5M EDTA

0.5 ml/50 ml
0.0606 g/50 ml
0.438 g/50 ml
0.1 ml/50 ml

TE buffer pH 7.5
Tris
EDTA

1.21 g/l
0.37 g/l

1-D SDS-PAGE gels/4 gels
MilliQ water
30% acrylamide
1.5 M Tris pH 8.8
1.0 M Tris pH 6.8
10% w/v SDS
APS
TEMED

12% resolving gel
13.2 ml
16 ml
10 ml

15% resolving gel
9.2 ml
20 ml
10 ml

0.4 ml
45 mg
16 µl

0.4 ml
45 mg
16 µl
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4% stacking gel
10.8 ml
1.95 ml
1.95 ml
0.15 ml
10 mg
11 µl

2-D SDS-PAGE gels/ 6 gels
40% 37.5:1 Acrylamide
1.5 M Tris pH 8.8
MilliQ water
10% w/v SDS
10% APS (0.6g in 6 ml MilliQ)
TEMED

12.5% resolving gel
156 ml/500 ml
125 ml/500 ml
208 ml/500 ml
6 ml/500 ml
6 ml/500 ml
100 µl/500 ml

Electrophoresis reagents
1X SDS-PAGE buffer
Tris
Glycine
SDS

3.03 g/l
14.33 g/l
1.0 g/l

Reducing solution/cracking buffer
Tris pH 6.8
SDS
β-mercaptoethanol
Glycerol
Bromophenol Blue

0.73 g/100 ml
1 g/100 ml
1 g/100 ml
10 g/100 ml
0.01 g/100 ml

Coomassie stain 1-D
Coomassie R250
Methanol
Acetic Acid

1.25 g/500 ml
225 ml/500 ml
50 ml/500 ml

Coomassie de-stain 1-D
Acetic acid
Methanol

100 ml/l
450 ml/l

0.5X TBE for agarose gels
Boric acid
Tris
0.5 M EDTA

2.75 g/l
5.4 g/l
2 ml/l

1X TAE for agarose gels
Tris
Acetic Acid
0.5 M EDTA

4.84 g/l
1.14 ml/l
2 ml/l

Agarose gel loading buffer (bromophenol blue loading dye)
bromophenol blue
0.25 g/100 ml
ficoll
15 g/100 ml
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2-D Gel Electrophoresis Reagents
5X Tris buffer pH 8.8
Tris

227 g/l

Equilibration buffer
Urea
SDS
5X Tris buffer pH 8.8
Glycerol
DTT
40% Acrylamide

21.6 g/60 ml
1.2 g/60 ml
12 ml/60 ml
12 ml/60 ml
1.2 g/60 ml
3.75 ml/60 ml

Lysis buffer
Urea
DTT
CHAPS
Ampholytes pH 3-10
Tris
PMSF
EDTA 0.5 M

0.54 g/100 ml
1 g/100 ml
4 g/100 ml
0.8 ml/100 ml
0.42 g/100 ml
10 µl/ml
9 µl/ml

Standard solubilisation solution (SSS)
Urea
9.6 g/20 ml
DTT
0.308 g/20 ml
CHAPS
0.8 g/20 ml
Ampholytes pH 3-10
0.4 ml/20 ml
Tris
0.097 g/20 ml
Multiple surfactant solution (MSS)
Urea
6.0 g/20 ml
Thiourea
3.04 g/20 ml
DTT
0.2 g/20 ml
CHAPS
0.4 g/20 ml
Sulfobetaine
0.4 g/20 ml
0.8% Ampholytes 3-10
0.4 ml/20 ml
Tris
0.1 g/20 ml
Colloidal Coomassie 2-D
Ammonium sulfate
Phosphoric acid
Coomassie G250
Methanol

170 g/l
36 ml/l
1 g/l
340 ml/l

Colloidal Coomassie de-stain 2-D
Acetic acid
10 ml/l
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Western Transfer Reagents
1X western transfer buffer
Tris
Glycine
Methanol

3.03 g/l
14.33 g/l
200 ml/l

1X Tris-saline
Tris
NaCl

1.21 g/l
9 g/l

100 mM Tris pH 7.6
Tris

12.1 g/l

DAB solution
DAB
100 mM Tris pH 7.6
Hydrogen peroxide

25 mg
50 ml
15 µl

ELISA Reagents
Carbonate coating buffer pH 9.5
NaHCO3
Na2CO3

0.75 g/500 ml
1.45 g/500 ml

Wash solution
Tween20 in PBS

0.05% v/v

ABTS solution, per plate
0.1 M citric acid
4.41 ml
0.2 M Na2HPO4
3.09 ml
MilliQ water
7.5 ml
pH to 4.2 and add 8.25 mg ABTS and 4.5 µl hydrogen peroxide

Midi/Maxi Prep Kit (Qiagen) Reagents
P1 pH 8.0
Tris
EDTA
RNase A

6.06 g/l
3.72 g/l
100 mg/l

P2
NaOH
20% SDS solution

8 g/l
50 ml/l

P3 pH 5.5
Potassium acetate

294.5 g/l
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QBT pH 7.0
NaCl
MOPS
Isopropanol
10% Triton X-100 Solution

43.83 g/l
10.46 g/l
150 ml/l
15 ml/l

QC pH 7.0
NaCl
MOPS
Isopropanol

58.44 g/l
10.46 g/l
150 ml

QF pH 8.5
NaCl
Tris
Isopropanol

73.05 g/l
6.06 g/l
150 ml/l

Southern Reagents
Denaturation solution
NaOH
NaCl

20 g/l
87.66 g/l

Neutralisation solution
Tris

121.14 g/l

1.5M NaCl
NaCl

87.66 g/l

20X SSC buffer pH 7.0
NaCl
Sodium citrate

175.3 g/l
88.2 g/l

Culture Reagents
LB media
Tryptone
Yeast
NaCl

10 g/l
5 g/l
5 g/l

LB agar
Tryptone
Yeast
NaCl
Agar

10 g/l
5 g/l
5 g/l
15 g/l
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NZY+ broth pH 7.6
NZ Amine
Yeast Extract
NaCl
MgCl2
MgSO4
Glucose

10 g/l
5 g/l
5 g/l
203.4 g/l
246.4 g/l
146 ml/l

SOCS medium
Tryptone
Yeast Extract
NaCl
KCl
MgCl2
MgSO4
Glucose

2 g/100 ml
0.5 g/100 ml
0.06 g/100 ml
0.02 g/100 ml
0.1 g/100 ml
0.12 g/100 ml
0.36 g/100 ml

Hank’s buffered salt solution for Friis media
Hanks A
NaCl
KCl
MgSO4
MgCl2
CaCl2

80 g/500 ml
4 g/500 ml
1 g/500 ml
1 g/500 ml
1.4 g/500 ml

Hanks B
Na2HPO4
KH2PO4

1.5 g/500 ml
0.6 g/500 ml

Friis Base Media for Mycoplasma culturing pH 7.4
Hanks A
30.4 ml/2 l
Hanks B
30.4 ml/2 l
Difco Brain Heart Infusion (BHI)
9.8 g/2 l
Difco PPLO
10.5 g/2 l
0.5% Phenol Red
5.2 ml/2 l
Sterile MilliQ water
1654 ml/2 l
Friis components added to base media before use
Bacitracin
0.288 g/11.4 ml
Methicillin (or Ampicillin)
0.288 g/11.4 ml
Yeast Extract
68 ml
Horse Serum
100 ml
Pig Serum
100 ml
PK15 culture growth media
Dulbecco’s Modified Eagle Medium (DMEM, Gibco) with 10% FCS and glutamine
PK15 culture infection media
DMEM/Hepes 25 mM (Gibco) with 1% FCS
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Trypsin solution
Trypsin-EDTA (1X) in HBSS without Ca and Mg (Gibco)
Cacodylate Buffer pH 6.9
Cacodylate
MgCl2
CaCl2
Sucrose

21.4 g/l
0.95 g/l
1.47 g/l
308.1 g/l

Bradford’s Reagent for protein concentration
Coomassie G250
95% Ethanol
Orthophosphoric Acid

50 mg/500 ml
25 ml/500 ml
50 ml/500 ml

Ni-NTA purification buffer for His-tag clones
Urea
480.48 g/l
NaH2PO4 0.1 M
15.6 g/l
Tris 0.01 M
1.21 g/l
Same buffer used but lysis buffer B at pH 8.0, wash buffer C at pH 6.3, elution buffers D
and E at pH 5.9 and pH 4.5, respectively.

Sequencing Reagents
PEG8000 solution
PEG8000
NaOAc
MgCl2

26.7 ml/100 ml
4.92 g/100 ml
0.062 g/100 ml

Stop Solution
3 M NaOAc pH 5.2
100 mM EDTA pH 8.0
Glycogen (from DTCS kit)

30 µl
30 µl
15 µl
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Appendix B: Source of ECM compounds and their antibodies

In Australia:
Laminin

mouse

rabbit anti-laminin

(Sigma L2020)
(Sigma L9393)

Fibronectin

human

rabbit anti-fibronectin

(Sigma F3648 and Calbiochem 341635)
(ICN/CAPPEL)

Biotinylated heparin

porcine

streptavidin-peroxidase
Fibrinogen

(Sigma B9806)
(Roche)

human

goat anti-fibrinogen

(Sigma F3879)
(Sigma F8152)

Chondroitin sulphate A

bovine

(Sigma C8529)

mAb against chondroitin sulphate mouse

(Sigma C8035)

Chondroitin sulphate B

porcine

(Sigma C3788) no antibody used

Heparan sulphate

porcine

(Sigma H9902) no antibody used

Fucoidan

Fucus vesiculosus

(Sigma F5631) no antibody used

In Germany (no antibodies used):
Laminin (Calbiochem); Fibronectin: whole (ICN), alpha-chymotryptic 120kDa fragment
(Chemicon), proteolytic fragments 70, 45 and 30 kDa (Sigma); Type IV Collagen
(Sigma); Keratin (Sigma); Fibrinogen (Calbiochem).
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Appendix C: Commercial kits used in this study

QIAquick PCR Purification Kit

QIAGEN

Midi/Maxi Plasmid Purification Kit

QIAGEN

Mini Plasmid Purification Kit

QIAGEN

GenElute Gel Extraction Kit

Sigma

FlexiPrep Plasmid Purification Kit

Amersham Pharmacia Biotech.

pPCR-Script Amp SK(+) Cloning Kit

Stratagene

DIG Wash and Block Buffer Set

Roche
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Appendix D: Cell lines used in this study

•

Escherichia coli JM109 containing the pQE-9 plasmid from Qiagen (University of
Wollongong, Australia).

•

Escherichia coli M15 containing the pREP4 plasmid from Qiagen (University of
Wollongong, Australia).

•

XL10-Gold Kan ultra competent cells from pPCR-Script cloning kit (Stratagene).

•

pPCR2.1 plasmid in E. coli TOP10 cells containing entire p159 gene inserted in
this plasmid after mutagenesis of all TGA codons to TGG, supplied by S. Geary
(University of Connecticut, USA).

•

M. hyopneumoniae strains:
o J strain used in Germany supplied by the Microbiology Institute
(Hannover, Germany).
o J strain (NCTC 10110) supplied by A. Pointon (South Australian Research
and Development Institute, Australia).
o 232 strain isolated from a porcine lung homogenate suspension containing
M. hyopneumoniae strain 11 supplied by T.F. Young (Veterinary Medical
Research Institute, Iowa State University, USA) (Bereiter et al., 1990).
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Appendix E: Vector maps

3439
1-6
7-87
61
127-144
145-170
186-280
1042-1140
1616
3243-2374

BamH1
SalI
PstI
HinDIII

Positions of elements in bases
Vector size (bp)
Start of numbering at XhoI
T5 promoter/lac operator element
T5 transcription start
6x His-tag coding sequence
Multiple cloning site
Lambda to transcriptional termination region
rrnB T1 transcriptional termination region
ColE1 origin of replication
β-lactamase coding sequence

lac O

Ampicillin

PT5

lac O

RBS

ATG

6xHis

MCS Stop codons

pQE-9
3.4 kb

ColE1

Fig. A1. Map of the prokaryotic expression vector pQE-9 (Qiagen) used to express
rpL7/L12 and P159 proteins in this study. For further information including the complete
vector sequence please see this website: www1.qiagen.com/literature/vectors_pqe.aspx.
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lacZ

MCS
P lac

Ampicillin

f1 (+) ori

pPCR-Script Amp SK(+)
3.0 kb

pUC ori

Positions of elements in bases
Vector size (bp)
f1 (+) origin
β-galactosidase α-fragment
multiple cloning site
lac promoter
pUC origin
ampicillin resistance (bla) ORF

2961
135-441
460-816
653-760
817-938
1158-1825
1978-2833

MCS contains restriction enzyme sites for:
Kpn I, Apa I/Eco01091/Dra II, Xho I, Acc I/Hinc II/Sal I, Bsp 106 I/Cla I, Hind III,
EcoR V, EcoR I, Pst I, Sma I, BamH I, Srf I, Sma I, Not I, Eag I, BstX I, Sac II, Sac I,
BssH II.

Fig. A2. Map of the prokaryotic cloning vector pPCR-Script Amp SK(+) (Stratagene)
used to clone P159 proteins in this study before being further cloned into the pQE-9
expression vector. For further information including the complete vector sequence please
see this website: www.stratagene.com/lit/vector.aspx.
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Appendix F: Presentation of Results at Conferences
Poster presentations
Burnett, T.A., Cordwell, S., Geary, S., Minion, C., Walker, M. and Djordjevic, S.P.
Analysis of a novel surface exposed protein of Mycoplasma hyopneumoniae. Presented at
the 14th International Congress of the International Organization for Mycoplasmology,
Vienna, Austria, July, 2002.
Burnett, T.A., Cordwell, S., Geary, S., Minion, F.C., Walker, M. and Djordjevic, S.P.
Analysis of a novel surface exposed protein of Mycoplasma hyopneumoniae. Presented at
the Australian Society for Microbiology Conference in Melbourne, Australia, October,
2002.

Oral presentations
Burnett, T.A., Cordwell, S., Geary, S., Minion, F.C., Walker, M. and Djordjevic, S.P
Molecular characterization of P159, a major surface antigen of Mycoplasma
hyopneumoniae. Presented at the Biannual Bacterial Pathogenesis Meeting (Branch of the
Australian Society for Microbiology), Jamberoo, Australia, May, 2003.

Burnett, T.A., Cordwell, S., Geary, S., Minion, F.C., Walker, M. and Djordjevic, S.P
Molecular characterization of P159, a major surface antigen of Mycoplasma
hyopneumoniae and an ECM binding protein. Presented at the Elizabeth Macarthur
Agricultural Institute in August 2003.
Burnett, T.A., Dinkla, K., Rohde, M., Chhatwal, G.S., Cordwell, S., Geary, S., Minion,
F.C., Walker, M. and Djordjevic, S.P. Domains within the surface antigen P159 of
Mycoplasma hyopneumoniae promote adhesion to and invasion of eukaryote cells and
bind the glycosaminoglycan, heparin. Presented at the 15th International Congress of the
International Organization for Mycoplasmology, Athens, U.S.A., July, 2004.
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